,BARCODE,COMBI_ID,Tissue,CELL_LINE_NAME,SIDM,COSMIC_ID,ANCHOR_ID,ANCHOR_NAME,ANCHOR_TARGET,ANCHOR_PATHWAY,ANCHOR_DRUG_TYPE,ANCHOR_Clin_Rel,ANCHOR_CONC,LIBRARY_ID,LIBRARY_NAME,LIBRARY_TARGET,LIBRARY_PATHWAY,LIBRARY_DRUG_TYPE,LIBRARY_Clin_Rel,LIBRARY_CONC,ANCHOR_VIABILITY,LIBRARY_RMSE,LIBRARY_EMAX,LIBRARY_XMID,LIBRARY_XMID_uM,LIBRARY_AUC,LIBRARY_fAUC,SYNERGY_RMSE,SYNERGY_EXP_EMAX,SYNERGY_OBS_EMAX,SYNERGY_DELTA_EMAX,SYNERGY_XMID,SYNERGY_XMID_uM,SYNERGY_DELTA_XMID,SYNERGY_DELTA_XMID_uM,SYNERGY_EXP_AUC,SYNERGY_OBS_AUC,SYNERGY_EXP_fAUC,SYNERGY_OBS_fAUC,SYNERGY_DELTA_AUC,SYNERGY_DELTA_fAUC,Synergy,DAY1_NORM_MEAN,DAY1_NORM_SD,GROWTH_RATE,DOUBLING_TIME
1441,19424,2171:1372,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.858190812139455,0.157721531067687,0.110318131055021,3.34697017609804,0.0199,0.439948221619536,0.452607118615724,0.103177396827575,0.0946740064838149,0.0299931446180753,0.0646808618657395,0.0139440161216431,0.002,3.3330261599764,0.0179,0.377559521610978,0.226340594293053,0.388423270704927,0.200377923493353,0.151218927317926,0.188045347211574,True,0.499774390407091,0.0575571633222263,0.650242614740972,74.2496679568235
1442,21248,1083:1549,Colon,RCM-1,SIDM00359,909263,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.968599398179118,0.0809576777141758,0.625235418608138,10.3860586451506,13.0682,0.842019051282056,0.876835567413566,0.0633236363439867,0.605602650184111,0.362197988769745,0.243404661414366,7.60440643196361,1.9004,2.78165221318694,11.1678,0.815579146327151,0.691485456419626,0.849302402898826,0.721299422070875,0.124093689907526,0.128002980827951,True,0.607094293335371,0.0800870938872699,0.465526030274622,102.683196581919
1443,20647,2171:2048,Colon,RCM-1,SIDM00359,909263,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.812643534084649,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.181326150587483,0.637426037466283,0.338850911348265,0.298575126118019,8.09223796670208,0.0533,4.40495754332305,1.0759,0.724234105433601,0.508367880109397,0.760700625552753,0.62767631308908,0.215866225324204,0.133024312463672,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
1444,20647,1011:2048,Colon,RCM-1,SIDM00359,909263,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.754403272190948,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.179613620736749,0.591743203846354,0.330378270777466,0.261364933068888,8.32419642355654,0.0626,4.17299908646859,1.0666,0.672329940564667,0.5068949199363,0.706182990456084,0.592146484231394,0.165435020628367,0.114036506224691,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
1445,20647,1083:2048,Colon,RCM-1,SIDM00359,909263,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.987236519938329,0.114484750563863,0.784385786302074,12.4971955100251,1.1292,0.891207614479293,0.936081558083885,0.12255056708802,0.774374293957949,0.558668657904266,0.215705636053683,9.71792263308254,0.1645,2.77927287694259,0.9647,0.879832703861077,0.751272483445749,0.924133899781184,0.840080602568262,0.128560220415328,0.0840532972129211,True,0.301789315323562,0.0468918373025813,0.999273940067492,46.9257595822263
1446,19405,1549:1011,Colon,LS-513,SIDM00677,907795,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.708127890725862,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0761019129462971,0.403574028503732,0.178854823298025,0.224719205205707,6.37998192625988,1.6267,3.29984666076339,14.3928,0.597339574369704,0.478362612967169,0.614017302944122,0.480680025637376,0.118976961402535,0.133337277306746,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1447,19405,1032:1011,Colon,LS-513,SIDM00677,907795,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.686569398478188,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.197107147193943,0.391287480157299,0.229952945430548,0.161334534726751,7.34344036340125,3.1719,2.33638822362202,12.8476,0.579153960228622,0.421604610687364,0.595323946223079,0.510367335577604,0.157549349541258,0.0849566106454744,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1448,19405,1372:1011,Colon,LS-513,SIDM00677,907795,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.230464339553583,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0764668514736289,0.131345514218841,0.0346691630292373,0.0966763511896033,4.81924783540287,0.5514,4.8605807516204,15.4681,0.194407637800029,0.0842185217112405,0.199835501539752,0.129827750203793,0.110189116088789,0.0700077513359594,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1449,19405,1564:1011,Colon,LS-513,SIDM00677,907795,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.612761765429763,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0725017994648285,0.349223265212814,0.0724069413417812,0.276816323871032,4.14619700528872,0.3458,5.53363158173455,15.6737,0.516893709378752,0.306827963351003,0.531325388371291,0.313331733745385,0.210065746027749,0.217993654625907,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1450,19405,1053:1011,Colon,LS-513,SIDM00677,907795,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.64721183083494,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.153027244340561,0.368856938536333,0.315120014866412,0.053736923669921,8.87331838170139,9.1594,0.806510205321878,6.8601,0.545953978965145,0.483338962809268,0.561197021057094,0.537320740268151,0.0626150161558765,0.0238762807889427,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1451,19405,2048:1011,Colon,LS-513,SIDM00677,907795,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.932962595272526,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.117723119292372,0.531711118780367,0.401928128375384,0.129782990404984,8.32731555640948,6.2734,1.35251303061379,9.7461,0.786998347137115,0.799281275924065,0.808971351078664,0.747923224021766,-0.01228292878695,0.0610481270568977,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1452,19405,1510:1011,Colon,LS-513,SIDM00677,907795,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.438395359457188,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.130352562738449,0.249848909512832,0.0857655312167481,0.164083378296084,5.58578367159896,0.938,4.09404491542431,15.0815,0.369807348154838,0.240383459616198,0.380132374056327,0.272377330168717,0.129423888538639,0.10775504388761,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1453,19405,1561:1011,Colon,LS-513,SIDM00677,907795,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.821968435762224,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0826608490510419,0.46845367520186,0.30735693199328,0.161096743208581,7.75534468814107,4.2201,1.92448389888219,11.7994,0.693369491576228,0.638578678962002,0.712728376670177,0.631924648109523,0.0547908126142259,0.0808037285606539,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1454,19405,2171:1011,Colon,LS-513,SIDM00677,907795,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.578559326284305,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0706048595150753,0.329730718271276,0.0948322574512162,0.234898460820059,5.06510409959429,0.6539,4.61472448742897,15.3656,0.488042324326525,0.342283729042812,0.501668472278525,0.336790886997084,0.145758595283713,0.164877585281441,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1455,19405,1025:1011,Colon,LS-513,SIDM00677,907795,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.73506662625289,0.0664950446263123,0.569916866415261,9.67982858702327,16.0195,0.84354758821518,0.867099447692602,0.0516147471698864,0.418926868240485,0.148045686812694,0.270881181427791,5.67335369978599,0.9967,4.00647488723727,15.0228,0.620063679753095,0.456502091720897,0.637375865641145,0.461471397688655,0.163561588032197,0.17590446795249,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1456,19721,1011:1025,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.794447737576824,0.0466427786243916,0.633711848655504,10.3237958113642,25.0324,0.885933202861952,0.892051198840852,0.0461562605471812,0.503450944439992,0.253994819109551,0.249456125330441,7.17651008205781,2.8254,3.14728572930642,22.207,0.703827628657867,0.587628490172393,0.708688056721808,0.58205834560039,0.116199138485474,0.126629711121418,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
1457,19402,1011:1032,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.915927925628808,0.0721101658480534,0.1930972521607,5.5466438226602,0.9129,0.608598265697773,0.618394106859768,0.0716354607793551,0.176863165616173,0.0553628978007714,0.121500267815402,2.37423653932184,0.1013,3.17240728333836,0.8116,0.557432147041851,0.325159279812804,0.566404431517147,0.344139497481012,0.232272867229047,0.222264934036135,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1458,19406,1194:1053,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.929482097228895,0.063918002847933,0.320201529238136,7.18193844543321,2.836,0.746219028221477,0.733009215867958,0.0747053902038199,0.297621588932162,0.256242171964895,0.0413794169672673,6.66723960408089,1.985,0.514698841352321,0.851,0.693597227343406,0.680380811670666,0.681318943253057,0.649452226847379,0.0132164156727408,0.0318667164056777,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1459,19407,1194:1054,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.606560944943108,0.112584031412609,0.506743603974924,9.06514497616925,4.1848,0.75881595626918,0.839556638362106,0.0514249463287895,0.307370879270906,0.118523971754861,0.188846907516045,5.58222344243103,0.3743,3.48292153373822,3.8105,0.460268123472542,0.366419310359214,0.509242267898178,0.376699027510274,0.0938488131133279,0.132543240387905,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1460,19405,1194:1510,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.928178247933959,0.0788038890358887,0.413904443728125,8.15997600990017,5.5863,0.795938016986316,0.792354660925284,0.0445894381127398,0.384177101391651,0.339617351963288,0.0445597494283629,7.6721306596119,3.9836,0.487845350288269,1.6027,0.738772354070388,0.723784877202249,0.735446360919936,0.708915248789352,0.0149874768681392,0.0265311121305839,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1461,19724,1083:1549,Colon,LS-513,SIDM00677,907795,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.94994514033772,0.107421383082734,0.463006440391146,8.64200002144262,3.9012,0.742757506319527,0.818462756519107,0.124148028727314,0.439830717994636,0.322360236414275,0.117470481580361,7.39115859104617,1.6393,1.25084143039645,2.2619,0.705578883577598,0.62709957314857,0.77749471810274,0.709017243077405,0.0784793104290282,0.0684774750253354,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
1462,19725,1011:1561,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.716192672258855,0.0915591756126658,0.287437643559889,6.80758817884553,2.1879,0.658823360711808,0.708260744506956,0.0478707333703624,0.205860734048945,0.0517421865929477,0.154118547455998,2.8354681808185,0.1394,3.97211999802703,2.0485,0.471844463254749,0.277172495294928,0.507251155264483,0.293873616449514,0.19467196795982,0.213377538814968,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
1463,19727,1011:2048,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.739133611968459,0.0674810822544332,0.32270853367909,7.20969467291638,0.0289,0.73577499047608,0.734802425586033,0.12331692114478,0.238524724111271,0.0881431095200936,0.150381614591177,4.17128927033007,0.0035,3.03840540258631,0.0254,0.543836026306643,0.392586305656888,0.54311717090659,0.379389741386245,0.151249720649756,0.163727429520345,True,0.241984047229246,0.0274981859161809,1.32862384943808,36.9343636406378
1464,19406,1194:2171,Colon,LS-513,SIDM00677,907795,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.6010226992753,0.157570981272325,0.10514369791545,3.82884926343641,0.2775,0.465851275599139,0.48672094816622,0.0407641423096621,0.0631937491329306,0.0107425065442235,0.0524512425887071,-0.675104102959119,0.0122,4.50395336639553,0.2653,0.279987191121436,0.0882719894619174,0.292530338060695,0.108078779617693,0.191715201659518,0.184451558443002,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1465,19406,1011:2171,Colon,LS-513,SIDM00677,907795,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.851981721985101,0.157570981272325,0.10514369791545,3.82884926343641,0.2775,0.465851275599139,0.48672094816622,0.0414961975148943,0.0895805088058866,0.0212589511180732,0.0683215576878135,0.148071191919841,0.0216,3.68077807151657,0.2559,0.39689677197391,0.182934422471845,0.414677351544877,0.192079247332364,0.213962349502065,0.222598104212513,True,0.358157203394903,0.0352757689158785,0.96933213054103,50.3959381371787
1466,22638,1372:1025,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.491398715717472,0.0877148835945572,0.787979366653781,12.6493639776738,125.4781,0.916352525749916,0.93580236013754,0.0297569480749001,0.387212048785536,0.41343206879238,-0.0262200200068446,13.6373913111654,248.8822,-0.988027333491582,-123.4041,0.450294454297971,0.478486812725138,0.459852077936967,0.468502990432843,-0.0281923584271671,-0.008650912495876,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1467,22638,1011:1025,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.762517524118791,0.0877148835945572,0.787979366653781,12.6493639776738,125.4781,0.916352525749916,0.93580236013754,0.0942339090352165,0.600848075717535,0.322788800260145,0.278059275457389,8.1405800278549,5.5117,4.5087839498189,119.9664,0.698734859154827,0.5301242189304,0.713565698716598,0.588070453404247,0.168610640224427,0.125495245312351,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1468,22637,1011:1032,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.698335782455466,0.141060094881863,0.244328039907473,5.86127546033281,1.1354,0.59247925669448,0.6308609219496,0.0757142904662361,0.170623012924595,0.0615908173578285,0.109032195566767,2.50665281694858,0.111,3.35462264338423,1.0244,0.413749465312372,0.263177977777416,0.440552755550251,0.275371658988889,0.150571487534957,0.165181096561362,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1469,22637,1564:1032,Colon,SW48,SIDM00837,909751,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.717168041465671,0.141060094881863,0.244328039907473,5.86127546033281,1.1354,0.59247925669448,0.6308609219496,0.0831493319558481,0.175224261855589,0.105834632264519,0.0693896295910694,4.1247846825629,0.3407,1.73649077776991,0.7947,0.424907188132616,0.350055697723929,0.452433291831822,0.364990824695966,0.0748514904086879,0.0874424671358554,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1470,22251,2171:1053,Colon,SW48,SIDM00837,909751,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.137431700850319,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.0438108868346505,0.0645088328643926,0.0296854864959847,0.0348233463684079,5.41642959669898,0.8341,3.24275957756762,7.0619,0.102380935132434,0.0749071444357947,0.109702287362335,0.0825070149872752,0.0274737906966392,0.02719527237506,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1471,22251,1011:1053,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.569152858568797,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.0719543628349542,0.26715369453001,0.0906389445081515,0.176514750021858,4.37486999552089,0.4052,4.2843191787457,7.4908,0.423995348475207,0.30191650982311,0.454315635020854,0.299840965750778,0.122078838652097,0.154474669270077,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1472,22251,1054:1053,Colon,SW48,SIDM00837,909751,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.736249558672805,0.125876477997761,0.469388303173597,8.6591891742666,7.896,0.744958655819447,0.798231315508605,0.159372407584313,0.345586931057738,0.128830527502717,0.216756403555021,4.68921689156867,0.5039,3.96997228269793,7.3921,0.548475481576554,0.370407886494294,0.587697453762023,0.404365067183264,0.17806759508226,0.18333238657876,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1473,22638,1011:1194,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.762517524118791,0.0800358643879309,0.68429328461312,11.1504222695113,44.3958,0.896645046897748,0.898032675947866,0.183861019742211,0.521785621154312,0.270050559404303,0.251735061750009,7.32981127177522,3.1421,3.82061099773605,41.2537,0.683707561173848,0.559933107213934,0.684765652641539,0.552824635880559,0.123774453959913,0.13194101676098,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1474,22248,2171:1372,Colon,SW48,SIDM00837,909751,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.12584462493961,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.0460775205567511,0.0280847505770218,0.0199607924688013,0.0081239581082204,4.36160651050321,0.0402,1.17111249840658,0.0502,0.0682852406389791,0.018769326828996,0.0765629580573126,0.0661781837360914,0.049515913809983,0.0103847743212212,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1475,22248,1032:1372,Colon,SW48,SIDM00837,909751,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.701039659132728,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.161890470697879,0.156451052087374,0.0751927561321656,0.0812582959552079,3.10934124151392,0.0169,2.42337776739588,0.0735,0.380394965969489,0.294281438744526,0.426507449519186,0.306001535161877,0.086113527224963,0.120505914357309,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1476,22248,1561:1372,Colon,SW48,SIDM00837,909751,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.366399528394851,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.0642390212612208,0.0817693991415667,0.0292561485094711,0.0525132506320956,2.20486561269932,0.009,3.32785339621048,0.0814,0.198814053269713,0.105981746229688,0.222914818476957,0.136897586077558,0.0928323070400257,0.0860172323993996,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1477,22248,1549:1372,Colon,SW48,SIDM00837,909751,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.624066861889804,0.179607274694157,0.223170044731739,5.53271900890979,0.0904,0.542615472625449,0.608392754907515,0.104648887428312,0.139273029483543,0.0494541425994861,0.0898188868840571,2.18198207397747,0.0089,3.35073693493232,0.0815,0.338628335214217,0.223677752759605,0.379677757351626,0.232198914536266,0.114950582454612,0.147478842815359,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1478,22250,1011:1510,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.832026604332322,0.0852583515543169,0.276242603149647,6.32250615268692,1.5631,0.649111841272549,0.661648654362816,0.0475725216722615,0.229841195070522,0.222470389080481,0.007370805990041,6.19807865096953,1.434,0.124427501717393,0.1291,0.5400783211259,0.546652818231174,0.550509283150544,0.543678455263381,-0.0065744971052736,0.0068308278871623,True,0.180694267683178,0.0410040507259235,1.61572689118342,30.5497392311884
1479,22641,1011:1549,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.656073608811241,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.10871067976924,0.286057892937994,0.0890519795894373,0.197005913348557,3.85399177773557,0.1412,4.43060846040021,2.904,0.454820055069639,0.292343870941045,0.511035952305175,0.321179143733364,0.162476184128594,0.189856808571812,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1480,22641,1372:1549,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.670051033940997,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.1034931881066,0.292152259069504,0.0800653924984369,0.212086866571067,3.44791779706514,0.1066,4.83668244107063,2.9386,0.464509841675697,0.287285039111549,0.521923399484923,0.30858251539316,0.177224802564147,0.213340884091763,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1481,22641,1564:1549,Colon,SW48,SIDM00837,909751,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.764259851829943,0.156294998692666,0.436014936580533,8.28460023813578,3.0452,0.693245466608146,0.778930817276946,0.107737876033876,0.33322871082668,0.202178546748,0.13105016407868,6.15760909526897,0.6971,2.1269911428668,2.3481,0.529819677591721,0.446033293151086,0.595305550997855,0.497344136917627,0.0837863844406347,0.0979614140802277,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1482,22642,1372:1561,Colon,SW48,SIDM00837,909751,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.617049734726854,0.179653513571102,0.172381613765074,4.63884483971986,0.4866,0.502312319483829,0.545641374896892,0.0613731929729481,0.106368029045526,0.0242304070160254,0.0821376220295006,0.112014560887577,0.0211,4.52683027883228,0.4655,0.309951683487528,0.14669680039486,0.336687865636123,0.149741555293017,0.163254883092668,0.186946310343106,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1483,22642,1011:1561,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.709388436080151,0.179653513571102,0.172381613765074,4.63884483971986,0.4866,0.502312319483829,0.545641374896892,0.0819447287311861,0.122285523397778,0.0279846940280506,0.0943008293697278,0.125313583172253,0.0213,4.51353125654761,0.4653,0.356334550742427,0.122718904300859,0.387071681598729,0.172677930250277,0.233615646441567,0.214393751348452,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1484,22642,1011:1564,Colon,SW48,SIDM00837,909751,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.709388436080151,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.0645956983995738,0.16869392536225,0.0553389978658734,0.113354927496377,2.13457265941124,0.0429,3.62753738677056,0.4871,0.401785923493032,0.260256180479575,0.442745161998687,0.261663458061428,0.141529743013457,0.18108170393726,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1485,22642,1054:1564,Colon,SW48,SIDM00837,909751,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.783584593701381,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.148673090688627,0.186337913393805,0.0576058704824151,0.12873204291139,1.95613043078535,0.0379,3.80597961539644,0.4921,0.443809404837338,0.289368758761896,0.489052640602667,0.27961188238485,0.154440646075442,0.209440758217817,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1486,22642,1053:1564,Colon,SW48,SIDM00837,909751,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.674857698363695,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.0545881770841811,0.160482449963482,0.0525899381640125,0.107892511799469,2.13140197024844,0.0428,3.63070807593336,0.4872,0.382228282521374,0.241709815387907,0.421193757596489,0.248781595127674,0.140518467133467,0.172412162468815,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1487,22642,1083:1564,Colon,SW48,SIDM00837,909751,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.857791448577171,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.105722134711013,0.203984445252931,0.074023831499602,0.129960613753329,2.44030022599423,0.053,3.32180982018756,0.477,0.485838944930396,0.335872398643513,0.535366795602062,0.334322021488879,0.149966546286883,0.201044774113183,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1488,22642,1561:1564,Colon,SW48,SIDM00837,909751,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.453970088974884,0.152712097437308,0.237801910465863,5.7621100461818,0.53,0.566383525664966,0.624122327740713,0.046360147931788,0.107954954452585,0.0452312747572516,0.0627236796953334,2.88073493434235,0.0719,2.88137511183945,0.4581,0.257121179540033,0.171314392311489,0.283332868655663,0.190844322839982,0.085806787228544,0.0924885458156807,True,0.206902700647126,0.0392166777439462,1.47333149252402,33.3746269959984
1489,18369,1032:1011,Colon,CW-2,SIDM00282,910554,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.624005686737914,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0628914103342492,0.423485412370392,0.250611772643474,0.172873639726917,7.73307085735443,4.1554,3.6423799634928,47.7344,0.568824555447222,0.457597212091483,0.551140939366051,0.455435061782982,0.11122734335574,0.0957058775830691,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1490,18369,2171:1011,Colon,CW-2,SIDM00282,910554,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.873699165851879,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0975721782809439,0.592941473775145,0.552657353940924,0.0402841198342208,10.7258690281297,33.0779,0.649581792717536,18.8119,0.796437516793079,0.788518134146926,0.771677869649265,0.753398773734202,0.0079193826461522,0.0182790959150624,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1491,18369,1549:1011,Colon,CW-2,SIDM00282,910554,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.602493468996483,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.0891104601159191,0.408886009520625,0.266471884876899,0.142414124643726,8.26313520012046,6.0004,3.11231562072677,45.8894,0.549214673752998,0.487767667703715,0.53214068961538,0.456419492408407,0.0614470060492835,0.0757211972069733,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1492,18369,2048:1011,Colon,CW-2,SIDM00282,910554,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.917001378952603,0.112356009725444,0.678656334983462,11.3754508208472,51.8898,0.91156950575377,0.883230635680943,0.160834768797555,0.622328795014755,0.5801233618661,0.0422054331486551,10.726990814724,33.1037,0.648460006123267,18.7861,0.83591049378735,0.850612684280284,0.809923710852609,0.790773957602688,-0.0147021904929338,0.0191497532499205,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1493,18988,1032:1564,Colon,CW-2,SIDM00282,910554,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.512584924028395,0.085771330527585,0.712284698868183,11.8803508610102,36.8165,0.880249032471207,0.89766524546352,0.078522154892884,0.365106398255936,0.318311615781065,0.046794782474871,10.5688982218553,14.8339,1.31145263915487,21.9826,0.451202383435322,0.393113135989953,0.460129671648849,0.439204483809655,0.0580892474453694,0.0209251878391946,True,0.337310389856464,0.0492710106596731,1.01905549149413,47.8763510471682
1494,18370,1549:2171,Colon,CW-2,SIDM00282,910554,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.616186940829543,0.100504973154953,0.698139206783558,11.6641157574185,63.3839,0.846314107528984,0.891673151703198,0.0792394037747693,0.430184262101124,0.290087188964657,0.140097073136468,8.62817263979674,7.728,3.03594311762179,55.6559,0.521487700899169,0.425087520923421,0.549437351567831,0.47792255908818,0.0964001799757478,0.0715147924796505,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1495,18370,1011:2171,Colon,CW-2,SIDM00282,910554,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.961022710524327,0.100504973154953,0.698139206783558,11.6641157574185,63.3839,0.846314107528984,0.891673151703198,0.125169295260474,0.670927632826439,0.461135467406184,0.209792165420255,8.7436117600835,8.3718,2.92050399733504,55.0121,0.813327077572481,0.66411622047534,0.856918149151577,0.75070011305637,0.149210857097141,0.106218036095207,True,0.561548075640563,0.06189365507892,0.529368520167496,89.691056552523
1496,19433,1372:1011,Colon,SNU-C1,SIDM01197,910905,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.434088624863765,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0742009654846761,0.210126251803832,0.0777062689702661,0.132419982833566,4.4748380856827,0.4343,4.33569741528258,8.335,0.319306110116047,0.210237905662386,0.345176796056867,0.231180171768974,0.109068204453661,0.113996624287892,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
1497,19433,1053:1011,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.649974478007745,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.050600788022557,0.314628610401351,0.138231699560372,0.17639691084098,5.11117687484463,0.6751,3.69935862612065,8.0942,0.478107027827545,0.360241126179334,0.516844015223527,0.374269786947688,0.117865901648211,0.142574228275839,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
1498,19433,1510:1011,Colon,SNU-C1,SIDM01197,910905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.381283089703728,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0485678672953193,0.184565044847174,0.059414881525644,0.12515016332153,3.98006606281994,0.3082,4.83046943814534,8.4611,0.280463511948819,0.151860908780218,0.303187109166706,0.190119717786885,0.128602603168601,0.113067391379821,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
1499,19433,1561:1011,Colon,SNU-C1,SIDM01197,910905,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.8502692835177,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.189945426714931,0.411583919356506,0.456207037991638,-0.0446231186351325,9.43507900015,13.5198,-0.624543499184723,-4.7505,0.625439511473957,0.659844699302993,0.676113609662814,0.70041089065102,-0.0344051878290359,-0.0242972809882062,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
1500,19433,2171:1011,Colon,SNU-C1,SIDM01197,910905,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.518919566047193,0.13237869829638,0.484063022544713,8.81053550096528,8.7693,0.735578155765446,0.7951758610703,0.0461286897980123,0.251189773598395,0.0612747846350385,0.189914988963357,3.02596985113775,0.1591,5.78456564982753,8.6102,0.3817058973836,0.188335374116186,0.412632312757803,0.224921181908394,0.193370523267413,0.187711130849409,True,0.455853436322891,0.0447323888560769,0.74813690467937,65.2048763158901
1501,20289,1011:1194,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.979339632657395,0.0953936333137623,0.616677011696618,10.412653200026,26.6226,0.908004185170224,0.862685418985531,0.12859185957137,0.603936238103226,0.402494599812176,0.20144163829105,7.93073113270701,4.7656,2.481922067319,21.857,0.889244485155984,0.790564068221667,0.84486202132818,0.734666593622728,0.0986804169343174,0.110195427705452,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1502,20289,1053:1194,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.450637544281325,0.0953936333137623,0.616677011696618,10.412653200026,26.6226,0.908004185170224,0.862685418985531,0.0586214470575143,0.27789781416571,0.199108620711635,0.0787891934540748,8.30563572575404,6.1798,2.10701747427196,20.4428,0.409180776202275,0.350271137716726,0.388758438698945,0.346993356245689,0.0589096384855488,0.0417650824532562,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1503,20292,1053:1549,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.431391709882768,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0282633901549464,0.403532342726786,0.330006850270294,0.0735254924564914,12.5064411795638,56.8217,4.43552282699484,1172.7091,0.419370618544791,0.401791813122465,0.423140320984899,0.398407266156099,0.0175788054223264,0.0247330548288,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1504,20292,1510:1549,Colon,SNU-C1,SIDM01197,910905,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.357692592779835,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0942447582638407,0.334592730072838,0.199239092155122,0.135353637917716,9.68050986010538,8.0135,7.26145414645328,1221.5173,0.347725189071747,0.231459969339787,0.350850874171669,0.298384241842078,0.11626521973196,0.0524666323295917,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1505,20292,2171:1549,Colon,SNU-C1,SIDM01197,910905,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.436936206154013,0.0542745432699108,0.935419790140257,16.9419640065587,1229.5308,0.972134162380534,0.980872629888713,0.0412842228505176,0.408718774265267,0.340532687435486,0.0681860868297812,12.7494126810383,67.2443,4.19255132552039,1162.2865,0.42476061278326,0.395367109109839,0.428578765623884,0.405838873855969,0.0293935036734213,0.0227398917679147,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1506,20293,1011:1564,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.934422454373305,0.159650447563463,0.131181782330276,3.38301966052003,0.1019,0.444839041151052,0.457720152615689,0.10717533313537,0.122579203014121,0.030271799538257,0.0923074034758639,-1.09211299880628,0.0046,4.47513265932631,0.0973,0.415667588633434,0.157926879799375,0.427703988423276,0.179021562420424,0.257740708834059,0.248682426002851,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1507,20295,1011:2048,Colon,SNU-C1,SIDM01197,910905,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.925460263070712,0.0909027382626263,0.467889580258233,8.61786320446855,0.0767,0.785658801089597,0.785785155959856,0.116775813227976,0.433013214033829,0.263983399905224,0.169029814128606,6.2707966452579,0.0151,2.34706655921065,0.0616,0.727096000740198,0.636865023982966,0.727212937151669,0.603367205651235,0.0902309767572319,0.123845731500434,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1508,20295,1053:2048,Colon,SNU-C1,SIDM01197,910905,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.244969459827175,0.0909027382626263,0.467889580258233,8.61786320446855,0.0767,0.785658801089597,0.785785155959856,0.0274602431578441,0.114618657734623,0.0592445358778744,0.0553741218567488,5.60526120944083,0.0095,3.01260199502773,0.0672,0.192462412111385,0.142349005041182,0.192493365195699,0.149139332252528,0.0501134070702024,0.0433540329431704,True,0.21036747512769,0.0289222261476665,1.36945750665856,35.3346173802413
1509,19644,2048:1011,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.968431959201936,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.107850998330562,0.692889670843299,0.492611230476004,0.200278440367295,9.08169816917793,10.5826,2.09068405419252,34.4941,0.896635557173715,0.864815141860603,0.893344116942205,0.817352841583338,0.0318204153131121,0.0759912753588676,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1510,19644,2171:1011,Colon,COLO-320-HSR,SIDM00842,910569,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.468680801513755,0.115260297087967,0.715475841394468,11.1723822233704,45.0767,0.925863245893509,0.922464514366493,0.0373968814536269,0.335329790808487,0.191619431735372,0.143710359073116,8.13133949895472,5.4766,3.04104272441573,39.6001,0.433934328177496,0.357211143995385,0.432341407961284,0.372191689812395,0.076723184182111,0.0601497181488893,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1511,19641,1053:1032,Colon,COLO-320-HSR,SIDM00842,910569,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.939343201384596,0.164218664960135,0.529013520018838,9.27371135498524,12.0891,0.890887125384794,0.85298289308733,0.103437212334052,0.496925253470229,0.343359531599358,0.153565721870871,7.70091158952432,4.0638,1.57279976546092,8.0253,0.836848764431272,0.753858312547936,0.801243681518947,0.722073094055391,0.082990451883336,0.0791705874635559,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1512,19641,2048:1032,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.953254447333269,0.164218664960135,0.529013520018838,9.27371135498524,12.0891,0.890887125384794,0.85298289308733,0.168228639641484,0.504284490657384,0.349706446445931,0.154578044211453,7.71434848730838,4.1019,1.55936286767686,7.9872,0.849242114345006,0.804272132362707,0.813109736334695,0.733547479197843,0.0449699819822991,0.0795622571368519,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1513,19645,1194:1053,Colon,COLO-320-HSR,SIDM00842,910569,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1.0,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.0417804182841801,0.684460480977838,0.603983643765829,0.0804768372120088,9.99437674385474,19.9222,0.82985434311745,15.4896,0.913798248993331,0.891283665785484,0.912236823530067,0.883421555346464,0.0225145832078474,0.0288152681836028,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1514,19645,2048:1053,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93705273775662,0.0773018639766423,0.684460480977838,10.8242310869722,35.4118,0.913798248993331,0.912236823530067,0.0405794655308893,0.641375567586496,0.615630666336245,0.0257449012502515,10.531036336773,28.8993,0.293194750199198,6.5125,0.856277150976407,0.876308412501774,0.854814012971252,0.845962215097033,-0.0200312615253677,0.008851797874219,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1515,19642,2048:1372,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.950468500796917,0.0454428727826166,0.940179043382936,15.4896429973718,89.8622,0.971092930918482,0.985682897954008,0.038639427330528,0.893610565844858,0.872113628639483,0.0214969372053755,14.6767804682522,51.1542,0.812862529119549,38.708,0.922993242184574,0.950468500796916,0.936860546279506,0.93149223674739,-0.0274752586123429,0.0053683095321166,True,0.23045812477545,0.0284234415112103,1.38021306343624,35.6205725130981
1516,19499,2048:1549,Colon,COLO-320-HSR,SIDM00842,910569,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.869480343586352,0.0418115774838794,0.95410762279357,16.1487179028978,709.4937,0.980058336851687,0.989095009580064,0.0922245256452858,0.829577823684911,0.445107599776583,0.384470223908328,9.11238228125305,5.4051,7.03633562164478,704.0886,0.852141459460474,0.751324100960703,0.85999866876922,0.735108337957009,0.100817358499771,0.124890330812211,True,0.262882368562616,0.0363525112258181,1.26901169982246,38.7752195755996
1517,18411,2048:1011,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.780043770082816,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.141960512511925,0.345096904989082,0.134077823022683,0.211019081966398,6.20581811446049,1.4417,2.38296331356414,6.0782,0.680426314414387,0.576288092766004,0.667621755762306,0.538323778643226,0.104138221648383,0.12929797711908,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1518,18411,1083:1011,Colon,HCT-116,SIDM00783,905936,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.590102277815777,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0852067125273722,0.261065439545285,0.0527067393284055,0.20835870021688,4.87358870202885,0.5726,3.71519272599578,6.9473,0.514741779142848,0.327178342789377,0.505055144216943,0.340569320626644,0.187563436353471,0.164485823590299,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1519,18411,2171:1011,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.813813902106574,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0907698591597043,0.360037051285275,0.120407768861939,0.239629282423336,5.88877374368249,1.1573,2.70000768434214,6.3626,0.709883746614343,0.545437713130041,0.696524845176932,0.540428246164489,0.164446033484302,0.156096599012443,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1520,18411,1564:1011,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.915468750768867,0.1509399829445,0.442407103581435,8.58878142802463,7.5199,0.872292479615788,0.855877299925651,0.0982459738350943,0.405009878446969,0.270400879817555,0.134608998629415,7.45490014721957,3.4267,1.13388128080505,4.0932,0.798556506618943,0.714471363687808,0.783528922574367,0.718456540481903,0.084085142931135,0.0650723820924634,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1521,18412,1054:1053,Colon,HCT-116,SIDM00783,905936,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.75216016691743,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0545632180926884,0.552783811947588,0.321597805585166,0.231186006362422,8.48145905555863,6.9808,2.33077947102162,28.1379,0.700543256531283,0.612358411362494,0.711166665833824,0.639233307422558,0.0881848451687891,0.0719333584112661,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1522,18412,1510:1053,Colon,HCT-116,SIDM00783,905936,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.790144439796714,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0472578907219444,0.580699530008437,0.363020564007749,0.217678966000688,8.71101753392816,8.1848,2.10122099265209,26.9339,0.735920862778209,0.666406966610096,0.747080756855674,0.681527861357161,0.069513896168113,0.0655528954985138,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1523,18412,1372:1053,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.872591456079446,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.0998238262540726,0.641292177623977,0.355052030956862,0.286240146667114,8.33035060071221,6.2866,2.48188792586804,28.8321,0.812709961454758,0.683435497909552,0.825034326130732,0.733964923163162,0.129274463545206,0.0910694029675702,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1524,18412,1564:1053,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.82984578796036,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.123490349050999,0.609877175332705,0.275601932183838,0.334275243148867,7.75843374469255,4.2291,3.0538047818877,30.8896,0.772897710203175,0.601201701329495,0.784618340796552,0.668353550493781,0.171696008873679,0.116264790302771,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1525,18412,2048:1053,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.763827307303993,0.0522753789515214,0.73492832545634,10.8122385265803,35.1187,0.931375107780982,0.945498973640669,0.145136757280737,0.561358323894749,0.282698800819525,0.278659523075224,8.05502262778468,5.1944,2.75721589879557,29.9243,0.711409740666314,0.547278583513103,0.722197935094641,0.62973629086204,0.164131157153211,0.0924616442326017,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1526,18413,1372:1054,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.371459444642961,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0446680029089402,0.29104811878133,0.195010948625271,0.0960371701560588,9.17775745016059,4.5245,2.10818648602703,14.9828,0.351433810544266,0.306765915492431,0.355421330717146,0.329136925861411,0.0446678950518351,0.0262844048557354,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1527,18413,1053:1054,Colon,HCT-116,SIDM00783,905936,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.953111168427668,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0869675320586447,0.746787345323742,0.425676443215342,0.3211109021084,8.61908638101445,3.0718,2.66685755517317,16.4355,0.901728289920817,0.774657431323329,0.911959689514803,0.817337752795453,0.127070858597487,0.0946219367193507,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1528,18413,1561:1054,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.826115175379317,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.0903259730089374,0.64728268767527,0.379411667464597,0.267871020210673,8.70984700004768,3.2713,2.57609693613993,16.236,0.781578738187832,0.64049388320526,0.790446868947338,0.712502035931051,0.141084854982572,0.0779448330162866,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1529,18413,2171:1054,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.808828496061607,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.10125606348966,0.633738125629656,0.381354029797805,0.252384095831852,8.79711483762484,3.4752,2.48882909856278,16.0321,0.765223995639506,0.653129589304378,0.773906558409032,0.701337295947006,0.112094406335128,0.0725692624620266,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1530,18413,1025:1054,Colon,HCT-116,SIDM00783,905936,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.941923833172031,0.0513208846983554,0.783525962197783,11.2859439361876,19.5073,0.946089312339486,0.956824051300593,0.176651893962137,0.73802177770314,0.383350062815053,0.354671714888087,8.33103165442196,2.5158,2.95491228176565,16.9915,0.8911440716019,0.671000914694032,0.901255378072247,0.79232034025669,0.220143156907868,0.108935037815557,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1531,18409,2171:1372,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.811329651914799,0.100503309005755,0.0563557051874511,3.99201406949641,0.0311,0.495971890734475,0.49929180020899,0.067265004829162,0.0457230546731477,0.0070557449770081,0.0386673096961396,0.583478759987784,0.0029,3.40853530950862,0.0282,0.402396701469126,0.197485140506193,0.405090242467473,0.176775359552415,0.204911560962933,0.228314882915058,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1532,18409,1561:1372,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.780018926402389,0.100503309005755,0.0563557051874511,3.99201406949641,0.0311,0.495971890734475,0.49929180020899,0.0331119608334571,0.0439585166569652,0.0057171835560626,0.0382413331009025,0.277128627952774,0.0024,3.71488544154363,0.0287,0.386867461736468,0.149921713343649,0.389457053960532,0.1536343623022,0.236945748392819,0.235822691658333,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1533,18411,1564:1510,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.915468750768867,0.0473209471209297,0.784951548347036,11.3009161135202,49.2771,0.945652646933634,0.957145611055651,0.134548484735958,0.718598613379349,0.364993079759838,0.353605533619511,8.26978167687317,6.0281,3.03113443664703,43.249,0.865715447349606,0.672602979022837,0.876236896857021,0.766748368571003,0.193112468326769,0.109488528286017,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1534,18995,2171:1549,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.774676168171953,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.086101766127863,0.705951184940965,0.382194933167909,0.323756251773055,8.95280385151022,4.8391,4.18683304746929,83.2911,0.755539074598563,0.613020364609284,0.761935196436756,0.677919782879039,0.142518709989279,0.084015413557717,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1535,18995,1372:1549,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.770026868977011,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.0700878289028539,0.701714345845269,0.446855729568678,0.254858616276591,9.57587607936788,7.4529,3.56376081961163,80.6773,0.75100462865121,0.648396219174591,0.757362363502253,0.695914838875851,0.102608409476619,0.0614475246264018,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1536,18995,1564:1549,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.917110110942852,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.104148415306519,0.8357491764194,0.756008791897134,0.0797403845222654,11.7474319518864,33.576,1.39220494709314,54.5542,0.894454422370903,0.885734316806845,0.902026551538721,0.885751527496392,0.008720105564058,0.0162750240423288,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1537,18995,2048:1549,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.77959635679445,0.0419698602173015,0.911285533162634,13.1396368989795,88.1302,0.975296653802391,0.983553164201162,0.0611968091166629,0.710434881653077,0.66402502861097,0.0464098530421074,12.1071391402284,43.0836,1.03249775875108,45.0466,0.760337718098161,0.744735300511718,0.766774463524879,0.757453133640339,0.0156024175864434,0.0093213298845399,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1538,18996,1372:1561,Colon,HCT-116,SIDM00783,905936,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.323355127084174,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.0543197981004433,0.154481859758902,0.0054502483682439,0.149031611390658,1.77414791482413,0.0668,7.06756244670923,8.8941,0.258582628454967,0.0941714066363454,0.281133962780116,0.0996763390411838,0.164411221818622,0.181457623738932,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1539,18996,1564:1561,Colon,HCT-116,SIDM00783,905936,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.401051759516892,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.0548723442964858,0.191601173076874,0.0049321419705534,0.186669031106321,1.20573910237263,0.045,7.63597125916073,8.9159,0.32071555214701,0.0973062445408173,0.348685581235803,0.105674982102795,0.223409307606193,0.243010599133008,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1540,18996,2048:1561,Colon,HCT-116,SIDM00783,905936,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.798728893819998,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.129946317759396,0.381590129938977,0.172611682211417,0.208978447727559,6.71021831322105,2.0451,2.13149204831231,6.9158,0.638732463126027,0.505217251715725,0.694437169224601,0.583117715683075,0.133515211410302,0.111319453541526,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1541,18996,1054:1561,Colon,HCT-116,SIDM00783,905936,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.770855906101128,0.0957718630068749,0.477746745975327,8.84171036153336,8.9609,0.799686186474646,0.869427880470666,0.150104132560651,0.368273900755676,0.0702459878726156,0.298027912883061,4.9127613137378,0.5883,3.92894904779556,8.3726,0.616442819871469,0.409508351028924,0.670203616589799,0.447530223415182,0.206934468842545,0.222673393174617,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1542,18996,2171:1564,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.856353249382486,0.0587007476391837,0.0970114765150405,5.03550122374063,0.3203,0.586939338953733,0.591271056362451,0.102235586541832,0.0830760931410477,0.0091010989987717,0.0739749941422759,0.943331897138466,0.0188,4.09216932660216,0.3015,0.502627410103437,0.230744971460605,0.5063368903818,0.208765357200924,0.271882438642832,0.297571533180876,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1543,18996,1561:1564,Colon,HCT-116,SIDM00783,905936,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.755824984152481,0.0587007476391837,0.0970114765150405,5.03550122374063,0.3203,0.586939338953733,0.591271056362451,0.0415264377002455,0.0733236976995892,0.0131073695510467,0.0602163281485425,1.82559453927498,0.0346,3.20990668446564,0.2857,0.443623416563173,0.221350160123867,0.44689743680497,0.236143379796124,0.222273256439306,0.210754057008846,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1544,18998,2171:2048,Colon,HCT-116,SIDM00783,905936,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.862391913296365,0.128647277536441,0.0973102650650162,5.04155427647983,0.0064,0.603650458275944,0.591797962562243,0.143834764046195,0.0839195856727958,0.0137652622187796,0.0701543234540162,1.67573188846417,0.0006,3.36582238801567,0.0058,0.520583273674819,0.307176371046556,0.510361777218944,0.258996495908716,0.213406902628263,0.251365281310228,True,0.179796884489869,0.0327326016472857,1.59080944722518,30.9116686924603
1545,18412,1011:2171,Colon,HCT-116,SIDM00783,905936,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.948993282517246,0.0971622248504556,0.29658626285767,7.46528339556575,3.4515,0.738323092230323,0.785518548221426,0.145774647959137,0.281458371138823,0.0712248323013348,0.210233538837488,4.5367388854421,0.4533,2.92854451012365,2.9982,0.700663654853937,0.520229430022712,0.745451825554833,0.519593865657451,0.180434224831225,0.225857959897381,True,0.198437961774151,0.0472092711920723,1.46204940137925,33.3861560099397
1546,21228,1083:1053,Colon,LoVo,SIDM00839,907790,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.751397082081143,0.0979860228766124,0.142539248454415,4.79085877685431,0.5407,0.560690424078551,0.56208452595919,0.127626617993685,0.107103575370686,0.0320272405097974,0.075076334860889,1.70047649586393,0.0635,3.09038228099038,0.4772,0.421301148603462,0.265972693208746,0.422348672688698,0.243669656724412,0.155328455394716,0.178679015964286,True,0.247728507760508,0.0639012483496555,1.30316855966593,37.6134756524681
1547,18383,1032:1011,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.897219874968032,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.123702201144259,0.368425030634611,0.360943378931478,0.0074816517031333,8.12483841678383,5.4519,0.0764036024485719,0.2965,0.73978006441133,0.742545677626976,0.723764185084834,0.719802265099685,-0.0027656132156458,0.0039619199851482,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1548,18383,1083:1011,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.998645134964774,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0909989558874854,0.410073243702511,0.267385970161318,0.142687273541193,6.7761708474447,2.1407,1.4250711717877,3.6077,0.823407709614797,0.740086499225474,0.805581332360104,0.714225491407425,0.0833212103893234,0.0913558409526792,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1549,18383,1372:1011,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.535982142071991,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0464088879659497,0.220090127985087,0.0558971656352467,0.16419296234984,4.24664321376147,0.3708,3.95459880547093,5.3776,0.441930584294589,0.266753642746613,0.432363001645031,0.278713241795141,0.175176941547976,0.15364975984989,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1550,18383,1564:1011,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.633646652105381,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0310286565681239,0.260194065832259,0.0771371928254723,0.183056873006787,4.63202858219689,0.4843,3.56921343703552,5.2641,0.522457397775817,0.336238445004764,0.511146448699795,0.349241533882585,0.186218952771054,0.16190491481721,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1551,18383,1053:1011,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.992418721016472,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.161372906172771,0.407516493887168,0.273574040662756,0.133942453224412,6.86459071973652,2.276,1.33665129949588,3.4724,0.818273876715821,0.773342223133625,0.800558644451576,0.715915332429305,0.0449316535821968,0.0846433120222705,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1552,18383,2048:1011,Colon,LS-411N,SIDM00660,907794,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.979965893119869,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.113672855122353,0.402402994256481,0.202731988848948,0.199671005407533,6.02953754568391,1.2759,2.17170447354849,4.4725,0.808006210917869,0.674541339883102,0.790513268634519,0.647489069131864,0.133464871034767,0.143024199502655,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1553,18383,1510:1011,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.726647380351003,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0551531597102115,0.298382916869643,0.0808020637461196,0.217580853123524,4.40555324104793,0.4139,3.79568877818448,5.3345,0.59913880737377,0.385034769127644,0.586167742998907,0.387211280981379,0.214104038246126,0.198956462017528,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1554,18383,1194:1011,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.879196933553774,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.117338434477336,0.361024277566239,0.115558503090216,0.245465774476023,4.8260600842146,0.554,3.3751819350178,5.1944,0.724919701715067,0.495932217403212,0.70922554202815,0.498291273310636,0.228987484311855,0.210934268717515,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1555,18383,2171:1011,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.768679291706114,0.185294466723005,0.410629591378298,8.2012420192324,5.7484,0.824524829476932,0.806674267119441,0.0618266938987215,0.315642463454241,0.104690008866729,0.210952454587513,4.91680850563266,0.59,3.28443351359974,5.1584,0.633795161916432,0.444245988371097,0.62007380428692,0.441239219464799,0.189549173545335,0.178834584822121,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1556,18380,1011:1032,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.91061779529176,0.0795425216027764,0.430999553099844,8.38600755302356,6.5339,0.847566833603077,0.817104190589818,0.137716384547401,0.392475862815514,0.163218992249298,0.229256870566216,5.63686055009509,0.9718,2.74914700292847,5.5621,0.771809441378051,0.611662891993127,0.744069616558558,0.57436143542976,0.160146549384924,0.169708181128798,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1557,18384,2171:1053,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.794618064779359,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.136530516152084,0.683392546498515,0.127879390185322,0.555513156313193,5.34994044782289,0.7966,7.66306477335755,160.6522,0.770857615642329,0.426367297473562,0.768442300626782,0.483419639087113,0.344490318168767,0.285022661539669,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1558,18384,1054:1053,Colon,LS-411N,SIDM00660,907794,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.915821839318131,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.100115425909442,0.787630997395403,0.410665863384192,0.376965134011211,8.54225381125922,7.2812,4.47075140992123,154.1676,0.888437188507629,0.680471956734611,0.88565346342244,0.756144396671461,0.207965231773018,0.129509066750978,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1559,18384,1083:1053,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.987600030117075,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0501177772462687,0.849362139396016,0.730170352844555,0.119191786551461,11.3044127588841,49.3966,1.70859246229636,112.0522,0.958069087739316,0.937564996939954,0.955067186212249,0.922506739506655,0.0205040907993622,0.0325604467055938,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1560,18384,1510:1053,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.710625431746139,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.125735044719038,0.611156661209869,0.29759988662794,0.313556774581929,8.2755198463329,6.0522,4.73748537484754,155.3966,0.689376507042706,0.493059133850112,0.687216495394592,0.576253082914485,0.196317373192594,0.110963412480107,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1561,18384,1372:1053,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.856313684404275,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.140510617771027,0.736452410692494,0.41300796050818,0.323444450184314,8.84351951615457,8.9721,4.16948570502587,152.4767,0.830708429948753,0.614940799428272,0.82810558539785,0.720487188236353,0.215767630520481,0.107618397161497,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1562,18384,1032:1053,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.903607397083856,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0582645998364023,0.77712625410737,0.735574580407,0.0415516737003706,12.263641611602,96.0404,0.749363609578486,65.4084,0.876587979139693,0.892248830416538,0.873841380980058,0.863007818782527,-0.0156608512768445,0.0108335621975313,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1563,18384,1564:1053,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.940394475392494,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.0762366087311923,0.808764114153456,0.618896751347898,0.189867362805557,10.4476980617768,27.2772,2.5653071594036,134.1716,0.912275060428638,0.827064074885894,0.909416644546055,0.854599629205438,0.0852109855427433,0.0548170153406169,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1564,18384,1561:1053,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.993219513913982,0.0578222623761846,0.860026441367492,13.0130052211804,161.4488,0.970098277159572,0.967058684778523,0.1320500881766,0.854195044048192,0.304505421770965,0.549689622277227,7.19600877917534,2.8638,5.8169964420051,158.585,0.963520539289221,0.660090160757826,0.96050155682202,0.738983884110645,0.303430378531395,0.221517672711375,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1565,18385,1372:1054,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.540765394510602,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.095052756658326,0.486878130584842,0.243716832565797,0.243161298019045,8.56258672230926,2.9538,5.30277163985969,113.6409,0.507996254376356,0.367125432413401,0.528361424594394,0.447071470689856,0.140870821962956,0.0812899539045387,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1566,18385,1053:1054,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.9884358630575,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.12816192661692,0.889938243263485,0.495109828075968,0.394828415187517,9.00797806604015,4.0222,4.85738029612879,112.5725,0.92853892135405,0.78211199686953,0.96576331626748,0.839736443355058,0.146426924484519,0.126026872912422,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1567,18385,1510:1054,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.717451671732315,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.0922204169606624,0.645957622776749,0.498358827978163,0.147598794798586,10.8165627465583,14.0896,3.0487956156106,102.5051,0.673975749254284,0.578156016279364,0.700994906852687,0.660419703730072,0.0958197329749202,0.0405752031226154,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1568,18385,1561:1054,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.948810691011271,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.0358989436937446,0.854261719052037,0.802456955671164,0.051804763380873,12.7613335051584,54.2418,1.10402485701055,62.3529,0.891314943668273,0.919783811767708,0.927047058598863,0.914089598472668,-0.0284688680994348,0.0129574601261946,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1569,18385,2171:1054,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.812762035165602,0.0834711517224884,0.900350014122985,13.8653583621689,116.5947,0.939402298174236,0.977062197318612,0.12140394826746,0.731770309839976,0.436030597763618,0.295739712076358,9.32311617384418,5.0041,4.54224218832477,111.5906,0.763510523703336,0.597395961057184,0.79411905997605,0.702562929053731,0.166114562646152,0.0915561309223187,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1570,18381,2171:1372,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.76706862085781,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.0955342876318703,0.153857421880129,0.0265305917549092,0.127326830125219,1.64139969948043,0.0061,4.30231550710322,0.1141,0.441438383065024,0.259009575490259,0.501847947409669,0.241482815565077,0.182428807574765,0.260365131844592,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1571,18381,1011:1372,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.924538725346646,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.0657939415782005,0.185442528663343,0.0224669855231645,0.162975543140178,0.837767072305232,0.0035,5.10594813427842,0.1167,0.532060455740732,0.227490944745946,0.604871388295223,0.238750399239709,0.304569510994786,0.366120989055514,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1572,18381,1194:1372,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.941424937669217,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.157352941154894,0.188829538668218,0.237561556248298,-0.0487320175800805,6.59915577560088,0.1894,-0.655440569017233,-0.0692,0.541778259417061,0.577006196463089,0.615919045262509,0.661469190690984,-0.0352279370460279,-0.0455501454284748,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1573,18381,1053:1372,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.991061710812816,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.134623890269643,0.19878560483839,0.0452214343032826,0.153564170535107,2.27926850566609,0.0095,3.66444670091756,0.1107,0.570343600615052,0.377143607390759,0.648393470680013,0.359548571768992,0.193199993224293,0.288844898911021,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1574,18381,1083:1372,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.974787360412896,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.161409444531989,0.195521321139097,0.117518848196341,0.0780024729427554,4.60759513906372,0.0476,1.33612006751993,0.0726,0.560977915811077,0.498755683474879,0.637746119033048,0.535345614613593,0.0622222323361978,0.102400504419455,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1575,18381,1510:1372,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.723122327277117,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.110938607176835,0.145042743182998,0.0322326722233998,0.112810070959598,2.22512032200816,0.0091,3.7185948845755,0.1111,0.416147841577005,0.268871519155286,0.473096468558832,0.25933472454433,0.147276322421719,0.213761744014503,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1576,18381,2048:1372,Colon,LS-411N,SIDM00660,907794,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.99939645490487,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.155936819587648,0.200457374746798,0.127315537433203,0.0731418373135948,4.74671514231082,0.0524,1.19700006427283,0.0678,0.575140141439708,0.515099868682918,0.653846404226043,0.560050926598108,0.0600402727567904,0.0937954776279348,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1577,18381,1561:1372,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.980077659008966,0.179802644394344,0.200578432876149,5.94371520658365,0.1202,0.575487474081999,0.654241268334578,0.14596682226521,0.196582440940943,0.0289665079910657,0.167615932949877,1.28240362591008,0.0048,4.66131158067358,0.1154,0.564022416387268,0.328774442629176,0.641207250696409,0.283182543259902,0.235247973758092,0.358024707436508,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1578,18383,1011:1510,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.916540186910635,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.139501295552077,0.729769341048795,0.256178434399344,0.473590906649452,6.90694074973649,2.3438,5.10549631361014,78.3488,0.867366746216646,0.715573532183461,0.870935529544527,0.663875298268122,0.151793214033185,0.207060231276405,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1579,18383,1054:1510,Colon,LS-411N,SIDM00660,907794,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.898063889252271,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.064755794876917,0.715058108786723,0.45845304347367,0.256605065313054,9.09276608557329,10.6641,2.91967097777334,70.0285,0.849881723289193,0.729030077097214,0.853378564432775,0.766643948969093,0.120851646191978,0.0867346154636814,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1580,18383,1053:1510,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.992418721016472,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.121548001967115,0.790185489325734,0.292659373624696,0.497526115701038,7.07313306710257,2.63,4.93930399624406,78.0626,0.939174309240051,0.67569914979386,0.943038545021986,0.730160745640146,0.263475159446191,0.21287779938184,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1581,18383,1083:1510,Colon,LS-411N,SIDM00660,907794,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.998645134964774,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.043045102635175,0.795143096279625,0.669646892444145,0.12549620383548,10.5709282645646,29.7096,1.44150879878201,50.983,0.945066668881302,0.930275853059561,0.948955148796345,0.911599359723224,0.0147908158217409,0.0373557890731212,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1582,18383,1372:1510,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.893593405773511,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0735123428419607,0.711498612073916,0.340238226610378,0.371260385463538,7.92496229181382,4.7466,4.08747477153281,75.946,0.845651086417658,0.659293593587087,0.849130520591928,0.706320568200971,0.186357492830571,0.142809952390957,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1583,18383,1564:1510,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1.0,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.0910165963001918,0.796221869450826,0.523065502149119,0.273156367301707,9.20408093492018,11.5195,2.80835612842645,69.1731,0.946348843840948,0.8132308078087,0.950242599269077,0.858930240285728,0.133118036032248,0.0913123589833489,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1584,18383,1561:1510,Colon,LS-411N,SIDM00660,907794,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.991251569834839,0.066184553173974,0.796221869450826,12.0124370633466,80.6926,0.946348843840948,0.950242599269077,0.173842282113748,0.789256178029962,0.241933593958396,0.547322584071566,6.50114073291503,1.7692,5.5112963304316,78.9234,0.938069777068725,0.636232737256177,0.94192946824941,0.689483308776917,0.301837039812547,0.252446159472493,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1585,19684,1372:1549,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.445370430542139,0.0351971497779642,0.952216897855415,15.6137883951589,489.6871,0.985471328384324,0.98929759381899,0.0413054585288309,0.424089249767366,0.259889901572821,0.164199348194545,9.74558651058869,8.3833,5.86820188457019,481.3038,0.43889978980946,0.36093397522976,0.440603895293466,0.393102350040988,0.0779658145796999,0.0475015452524782,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1586,19684,1564:1549,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.985586654365455,0.0351971497779642,0.952216897855415,15.6137883951589,489.6871,0.985471328384324,0.98929759381899,0.0486212623279011,0.93849226658757,0.888714951445812,0.049777315141758,13.8991098774303,149.1932,1.71467851772854,340.4939,0.971267389515386,0.975346383361472,0.975038505663853,0.963304721174699,-0.0040789938460865,0.0117337844891536,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1587,19685,1372:1561,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.379956423595879,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0402139584685794,0.160451298351808,0.0593721117989412,0.101079186552867,5.27255414397469,0.755,3.03473889663121,5.4319,0.314608738384381,0.208541050286754,0.308792142395883,0.228839009813176,0.106067688097627,0.0799531325827073,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1588,19685,1053:1561,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.863180968089162,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0997655465586219,0.364511555645612,0.0987847802892231,0.265726775356389,4.47720305922233,0.435,3.83008998138358,5.7519,0.714724790800682,0.436748148240512,0.701510709804711,0.464967352760107,0.27797664256017,0.236543357044605,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1589,19685,1011:1561,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.972100620479235,0.0519679123863288,0.422288684668914,8.30729304060591,6.1869,0.82801268473618,0.812704097679142,0.0910400795460505,0.410507092388011,0.179395582482506,0.231111509905506,5.71565746584378,1.0264,2.59163557476213,5.1605,0.804911644596718,0.626920228084093,0.790030157619911,0.619051363025436,0.177991416512625,0.170978794594475,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1590,19685,1011:1564,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.972100620479235,0.0755191076872956,0.185444965305594,5.72886247194637,0.5179,0.62631854549108,0.637834197216803,0.135087105506661,0.180271165838318,0.0533958738774412,0.126875291960877,2.71089629048633,0.0639,3.01796618146005,0.454,0.608844646689531,0.368262213138874,0.620039018877328,0.3853588696201,0.240582433550657,0.234680149257229,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1591,19687,1510:2048,Colon,LS-411N,SIDM00660,907794,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.609966183345264,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.0808591930255009,0.329318771712677,0.179539755769749,0.149779015942927,7.06726965828079,0.0262,2.28623339365314,0.1016,0.517410634236686,0.422455021307326,0.528102220242963,0.44853242992053,0.0949556129293602,0.0795697903224332,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1592,19687,2171:2048,Colon,LS-411N,SIDM00660,907794,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.880269822550588,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.106215031703503,0.475254833224102,0.254981175855109,0.220273657368993,7.01721752398166,0.0253,2.33628552795227,0.1025,0.746698718095176,0.584572178239079,0.762128230047648,0.644290945047268,0.162126539856096,0.11783728500038,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1593,19687,1011:2048,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.976664867685392,0.0739605468714944,0.539896769205433,9.35350305193393,0.1278,0.848261179659222,0.865789341544592,0.0683579583898605,0.527298206659795,0.220156162497932,0.307142044161863,6.27153135464973,0.0151,3.0819716972842,0.1127,0.828466892794528,0.675046208616163,0.845586032703071,0.662940918323169,0.153420684178365,0.182645114379902,True,0.144492621214001,0.01982445528807,1.78284611409711,27.6301540347009
1594,18384,1032:2171,Colon,LS-411N,SIDM00660,907794,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.903607397083856,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.196779290323626,0.361652628468761,0.343732979412167,0.0179196490565944,7.92166141619211,4.7357,0.184234730133482,0.6451,0.6918286630555,0.627171519774402,0.723929141945499,0.714056318049736,0.0646571432810977,0.0098728238957622,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1595,18384,1372:2171,Colon,LS-411N,SIDM00660,907794,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.514056140641086,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.084730677222934,0.205741735894735,0.0363097440751655,0.16943199181957,3.30380868898199,0.1929,4.8020874573436,5.1879,0.393576650282987,0.200975627592262,0.411838395753616,0.228072768503629,0.192601022690724,0.183765627249987,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1596,18384,1564:2171,Colon,LS-411N,SIDM00660,907794,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.637424350544288,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.100370055187633,0.255117645747804,0.0694229503534827,0.185694695394322,4.35394289860847,0.3994,3.75195324771712,4.9814,0.488031016190487,0.301435394934104,0.510675393576786,0.337004205055564,0.186595621256383,0.173671188521222,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1597,18384,1053:2171,Colon,LS-411N,SIDM00660,907794,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.988761032406187,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.18918538353584,0.395733841324452,0.0439152202324229,0.351818621092029,2.21680640200825,0.0908,5.88908974431734,5.29,0.757024815576479,0.380199214814715,0.792150360974225,0.353971046495972,0.376825600761764,0.438179314478253,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1598,18384,1194:2171,Colon,LS-411N,SIDM00660,907794,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.861513710873595,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.0830078030977985,0.344805386725268,0.105408391613905,0.239396995111364,4.64476089079077,0.4886,3.46113525553483,4.8922,0.659600486584275,0.460097230016912,0.690205595372219,0.475716698503841,0.199503256567363,0.214488896868378,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1599,18384,1011:2171,Colon,LS-411N,SIDM00660,907794,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.925158259661309,0.120612860556824,0.400232036209415,8.10589614632559,5.3808,0.765629702997327,0.801154510556001,0.0942853165214894,0.370277974080205,0.0948168860232484,0.275461088056956,4.20367312712633,0.3599,3.90222301919927,5.0209,0.708328643570012,0.459740275144129,0.741194712705798,0.477864007892777,0.248588368425883,0.26333070481302,True,0.328390259601336,0.0463672746311286,1.02875982003898,47.1972251674879
1600,19591,2048:1011,Colon,SW620,SIDM00841,905962,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.965481488858102,0.155874429173341,0.205463057553927,5.85995974262785,1.1344,0.691980772481297,0.644388021268075,0.127071715256259,0.198370778712504,0.0889421306705814,0.109428648041922,3.68803368284209,0.2517,2.17192605978576,0.8827,0.668094626476422,0.449045364030779,0.622144706176227,0.458898844600104,0.219049262445643,0.163245861576123,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
1601,20746,1011:1372,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.8149764080959,0.198318269553233,0.113888764838415,4.2368188863478,0.0368,0.487240471178381,0.518750323619543,0.0708558746206124,0.0928166564904898,0.0148339205472725,0.0779827359432173,-0.258517899118315,0.0016,4.49533678546612,0.0352,0.397089489079911,0.149207760236963,0.422769275442041,0.160291803762745,0.247881728842948,0.262477471679297,True,0.181862921892115,0.0276104221850542,1.57742485945792,31.1571674504069
1602,20746,1083:1372,Colon,SW620,SIDM00841,905962,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.965451898920169,0.198318269553233,0.113888764838415,4.2368188863478,0.0368,0.487240471178381,0.518750323619543,0.195171539823313,0.10995412427892,0.114489456228065,-0.0045353319491451,4.34300038211002,0.0396,-0.106181495762222,-0.0028,0.470407238129925,0.461822631732105,0.50082848500394,0.508935740588293,0.00858460639782,-0.0081072555843525,True,0.181862921892115,0.0276104221850542,1.57742485945792,31.1571674504069
1603,20074,1011:1561,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.754725960263175,0.0782463639355061,0.696158344495058,10.9248263207109,37.9691,0.872519494779171,0.91727524082125,0.10898645643293,0.525408775044255,0.214957487852265,0.31045128719199,6.86244023918522,2.2726,4.06238608152572,35.6965,0.65851311354555,0.471930615557194,0.692291436954453,0.540490630962561,0.186582497988356,0.151800805991892,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
1604,20074,1011:1564,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.754725960263175,0.12743228493421,0.216027145865594,6.00743885829065,0.6282,0.59790670867553,0.655319786077597,0.1017939558389,0.163041295106323,0.0391173881764099,0.123923906929913,2.2519181493519,0.0465,3.75552070893876,0.5817,0.451255714852934,0.256873710936178,0.494586854826873,0.274703551880919,0.194382003916756,0.219883302945954,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
1605,20076,1011:2048,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.940676658409686,0.128461931868478,0.343271854404372,7.49382383048798,0.0352,0.723730612235461,0.757667098677711,0.154147832033826,0.3229078209272,0.200344358347351,0.122563462579849,5.96543723284136,0.0122,1.52838659764662,0.023,0.680796493906449,0.623281824499296,0.712719754571111,0.613526262389505,0.0575146694071532,0.0991934921816054,True,0.14538764884658,0.0214106837134932,1.77119448894505,27.7932803207291
1606,19592,1011:2171,Colon,SW620,SIDM00841,905962,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.6557672986741,0.0875086849227095,0.321319200732422,7.26405194903321,3.0021,0.710806578079307,0.742929743096626,0.076023660045925,0.210710624276421,0.0384068119387488,0.172303812337672,2.55222121382157,0.1146,4.71183073521164,2.8875,0.466123709586848,0.216413668779723,0.487189030735117,0.253595259563998,0.249710040807125,0.23359377117112,True,0.150087880964705,0.0197658542426096,1.74107388358514,28.2596068597113
1607,18548,1194:1053,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.486701531565185,0.095065541881932,0.650468946268895,10.6252698517615,30.85,0.856314240141537,0.890524002561726,0.0583353118871508,0.316584232384663,0.13271681589989,0.183867416484773,6.43286843111702,1.6874,4.19240142064451,29.1626,0.416769452177964,0.325762058526278,0.433419395942351,0.32843669720255,0.0910073936516856,0.104982698739801,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1608,18548,1372:1053,Colon,LS-123,SIDM00776,907792,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.818975778673591,0.095065541881932,0.650468946268895,10.6252698517615,30.85,0.856314240141537,0.890524002561726,0.0830968493427971,0.532718311773558,0.445080121364659,0.087638190408899,9.45604172984787,13.7177,1.16922812191365,17.1323,0.7013006216092,0.653235697867084,0.729317588425512,0.692197820901225,0.0480649237421159,0.0371197675242874,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1609,20622,1194:1083,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.95647819710583,0.0974038137217403,0.478541884406657,8.77525938762793,8.5575,0.841801732247298,0.813311812311513,0.0964107956375796,0.457714878836906,0.524788831888551,-0.0670739530516453,9.51102536936898,14.2506,-0.735765981741052,-5.6931,0.80516500318046,0.859244704106558,0.777915015924591,0.810708048341289,-0.0540797009260979,-0.0327930324166981,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
1610,18545,1011:1372,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.621379612557168,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.0614504076650754,0.26205516569471,0.0392669215368894,0.222788244157821,1.94449032034553,0.0075,6.22947665184939,0.5566,0.424406390541061,0.192096404771672,0.485802573510957,0.21805563012391,0.232309985769389,0.267746943387047,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1611,18545,1194:1372,Colon,LS-123,SIDM00776,907792,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.979136745525796,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.119182840860889,0.412932508407548,0.439010054417143,-0.0260775460095952,8.45759523053613,0.6866,-0.28362825834121,-0.1225,0.668756881650173,0.694613829821811,0.765501701670028,0.780423659998506,-0.0258569481716375,-0.0149219583284779,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1612,18545,1053:1372,Colon,LS-123,SIDM00776,907792,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.775104581657391,0.1503941213366,0.421731193619746,8.17396697219492,0.5641,0.683006622625577,0.781812862368835,0.123713336053464,0.326885780402506,0.123597086633992,0.203288693768513,4.65026694911358,0.049,3.52370002308134,0.5151,0.529401562499425,0.384377728811967,0.605986731620763,0.424875140137522,0.145023833687459,0.181111591483241,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1613,20627,1011:1561,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.700722289551856,0.120524109635957,0.438951134089575,8.35779609452999,6.4073,0.730902567718445,0.791767193717798,0.0395496265807164,0.307582843680631,0.113022541459482,0.194560302221148,4.68594123635663,0.5027,3.67185485817336,5.9046,0.512159720690999,0.363227268359511,0.554808920773983,0.385944138034409,0.148932452331488,0.168864782739574,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
1614,20627,1011:1564,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.700722289551856,0.0992516390258821,0.523361865186075,9.24470733537422,5.9243,0.797396145997432,0.835736148404159,0.069263763425226,0.366731324437316,0.114841234525544,0.251890089911772,4.7358237091205,0.2602,4.50888362625372,5.6641,0.558753253103146,0.380915162203921,0.585618947371012,0.388516979783296,0.177838090899225,0.197101967587717,True,0.364550537533847,0.0579711384084306,0.830986080866088,55.473761892262
1615,22628,1011:2048,Colon,LS-123,SIDM00776,907792,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.722928023494129,0.0965730418036315,0.69521641217993,11.1578320788632,0.4462,0.867528187491823,0.907372255650611,0.0858442993535287,0.502591426757916,0.152587578470785,0.350003848287132,5.54982163314805,0.0091,5.60801044571518,0.4371,0.627160437908908,0.433274937391613,0.655964831350906,0.44353697267144,0.193885500517295,0.212427858679466,True,,,,
1616,18548,1053:2171,Colon,LS-123,SIDM00776,907792,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.821986886703594,0.09972244795897,0.509708403963248,9.10163085144433,10.7299,0.847761177354928,0.829106275974229,0.101339893547406,0.418973624100409,0.213221792549437,0.205751831550971,6.25476293388633,1.4914,2.846867917558,9.2385,0.696848570842151,0.486494588072446,0.681514486534468,0.544783071167901,0.210353982769704,0.136731415366566,True,0.4656830891927,0.0670148805380014,0.708840224043507,67.8977301029373
1617,19398,1372:1011,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.264425378410421,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0452072924890737,0.0748934004249551,0.0183953087494846,0.0564980916754705,3.58792833105103,0.2349,3.47440437004383,2.3755,0.204706450353799,0.0874048392263479,0.195959323916864,0.123144854847787,0.117301611127451,0.0728144690690774,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1618,19398,1564:1011,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.332277199858641,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0382539274808884,0.0941111232616668,0.0212193331037857,0.0728917901578812,3.39654281731207,0.2057,3.66578988378279,2.4047,0.257234334031993,0.116882599279376,0.246242686041371,0.1494707588504,0.140351734752617,0.0967719271909715,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1619,19398,2048:1011,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.65933750381268,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0524915955479586,0.186744661140617,0.0497776866195886,0.136966974521028,3.77196726063655,0.2668,3.29036544045831,2.3436,0.510429977644344,0.308370257282598,0.488619255295633,0.317147938344496,0.202059720361746,0.171471316951137,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1620,19398,1053:1011,Colon,HCC2998,SIDM00118,905971,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.583308715127204,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.167220691136408,0.165210969673197,0.0500041814639856,0.115206788209212,4.06034363202141,0.3258,3.00198906907344,2.2846,0.451571847044087,0.269255028958228,0.43227613831274,0.294586469155324,0.182316818085859,0.137689669157416,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1621,19398,2171:1011,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.538820313840297,0.113774881282936,0.283230758239518,7.06233270109485,2.6104,0.774155837780705,0.741076083902624,0.0445182319707795,0.152610486043842,0.0411864129516483,0.111424073092194,3.79996092663639,0.272,3.26237177445846,2.3384,0.417130891474297,0.247678223279839,0.39930684810795,0.260433454087316,0.169452668194459,0.138873394020634,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1622,20603,1510:1025,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.774349963922381,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0915625775574877,0.732371460550497,0.4465954427472,0.285776017803297,9.6456613975562,15.6446,5.32104929955019,609.7569,0.760682190063596,0.616075439968636,0.765419914887022,0.686391734420413,0.14460675009496,0.0790281804666082,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1623,20603,1011:1025,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.812782134409303,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0731286274984283,0.768720173849402,0.43136820217973,0.337351971669672,9.25684862842961,11.9487,5.70986206867677,613.4528,0.798436008074776,0.685008135450576,0.803408873411686,0.706568028354811,0.113427872624199,0.0968408450568755,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1624,20603,2171:1025,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.629642231930706,0.0315080086991414,0.945788719148062,14.9667106971064,625.4015,0.98234935817708,0.988467683280922,0.0746246613415898,0.595508520059269,0.319186161219008,0.276322358840261,9.05787403669973,10.4093,5.90883666040666,614.9922,0.618528642418313,0.534785504884122,0.622380998292374,0.54142836645146,0.0837431375341918,0.0809526318409136,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1625,19399,1510:1053,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.78662276679527,0.0645133781661023,0.482564379086157,8.85439557031027,9.04,0.823220728761649,0.849788646390852,0.13253232000812,0.379596127033595,0.155422436761271,0.224173690272324,6.07526268587752,1.3169,2.77913288443275,7.7231,0.647564167341707,0.44679257752844,0.66846309621518,0.525861099676403,0.200771589813266,0.142601996538777,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1626,19398,1011:1510,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.820289084333769,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0784666031243639,0.561679972009505,0.257112370706677,0.304567601302828,7.36370518806256,3.2168,3.254922603534,27.4915,0.741792948780132,0.592678444027231,0.756109519031447,0.62477218645414,0.149114504752902,0.131337332577307,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1627,19398,1053:1510,Colon,HCC2998,SIDM00118,905971,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.847106525837222,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.091831524555758,0.580042790777549,0.283919177285628,0.296123613491922,7.57063668949658,3.7129,3.04799110209998,26.9954,0.766044141916199,0.614095295540439,0.780828759094599,0.656745131358031,0.15194884637576,0.124083627736567,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1628,19398,1032:1510,Colon,HCC2998,SIDM00118,905971,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952804973610103,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.082936444029896,0.652418130545405,0.43154037359334,0.220877756952064,8.60579198867234,7.6091,2.01283580292422,23.0992,0.861627960782457,0.749918444422359,0.878257341327695,0.797296433514144,0.111709516360098,0.0809609078135503,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1629,19398,2048:1510,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.65933750381268,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0918077592654715,0.451470923798903,0.338021461227452,0.113449462571452,9.10577269936337,10.7607,1.51285509223319,19.9476,0.596243349491571,0.503584433659966,0.607750819081181,0.568486403315368,0.0926589158316051,0.0392644157658132,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1630,19398,1549:1510,Colon,HCC2998,SIDM00118,905971,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952182002293757,0.065574149217232,0.68473417815342,10.6186277915966,30.7083,0.904306741302805,0.921759820375461,0.0742899697418031,0.651991560793094,0.421734775256877,0.230256785536217,8.5213829602273,7.1767,2.09724483136926,23.5316,0.861064603621447,0.790266326184814,0.87768311139904,0.792419223467379,0.0707982774366334,0.085263887931661,True,0.404070935266718,0.0499616027026634,0.848106670081728,57.2340703121238
1631,20606,2171:1549,Colon,HCC2998,SIDM00118,905971,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.772613762302539,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.105242846399015,0.735452131394005,0.443612037421965,0.291840093972039,9.62374726477051,7.7044,5.60607623674241,367.5569,0.755961065021647,0.608151798858655,0.764733385234066,0.684144242602944,0.147809266162991,0.0805891426311227,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1632,20606,1510:1549,Colon,HCC2998,SIDM00118,905971,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.786460458192044,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.100019647791858,0.748632820765045,0.406032010852476,0.342600809912569,9.13592773176178,5.494,6.09389576975114,369.7673,0.769509313166315,0.596789984285832,0.778438849902894,0.679225931821127,0.172719328880483,0.099212918081767,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1633,20606,1372:1549,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.271369531056157,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0573466442956214,0.258317039830947,0.074193440871165,0.184123598959782,6.96022195918624,1.216,8.26960154232668,374.0453,0.265520509368441,0.150342941030519,0.26860166134692,0.199164032063984,0.115177568337922,0.0694376292829358,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1634,20606,1564:1549,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.818413017947233,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.129048701145351,0.779048507518301,0.57343848400748,0.205610023510822,10.7748985432136,17.1107,4.45492495829927,358.1506,0.800773176536694,0.684582964188239,0.810065505265152,0.758262991970545,0.116190212348455,0.0518025132946071,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1635,20606,2048:1549,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.568481697130097,0.0387992068398078,0.951901412165135,15.2298235015129,375.2613,0.978446284426433,0.98980036668647,0.0411217479817353,0.541138530288171,0.447657164365739,0.0934813659224324,11.7331848759443,33.2461,3.49663862556862,342.0152,0.556228804321376,0.542388793317344,0.562683392273917,0.540399964782216,0.0138400110040323,0.0222834274917004,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1636,20607,1372:1561,Colon,HCC2998,SIDM00118,905971,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.233865919627986,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0365753638332038,0.0659298488270152,0.0138449035695898,0.0520849452574255,3.22804753023049,0.183,3.82072010733676,2.403,0.164104915609663,0.0840054346894726,0.173091387790257,0.1019465273676,0.08009948092019,0.0711448604226571,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1637,20607,1564:1561,Colon,HCC2998,SIDM00118,905971,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.321136599691983,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0441356496928237,0.0905325902303062,0.0148540227347191,0.0756785674955871,2.6845537012301,0.1256,4.36421393633715,2.4604,0.225343199536973,0.11342026668328,0.237683112611496,0.125735109895399,0.111922932853693,0.111948002716097,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1638,20607,2048:1561,Colon,HCC2998,SIDM00118,905971,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.720615458526306,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.078949725605812,0.203150883714159,0.109271655603466,0.0938792281106932,5.40673358498451,0.8286,1.64203405258274,1.7574,0.505659564234885,0.416735968523433,0.5333497500527,0.443772873522911,0.0889235957114519,0.0895768765297889,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1639,20607,1011:1561,Colon,HCC2998,SIDM00118,905971,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.729980865196281,0.0824129054334678,0.281913024915691,7.04876763756725,2.586,0.701705130318719,0.740130875270739,0.0536645043168354,0.205791113838057,0.051839442084295,0.153951671753762,3.63416045953568,0.2425,3.41460717803157,2.3435,0.512231318142728,0.336644351925192,0.540281376688615,0.34276135792532,0.175586966217536,0.197520018763295,True,0.208093821689184,0.0338009464970596,1.30869555843349,36.4568241004816
1640,21208,1561:1025,Colon,COLO-205,SIDM00826,905961,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.839177924507033,0.101041192961635,0.651221828631918,10.4594120926987,27.4996,0.883378877803048,0.901483116761171,0.119207792809636,0.546490982545008,0.32017094660873,0.226320035936278,7.87096276274443,4.5722,2.58844932995428,22.9274,0.741312053228113,0.573445273240269,0.756504730901771,0.654545647842189,0.167866779987844,0.101959083059582,True,0.275120103108335,0.034089133402475,1.2285655485732,40.053299014619
1641,19374,1011:1032,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.469371851716622,0.0967214006279397,0.564264815459688,9.6041533636666,15.2009,0.892586742567571,0.868743958128108,0.0517806577611564,0.264850021290851,0.104923233497153,0.159926787793698,6.08975784645125,1.3302,3.51439551721534,13.8707,0.418955092176648,0.284616283182672,0.407763960294217,0.310176421113793,0.134338808993976,0.0975875391804242,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
1642,19378,1011:1053,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.375284827028864,0.0460947359935408,0.26319616701365,6.59398340869491,1.8868,0.692819733035104,0.696909859511909,0.0632532257327996,0.0987735280123777,0.0318382961665481,0.0669352318458296,3.44117459174829,0.2121,3.15280881694662,1.6747,0.260004733674263,0.163633480596348,0.261539696081637,0.171118551214852,0.0963712530779144,0.0904211448667843,True,0.470030446985157,0.0401915957219674,0.714148009281862,68.0355140430849
1643,18963,1372:1549,Colon,COLO-205,SIDM00826,905961,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.258811845821125,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0412519600863459,0.228848480350078,0.156252271726665,0.0725962086234124,9.98404762329951,9.89,3.76777926525828,124.8239,0.244589810675504,0.201597447350902,0.251478682279716,0.228834338405802,0.0429923633246022,0.0226443438739135,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1644,18963,1510:1549,Colon,COLO-205,SIDM00826,905961,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.473241957141997,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0352970332334762,0.418453422741297,0.321055957709467,0.0973974650318298,10.7447850497714,16.7572,3.00704183878637,117.9567,0.447236718759255,0.423263073317429,0.459833140187083,0.431051288214306,0.0239736454418255,0.0287818519727761,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1645,18963,2171:1549,Colon,COLO-205,SIDM00826,905961,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.441011369541218,0.0749813619697217,0.884227225473458,13.7518268885578,134.7139,0.945048747283963,0.971666043653668,0.0468327621619652,0.389954259691681,0.250329715982821,0.13962454370886,9.63613774587096,7.7708,4.11568914268683,126.9431,0.416777242322913,0.352572463124173,0.428515772648401,0.383723376777208,0.06420477919874,0.044792395871193,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1646,18964,1372:1561,Colon,COLO-205,SIDM00826,905961,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.222631138240908,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0298895110634548,0.0686993130318897,0.0181690483413258,0.0505302646905639,3.34230546043603,0.1981,3.77207000426746,2.5082,0.14795354306136,0.079979054877108,0.163041922613256,0.0997867770546661,0.0679744881842516,0.0632551455585896,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1647,18964,1564:1561,Colon,COLO-205,SIDM00826,905961,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.238027532591834,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0288312373006915,0.0734503183199822,0.0195381046034762,0.053912213716506,3.35701163611753,0.2001,3.75736382858596,2.5062,0.158185494946384,0.0871727471574098,0.174317334292508,0.106961969244317,0.0710127477889747,0.0673553650481907,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1648,18964,1011:1561,Colon,COLO-205,SIDM00826,905961,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.781544344265962,0.127852485371114,0.308579085453673,7.11437546470349,2.7063,0.664568057417285,0.732341054811607,0.0579844885403411,0.241168238995081,0.0529663246241522,0.188201914370928,2.87304337212796,0.1431,4.24133209257553,2.5632,0.519389406654296,0.31143416810494,0.572357009461781,0.321758166422937,0.207955238549357,0.250598843038843,True,0.256454194040285,0.0329463405048502,1.27736688997614,38.4063021517707
1649,19097,2048:1025,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.927589696586466,0.0509719329044523,0.885287252133022,13.796053271294,277.8151,0.976981153812548,0.971832169839917,0.0990151051412488,0.821183333597937,0.687169539346193,0.134013794251743,11.4648046760844,55.2052,2.3312485952096,222.6099,0.906237652035677,0.837855168515117,0.901461507554776,0.863348439918114,0.0683824835205595,0.0381130676366614,True,,,,
1650,19097,1011:1194,Colon,GP5d,SIDM00537,907291,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.927022651620795,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.047831515855386,0.672578714511189,0.603704025017044,0.0688746894941442,10.4655752086152,27.6174,0.815801035534683,20.9967,0.862281529649312,0.862726310928516,0.858371072039028,0.835345323074658,-0.0004447812792042,0.0230257489643702,True,,,,
1651,19097,1025:1194,Colon,GP5d,SIDM00537,907291,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.923320217673401,0.0673496028799784,0.725525652836271,11.2813762441499,48.6141,0.930162308484813,0.925944010686538,0.0309819132155842,0.669892503704423,0.564152752483803,0.10573975122062,10.0597564237998,20.8458,1.22161982035008,27.7683,0.858837665141791,0.819458581627877,0.854942825500477,0.81849926202884,0.0393790835139148,0.0364435634716365,True,,,,
1652,19194,1025:1510,Colon,GP5d,SIDM00537,907291,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.963913824723184,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0448186007425095,0.785231770401868,0.54865134479318,0.236580425608688,9.65376285413378,15.7327,2.82067013401349,95.4171,0.904035305900662,0.810152483948596,0.918256623975862,0.838827556728901,0.0938828219520658,0.0794290672469613,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
1653,19194,1032:1510,Colon,GP5d,SIDM00537,907291,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.686926366970584,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0542479194086141,0.559589865231924,0.337760136683653,0.221829728548271,8.922051089404,9.474,3.55238189874328,101.6758,0.644254364205039,0.552684212605474,0.654389085907714,0.574811434869639,0.0915701515995652,0.0795776510380749,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
1654,19194,2048:1510,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.900178242631775,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0677298396309021,0.733310942336555,0.527331763699902,0.205979178636653,9.81361893863432,17.5761,2.66081404951295,93.5737,0.844258990866161,0.757770967884041,0.857539971784261,0.789295352101864,0.0864880229821204,0.0682446196823973,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
1655,19194,1549:1510,Colon,GP5d,SIDM00537,907291,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.697105642441553,0.0656760951991101,0.814628600878684,12.4744329881473,111.1498,0.937879800780202,0.952633524308635,0.0363766346381298,0.567882194166798,0.30867762774139,0.259204566425408,8.46063460219295,6.8807,4.01379838595432,104.2691,0.653801301055838,0.55830648684816,0.664086204974532,0.566701645054005,0.0954948142076778,0.0973845599205261,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
1656,19100,2171:1549,Colon,GP5d,SIDM00537,907291,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.781461363627102,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.156793084550806,0.569438804101622,0.15207729063741,0.417361513464212,5.66642966774619,0.496,5.65231087255913,24.4488,0.691070651654239,0.418361867076696,0.724370899694114,0.491671950334961,0.272708784577543,0.232698949359153,True,,,,
1657,19100,1083:1549,Colon,GP5d,SIDM00537,907291,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.954249069101905,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.129244083123178,0.695346531532131,0.374986733103974,0.320359798428157,7.97937157486434,2.4645,3.33936896544097,22.4803,0.84387220753166,0.655649400216582,0.884535421571345,0.749890252867375,0.188222807315078,0.13464516870397,True,,,,
1658,19100,1510:1549,Colon,GP5d,SIDM00537,907291,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.798730930825172,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.0788418375624045,0.582022870506362,0.408770223216409,0.173252647289953,9.11056070444801,5.3982,2.20817983585731,19.5466,0.706342668433116,0.631501530424137,0.740378820892587,0.675662233902146,0.0748411380089787,0.0647165869904412,True,,,,
1659,19100,2048:1549,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.893930722436119,0.0840046632613145,0.728684526972145,11.3187405403053,24.9448,0.884331182346213,0.926943971141444,0.142750112746079,0.651393485624231,0.576609094312394,0.0747843913118373,10.4017436694343,13.211,0.916996870871017,11.7338,0.790530812707537,0.698686288896806,0.828623693780275,0.80356159013798,0.0918445238107314,0.0250621036422951,True,,,,
1660,19101,2048:1564,Colon,GP5d,SIDM00537,907291,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.777576630648854,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0870346953061653,0.543092655489048,0.447484621071667,0.095608034417381,9.7141239195059,8.2024,1.25710560037563,11.4027,0.672293792763455,0.642749507289804,0.713186460913279,0.678629439057081,0.0295442854736507,0.0345570218561989,True,,,,
1661,19101,1510:1564,Colon,GP5d,SIDM00537,907291,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.938185368137049,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0906358785433379,0.65526864213672,0.533075295505631,0.122193346631089,9.64426102419168,7.8147,1.32696849568985,11.7904,0.811156321575294,0.747471432511116,0.860495385289484,0.816062813422221,0.0636848890641778,0.0444325718672637,True,,,,
1662,19101,1011:1564,Colon,GP5d,SIDM00537,907291,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.91588713106262,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0772084309857174,0.639694603118378,0.57178347203535,0.067911131083028,10.1918483323981,11.4223,0.779381187483409,8.1828,0.791877236037194,0.792813750075924,0.840043637954373,0.816430797904593,-0.0009365140387307,0.0236128400497799,True,,,,
1663,19101,1053:1564,Colon,GP5d,SIDM00537,907291,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.580638624093443,0.101293513917967,0.698442615277495,10.9712295198815,19.6051,0.864601334793787,0.917191223092901,0.0585705162427026,0.405542759142951,0.195468735174356,0.210074023968595,7.40806619776864,1.6586,3.56316332211288,17.9465,0.502020929424019,0.400686886005724,0.532556649807245,0.436008813722497,0.101334043418296,0.0965478360847473,True,,,,
1664,19195,1032:2171,Colon,GP5d,SIDM00537,907291,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.748298141195386,0.127727570795384,0.17053357129252,5.28739438652582,0.7628,0.553971050986514,0.600437545301501,0.0783118400789877,0.127609954409604,0.0288873789681255,0.0987225754414782,1.45432472725483,0.0535,3.83306965927099,0.7093,0.414535507729262,0.233935863559474,0.449306299053033,0.229635244955745,0.180599644169788,0.219671054097288,True,0.407105143114998,0.0495901856250191,0.846463078464426,57.4925995795047
1665,22194,1549:1011,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.467306812054025,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0798926411670998,0.19320921218467,0.0914764740047754,0.101732738179895,5.06428772838981,0.6535,2.96168117532915,4.4373,0.388071096169953,0.271430741400283,0.35734796329786,0.26900911542981,0.11664035476967,0.0883388478680502,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1666,22194,1032:1011,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.498396464804806,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0650362738302444,0.206063309664377,0.0617179233709511,0.144345386293426,3.55031861433331,0.2288,4.47565028938566,4.862,0.413889242431309,0.212418360692743,0.381122117244593,0.233187982113985,0.201470881738566,0.147934135130608,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1667,22194,2171:1011,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.73385388319685,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0936613035030276,0.303413789343033,0.136853954591954,0.16655983475108,4.89732133883272,0.5821,3.12864756488624,4.5087,0.609422917737939,0.429609774143791,0.561175621142673,0.413819286926949,0.179813143594148,0.147356334215725,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1668,22194,1025:1011,Colon,CCK-81,SIDM00487,1240123,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.725781248040531,0.180956732844327,0.413452590890829,8.02596890371897,5.0908,0.830441770074366,0.7646966705389,0.0796987046000573,0.300076137422337,0.100638603890255,0.199437533532082,3.91289951535203,0.2942,4.11306938836694,4.7966,0.602719064309561,0.353272500971897,0.555002503916161,0.358370106259419,0.249446563337664,0.196632397656742,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1669,21293,1032:1025,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.347123155230949,0.110031484158372,0.701997748884093,11.3864822444811,52.2881,0.860231902344448,0.90469394373235,0.0516240458926058,0.24367967355767,0.183211831586556,0.0604678419711144,9.3100468068361,12.3975,2.07643543764504,39.8906,0.298606412172127,0.248059485987301,0.314040216266704,0.287696932520497,0.0505469261848252,0.0263432837462073,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
1670,22195,1372:1053,Colon,CCK-81,SIDM00487,1240123,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.844024787488374,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0635506892504241,0.428664688276845,0.282876032274182,0.145788656002663,7.09216796723103,2.6649,1.99564854930502,7.9627,0.664028925374294,0.570332204433057,0.690957004996332,0.599565598557425,0.0936967209412374,0.0913914064389074,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1671,22195,1032:1053,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.465749943411885,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0427335602414204,0.236545842334475,0.0964239488597478,0.140121893474727,5.25961967570336,0.7482,3.82819684083268,9.8794,0.366424587288786,0.257109373862293,0.381284046093871,0.274481082787155,0.109315213426493,0.106802963306716,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1672,22195,1564:1053,Colon,CCK-81,SIDM00487,1240123,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.873232723073969,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0558419170880239,0.443498862330272,0.451675485536809,-0.0081766232065371,9.19220557053305,11.4251,-0.104389053997,-0.797500000000001,0.687008006518367,0.727182980921324,0.714867946942011,0.719078156310998,-0.0401749744029571,-0.0042102093689874,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1673,22195,1549:1053,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.480913218116648,0.0954514559074277,0.50788163408382,9.08781651653605,10.6276,0.786741023744449,0.818645394352058,0.0422846639033684,0.244246991069592,0.101374398731437,0.142872592338155,5.32309216104624,0.7819,3.76472435548981,9.8457,0.378354157553329,0.271632710009669,0.393697391094221,0.285543320947835,0.10672144754366,0.108154070146385,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1674,22196,1032:1054,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.503680092015429,0.102344314789069,0.769760419759012,12.361680645174,41.1175,0.901774277520605,0.929405689147044,0.119421403573326,0.387712999054054,0.167122792329136,0.220590206724919,7.05021568229496,1.0354,5.31146496287908,40.0821,0.454205751078726,0.268642051871769,0.468123143029246,0.356498696889593,0.185563699206957,0.111624446139654,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1675,22192,1510:1372,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.671323642635989,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0801855529494629,0.262446110300302,0.147381422342496,0.115064687957806,5.46730906498459,0.0864,2.29779548899818,0.3385,0.455651186944083,0.374015309807454,0.503579541286654,0.405313182464739,0.0816358771366293,0.0982663588219156,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1676,22192,1561:1372,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.489584515858273,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0626018139953876,0.191397328635319,0.0528459692984879,0.138551359336831,3.11768499169873,0.017,4.64741956228404,0.4079,0.332298390213596,0.190704119956855,0.367251695395214,0.214027284931979,0.141594270256741,0.153224410463235,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1677,22192,1053:1372,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.535808273027482,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0448665559940484,0.209467964766784,0.0390804297028573,0.170387535063927,1.91872688376503,0.0074,5.84637767021774,0.4175,0.363672095058049,0.164569798011152,0.401925490497106,0.189945455970144,0.199102297046897,0.211980034526962,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1678,22192,2171:1372,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.697936845218125,0.136184921487553,0.390938280185981,7.76510455398277,0.4249,0.678735498060136,0.750129310669473,0.0854508119137753,0.272850229948003,0.107880358851333,0.16496987109667,4.26731818954923,0.0376,3.49778636443354,0.3873,0.473714512253645,0.335698971016079,0.523542884594299,0.362305507398813,0.138015541237566,0.161237377195487,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1679,22194,1032:1510,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.498396464804806,0.107786485230125,0.493284106055415,8.92517376197826,9.4946,0.780829486242961,0.810958470572606,0.0469203755992071,0.245851054602418,0.0737010581488546,0.172149996453563,4.12204068470507,0.3401,4.80313307727319,9.1545,0.389162655558845,0.236392335812192,0.404178834836899,0.253547586804481,0.152770319746653,0.150631248032418,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1680,22194,1549:1510,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.467306812054025,0.107786485230125,0.493284106055415,8.92517376197826,9.4946,0.780829486242961,0.810958470572606,0.0673702345634909,0.230515023037675,0.0925299545832799,0.137985068454396,5.10399872216018,0.6717,3.82117503981809,8.8229,0.36488693797398,0.26412534016378,0.378966417591492,0.270311762888943,0.1007615978102,0.108654654702549,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1681,22885,2171:1549,Colon,CCK-81,SIDM00487,1240123,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.604270588800342,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0629897281369188,0.136274042046959,0.0493231650167713,0.0869508770301878,2.25836268379651,0.0467,3.30521691758608,0.4152,0.342951017617709,0.208120741385535,0.368841129455853,0.228061673047679,0.134830276232174,0.140779456408174,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
1682,22885,1011:1549,Colon,CCK-81,SIDM00487,1240123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.882720541867175,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.103199554020189,0.199069586485977,0.071717724771682,0.127351861714295,2.24428582761506,0.0463,3.31929377376753,0.4156,0.500984018941601,0.31063339753049,0.538804382822193,0.332306782333993,0.190350621411111,0.206497600488201,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
1683,22885,1053:1549,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.816923895128257,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0570721439124874,0.184231242256699,0.0480528455787091,0.136178396677989,1.27755857982612,0.0237,4.28602102155646,0.4382,0.463641432072127,0.254900334842224,0.498642723546717,0.255460891201992,0.208741097229903,0.243181832344725,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
1684,22885,1510:1549,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.696383345459049,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0423299050947919,0.157047149172511,0.0430840603206689,0.113963088851842,1.42723691050658,0.0263,4.13634269087601,0.4356,0.3952291926889,0.207617358169152,0.425065896692564,0.224428005205827,0.187611834519748,0.200637891486737,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
1685,22885,1561:1549,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.543214665010654,0.131511919924888,0.225518243933573,5.56357960138259,0.4619,0.567545440691676,0.610390669829079,0.0638919201656074,0.122504817332167,0.0310559974252769,0.0914488199068898,1.19338664893003,0.0223,4.37019295245256,0.4396,0.308299006443653,0.16614877624228,0.331573163236832,0.166976893365211,0.142150230201374,0.164596269871621,True,0.412532572045341,0.0758581816042552,0.812890189154335,59.1689122387981
1686,23240,1053:1564,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.788004085580777,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.070933950973604,0.378657781437537,0.144233043545948,0.234424737891589,4.83351093808033,0.2784,3.94943836376636,4.0232,0.609289680464244,0.44578711830755,0.633604806186571,0.440800952585211,0.163502562156694,0.19280385360136,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
1687,23240,1510:1564,Colon,CCK-81,SIDM00487,1240123,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.629135127663632,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.0412759152888182,0.302316848382777,0.144966277335542,0.157350571047235,5.64117796229916,0.4874,3.14177133954753,3.8142,0.486451209983875,0.375649351759272,0.505864180050139,0.387370098580063,0.110801858224603,0.118494081470076,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
1688,23240,1561:1564,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.543892351487537,0.09934796561465,0.480527688074685,8.78294930184669,4.3016,0.773206245517348,0.804062844064558,0.0387513459628151,0.26135533422181,0.114029907195644,0.147325427026166,5.30396251210917,0.3858,3.47898678973752,3.9158,0.420540963059281,0.312020143113765,0.437323631002029,0.322213317239356,0.108520819945515,0.115110313762673,True,0.269560506540268,0.0463355612699547,1.21074750620733,40.2873718252522
1689,21298,1561:2048,Colon,CCK-81,SIDM00487,1240123,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.500120783770988,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0346508743252374,0.223638739482858,0.0963381059963817,0.127300633486476,5.00870286370297,0.0063,3.40050718513492,0.0601,0.41887401622571,0.284371218042931,0.392684696029678,0.285944236233645,0.134502798182778,0.106740459796032,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
1690,21298,1032:2048,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.316477816680804,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0173437366293012,0.141519213545005,0.0615122811232364,0.0800069324217689,5.03967853877575,0.0064,3.36953151006214,0.06,0.265064637225985,0.191723773187234,0.248491962894198,0.181635826487701,0.0733408640387506,0.0668561364064964,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
1691,21298,1549:2048,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.445446380707973,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0414286995522403,0.199190016334832,0.0678671639761148,0.131322852358717,4.21987810411915,0.0036,4.18933194471874,0.0628,0.373081704570381,0.236194377290008,0.349755463644015,0.229725581640885,0.136887327280373,0.12002988200313,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
1692,21298,1053:2048,Colon,CCK-81,SIDM00487,1240123,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.683950121618437,0.140614011670072,0.447169457339059,8.40921004883789,0.0664,0.837545708593302,0.785179718124838,0.0934430228951832,0.3058416047311,0.199072111391129,0.106769493339971,6.52048752816369,0.0179,1.8887225206742,0.0485,0.572839489253389,0.458537232126206,0.537023763703813,0.46122442839603,0.114302257127183,0.0757993353077832,True,0.378102148325947,0.0598590154009765,0.908638786741109,53.4731209271498
1693,22195,1549:2171,Colon,CCK-81,SIDM00487,1240123,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.480913218116648,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.049776867955485,0.153909168289923,0.0292307850733541,0.124678383216568,1.3746662758933,0.0506,5.5263426530331,2.2836,0.308477351421525,0.10848375586494,0.335934970587119,0.153364552749862,0.199993595556584,0.182570417837257,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1694,22195,1032:2171,Colon,CCK-81,SIDM00487,1240123,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.465749943411885,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.0570936266852206,0.149056386310876,0.0268364107045161,0.12221997560636,1.21650330884894,0.0454,5.68450562007747,2.2888,0.298751008614562,0.0960597163077225,0.325342884426756,0.14384442402576,0.202691292306839,0.181498460400995,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1695,22195,1011:2171,Colon,CCK-81,SIDM00487,1240123,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.864777831567001,0.1517939936738,0.320035221515976,6.90100892892641,2.3342,0.641440783494335,0.698535531842329,0.101199444766446,0.276759364887651,0.107943888430397,0.168815476457253,3.57563823255923,0.2329,3.32537069636718,2.1013,0.554703769828869,0.386827919856246,0.604078042499111,0.406170316070564,0.167875849972624,0.197907726428547,True,0.288794438041452,0.0577032254482516,1.16688524104381,41.9673878103615
1696,19209,1510:1053,Colon,KM12,SIDM00150,905989,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.598313554728652,0.0717215400216426,0.591995026383325,9.86908679043694,18.2651,0.877909688868367,0.879802897027902,0.0647219659337998,0.354198648617089,0.100781057029746,0.253417591587343,5.27187096346814,0.7546,4.5972158269688,17.5105,0.525265266677558,0.331502267776452,0.52639799878133,0.358695520918285,0.193762998901105,0.167702477863045,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1697,19209,1561:1053,Colon,KM12,SIDM00150,905989,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.936392944736416,0.0717215400216426,0.591995026383325,9.86908679043694,18.2651,0.877909688868367,0.879802897027902,0.05012895893772,0.554339966024394,0.215584126320581,0.338755839703812,6.18174547885225,1.4178,3.68734131158469,16.8473,0.822068438772081,0.613440402693609,0.823841225535587,0.625149096479521,0.208628036078472,0.198692129056065,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1698,19208,1054:1510,Colon,KM12,SIDM00150,905989,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.434235330889305,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0458570279030598,0.358497315925735,0.214098503688325,0.14439881223741,8.9350597470779,9.5598,3.6948419979493,114.237,0.41689077716743,0.34081919218447,0.41509783136786,0.363967027210755,0.0760715849829597,0.0511308041571046,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1699,19208,1053:1510,Colon,KM12,SIDM00150,905989,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.816504631480979,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0487931924426132,0.674092359613828,0.265991437265691,0.408100922348138,7.30163831691788,3.0814,5.32826342810932,120.7154,0.78389119024883,0.611326008199228,0.780519864966879,0.608054075831055,0.172565182049602,0.172465789135824,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1700,19208,1083:1510,Colon,KM12,SIDM00150,905989,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.481471438446249,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0781761162178078,0.397494644262109,0.179816900831618,0.217677743430491,7.79206484841206,4.3289,4.83783689661514,119.4679,0.462240144639325,0.317032805898292,0.46025216224414,0.373323609859212,0.145207338741033,0.0869285523849275,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1701,19208,1372:1510,Colon,KM12,SIDM00150,905989,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.841871066378138,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0823625921127439,0.69503445754633,0.394933250623731,0.300101206922599,8.71116889492695,8.1857,3.91873285010025,115.6111,0.808244419951687,0.654380367613851,0.804768357354129,0.696134346475902,0.153864052337836,0.108634010878227,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1702,19208,1561:1510,Colon,KM12,SIDM00150,905989,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.855868958001233,0.048946155468007,0.825583020136894,12.6299017450272,123.7968,0.960057248942979,0.955928276305266,0.0674275713597659,0.706590879188075,0.332135771948363,0.374455107239711,7.93660519656821,4.785,4.693296548459,119.0118,0.821683197274358,0.618036267826063,0.818149337765303,0.671013073888483,0.203646929448296,0.147136263876819,True,0.343768098462956,0.0471873418052944,0.977647296068201,49.4340239490331
1703,19507,1083:1549,Colon,KM12,SIDM00150,905989,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.280021371083308,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.0655631752230894,0.259761852836143,0.10429514103646,0.155466711799683,7.78188671301712,2.1492,7.17472303905479,308.3698,0.273784004294495,0.168264159908778,0.275181512308025,0.216950889606684,0.105519844385717,0.0582306227013414,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
1704,19507,2171:1549,Colon,KM12,SIDM00150,905989,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.199841398578313,0.0423552189255571,0.927650099816353,14.9566097520719,310.519,0.977725390156176,0.982716109286377,0.0377040620776898,0.185382893338612,0.0702725985182908,0.115110294820321,7.57144954973191,1.8575,7.38516020234,308.6615,0.195390009394337,0.117288324343019,0.196387361685228,0.152247099805311,0.0781016850513188,0.0441402618799173,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
1705,19508,1053:1561,Colon,KM12,SIDM00150,905989,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.746284516344393,0.0683294907244375,0.3766270326976,7.82347769238624,4.4242,0.785723323552345,0.777273115263623,0.0767648504403669,0.281070922938952,0.109978662500022,0.17109226043893,4.90136616203094,0.5837,2.9221115303553,3.8405,0.586373150497771,0.393126648272076,0.580066890892012,0.426017553721506,0.193246502225694,0.154049337170507,True,0.157361806512615,0.0264679364226542,1.74523528479844,28.3185243573698
1706,19412,1053:1011,Colon,MDST8,SIDM00527,1240173,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.806145793474072,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0516132910390862,0.178106551909257,0.137390586583435,0.0407159653258218,5.75028527953679,1.0513,0.661958503982595,0.6121,0.563815337892102,0.519051018908254,0.56062684861673,0.519312262646573,0.0447643189838486,0.0413145859701568,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
1707,19412,2048:1011,Colon,MDST8,SIDM00527,1240173,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.494698028663165,0.0710900341588613,0.220935906818678,6.41224378351938,1.6634,0.699396241295696,0.695441014708664,0.0733609193922285,0.109296557564108,0.0189906536400488,0.0903059039240597,2.38624558913725,0.1021,4.02599819438213,1.5613,0.345989941823408,0.151048603268808,0.344033299027887,0.181400943170079,0.1949413385546,0.162632355857808,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
1708,21235,1564:1025,Colon,MDST8,SIDM00527,1240173,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.409042263732551,0.0890604392796662,0.835881485782752,12.3427504581919,101.4538,0.925770748773466,0.963497902259636,0.0714466699292742,0.341910855156705,0.215207184342347,0.126703670814358,9.21477391989473,11.6052,3.12797653829718,89.8486,0.378679362775677,0.291697434360602,0.394111363041846,0.355678824262654,0.086981928415075,0.0384325387791913,True,0.258369000132148,0.0370443926243604,1.28939907431798,38.2038922759026
1709,21235,1011:1025,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.182403793828576,0.0890604392796662,0.835881485782752,12.3427504581919,101.4538,0.925770748773466,0.963497902259636,0.0357426497147361,0.152467954197841,0.109978034887483,0.0424899193103588,9.85774978230457,18.1221,2.48500067588734,83.3317,0.168864096791802,0.142633488211778,0.175745672718033,0.163642498413635,0.0262306085800242,0.0121031743043974,True,0.258369000132148,0.0370443926243604,1.28939907431798,38.2038922759026
1710,19412,1011:1510,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.537106484824315,0.0758863042593394,0.666712554085651,10.4237429490525,26.8281,0.886602429037135,0.91754152510339,0.0556813548580762,0.358095636313185,0.193795140052827,0.164300496260357,7.82578304262641,4.4312,2.59795990642611,22.3969,0.476199914096835,0.39141768821587,0.492817503228623,0.426166400538694,0.084782225880965,0.0666511026899289,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
1711,19412,1564:1510,Colon,MDST8,SIDM00527,1240173,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.94054250169803,0.0758863042593394,0.666712554085651,10.4237429490525,26.8281,0.886602429037135,0.91754152510339,0.098459358881798,0.627071493533201,0.425212631551529,0.201858861981672,8.60529692124539,7.6065,1.81844602780713,19.2216,0.833887266618137,0.71889705682563,0.862986801432568,0.78900882354033,0.114990209792507,0.0739779778922384,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
1712,18972,1011:1561,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.575547938175489,0.0470561056896502,0.439959559906889,8.50445716277136,7.0929,0.820281153295057,0.833395846801372,0.0668381163026039,0.253217817585005,0.0628504873339134,0.190367330251092,4.69003106407121,0.5042,3.81442609870015,6.5887,0.472111126503182,0.310300374406619,0.479659261310545,0.320998026506841,0.161810752096562,0.158661234803704,True,0.221931874671536,0.0324110473483048,1.39733934166966,35.0875192801639
1713,19413,1011:2171,Colon,MDST8,SIDM00527,1240173,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.516896072319438,0.107258049612141,0.239287520118026,6.62504134677294,1.9278,0.653839209749814,0.711292601304541,0.0427653753090953,0.123686779304066,0.0282863499932455,0.0954004293108204,3.14944098583433,0.1733,3.47560036093862,1.7545,0.337966919448124,0.196512593761541,0.367664351884193,0.221721645092602,0.141454325686583,0.145942706791592,True,0.327948776758786,0.039588145106418,1.04487579419688,46.7122268991962
1714,19573,1372:1011,Colon,HT-29,SIDM00136,905939,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.26229755254221,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0301649520302754,0.131043707830917,0.0409687416942202,0.0900749661366973,5.36191462153178,0.8032,3.63462966986569,9.1729,0.23193268126704,0.139677270823906,0.223586670268563,0.160150671756344,0.0922554104431336,0.0634359985122186,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
1715,19573,1564:1011,Colon,HT-29,SIDM00136,905939,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.322895140206696,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0337667244240885,0.161318228108362,0.0380552363507063,0.123262991757656,4.65871076697651,0.4933,4.33783352442095,9.4828,0.285515190326391,0.157021625843243,0.275241032731702,0.178860477587812,0.128493564483148,0.09638055514389,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
1716,19573,2048:1011,Colon,HT-29,SIDM00136,905939,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.733844679040182,0.118836982054705,0.499599430344778,8.99654429139746,9.9761,0.884235018661549,0.852416151433905,0.0969131640435602,0.366628383610021,0.0986995261697593,0.267928857440262,4.98462780238036,0.6184,4.0119164890171,9.3577,0.648891163465774,0.411760688110947,0.62554105705768,0.425891570993927,0.237130475354826,0.199649486063754,True,0.134872289698204,0.0212679676449138,1.85260163319187,26.6265026142081
1717,20043,2171:1549,Colon,HT-29,SIDM00136,905939,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.440492904937004,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.036897018780581,0.398863964621402,0.24913053526156,0.149733429359843,9.56896713375592,7.4173,4.30490078794468,139.1883,0.428004989696424,0.385686929488827,0.431157607751781,0.387053506014119,0.0423180602075972,0.0441041017376624,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
1718,20043,1053:1549,Colon,HT-29,SIDM00136,905939,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.67758859033446,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.055464127832342,0.613552837046674,0.47981568578628,0.133737151260393,10.911486408742,18.8098,2.96238151295857,127.7958,0.658379043962105,0.61134043001562,0.663228561400525,0.627733106089329,0.0470386139464845,0.0354954553111956,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
1719,20043,1083:1549,Colon,HT-29,SIDM00136,905939,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.920705052753331,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0710373939598974,0.833693490796792,0.655380947662457,0.178312543134336,10.9502688687734,19.3223,2.9235990529272,127.2833,0.894603187021801,0.819221566618997,0.901192694685684,0.853983106939375,0.0753816204028035,0.0472095877463085,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
1720,20043,1372:1549,Colon,HT-29,SIDM00136,905939,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.31995429270817,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0461983460439879,0.289716897268682,0.16454521648846,0.125171680780221,9.12320316752546,5.4458,4.75066475417514,141.1598,0.310883631084753,0.246398518522353,0.313173551464345,0.274694493633519,0.0644851125624008,0.0384790578308259,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
1721,20043,1564:1549,Colon,HT-29,SIDM00136,905939,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.758812890006148,0.0444891826402372,0.905494640551462,13.8738679217006,146.6056,0.971650133065445,0.978807156527168,0.0584327238398904,0.687101005081933,0.432532679999719,0.254568325082214,9.60798954527974,7.6207,4.26587837642085,138.9849,0.737300645546248,0.64043884464735,0.742731487203081,0.668013890610424,0.0968618008988981,0.0747175965926561,True,0.130024643598101,0.0255965750247918,1.86690335014021,26.3890862076322
1722,18376,2048:1011,Colon,SK-CO-1,SIDM01096,909718,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.704613456401546,0.0645554909354787,0.075957850594236,3.8201500409425,0.2759,0.485533790976054,0.484977294337462,0.0642579756648368,0.0535209236480368,0.0156179742559339,0.0379029493921029,1.14949033110022,0.0433,2.67065970984228,0.2326,0.342113642659383,0.191140077961382,0.341721527639389,0.192513504340575,0.150973564698001,0.149208023298814,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1723,20060,1011:1025,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.151135957632208,0.0764678896766165,0.713294720569026,10.8895227035599,37.0513,0.890034257806839,0.930626163230876,0.0242303615607596,0.107804480667198,0.055446486168539,0.0523579944986593,7.86872023208025,4.5651,3.02080247147966,32.4862,0.134516179879108,0.100723627219989,0.140651076377486,0.120148783533192,0.0337925526591192,0.0205022928442948,True,0.448613352570212,0.0453060903290271,0.752646058675902,64.4037944142825
1724,18377,1011:1053,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.425766276358491,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.0580370573641779,0.28117900361406,0.107289768153043,0.173889235461016,6.74441534799175,2.0941,3.63443261070114,23.912,0.370672964348862,0.283746359250561,0.389508686875652,0.306184794992589,0.0869266050983009,0.0833238918830631,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1725,18377,1372:1053,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.622006237510406,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.110361637967988,0.410777235812932,0.168115976291221,0.242661259521711,6.94097608628967,2.3998,3.43787187240322,23.6063,0.541519863605483,0.396261850868779,0.56903716018398,0.45607069601956,0.145258012736705,0.112966464164419,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1726,18377,1564:1053,Colon,SK-CO-1,SIDM01096,909718,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.778456296893858,0.0836587201308115,0.660406939739185,10.3788479586929,26.0061,0.870601982663275,0.914841565675552,0.110672148394971,0.514097940752371,0.186485124321248,0.327612816431124,6.60532769145657,1.9017,3.77352026723632,24.1044,0.677725595492503,0.485435891268551,0.71216417746037,0.551911753515209,0.192289704223952,0.160252423945161,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1727,18376,1011:1510,Colon,SK-CO-1,SIDM01096,909718,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.430566925850043,0.142961934346113,0.212301072704043,6.28191282921155,1.5198,0.620430832916438,0.684810393725872,0.0449284615025287,0.0914098202288464,0.0163997306214786,0.0750100896073678,2.30589110278929,0.0966,3.97602172642225,1.4232,0.267136996431412,0.150241780266485,0.294856706016707,0.155370164159938,0.116895216164927,0.139486541856769,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1728,18376,1372:1510,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.601389952315041,0.142961934346113,0.212301072704043,6.28191282921155,1.5198,0.620430832916438,0.684810393725872,0.0559721842385609,0.127675731989916,0.0264184476781087,0.101257284311808,2.61426100886517,0.1196,3.66765182034638,1.4002,0.373120869022397,0.234974448803638,0.411838090027647,0.231855499539418,0.138146420218759,0.179982590488229,True,0.588175135124897,0.065263922363461,0.48951868011935,97.1014133864232
1729,20959,1372:1561,Colon,SK-CO-1,SIDM01096,909718,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.227191171109154,0.0780323727580437,0.143654388087933,5.29893718863852,0.7689,0.579586646295679,0.60744567292886,0.0693476510349654,0.0326370086646666,0.0189472486063507,0.0136897600583159,4.03062903135557,0.3192,1.26830815728296,0.4497,0.131676968931143,0.106446166005049,0.138006293817896,0.114176941901038,0.0252308029260936,0.0238293519168581,True,0.624425835146665,0.0706405710843436,0.432662411163343,109.270745254226
1730,23802,1194:1025,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.223147985666559,0.0641530317480637,0.875203479851225,14.4746100159605,444.6536,0.971904375911065,0.963673575258862,0.0739762488708603,0.195299893577164,0.0987613368169221,0.0965385567602415,8.35160249799554,6.3799,6.12300751796495,438.2737,0.216878503745068,0.122360502222216,0.215041817159106,0.174234778849667,0.0945180015228519,0.0408070383094388,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1731,23437,2171:1032,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.902211253785553,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.168571175554994,0.596096466488505,0.33964728436038,0.256449182128125,7.58172673257158,3.7416,3.29144544087201,32.8921,0.772477519670685,0.564388822721931,0.80079854309252,0.666170603681325,0.208088696948754,0.134627939411196,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1732,23437,1011:1032,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.888671983269735,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.082325556123939,0.587150988054882,0.363434832734274,0.223716155320608,7.9649586250584,4.88,2.9082135483852,31.7537,0.760885132563646,0.61479817761856,0.788781149097366,0.675419182863405,0.146086954945085,0.113361966233961,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1733,23437,1053:1032,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.846715703347774,0.0727791682014609,0.660706086282306,10.8731721734436,36.6337,0.856204704197024,0.887595382713839,0.113317507388146,0.559430218552678,0.537789059575462,0.0216411589772154,10.5581490180362,29.4476,0.315023155407374,7.1861,0.724961968323856,0.652796698271778,0.751540948762784,0.742558607272503,0.0721652700520777,0.0089823414902808,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1734,23441,1194:1053,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.537058019939453,0.100709594650621,0.665527098870015,10.9338303589028,38.2068,0.828384142109533,0.889552264464874,0.0551445831657978,0.357426665935179,0.141383236421325,0.216043429513854,6.10745275684108,1.3467,4.82637760206169,36.8601,0.444890347110589,0.305960949077559,0.477741177786162,0.347177920503187,0.138929398033029,0.130563257282976,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1735,23439,1194:1083,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.433474666301434,0.0738577382528677,0.720106038786311,11.6560805483849,63.0318,0.911638558062848,0.910805136090684,0.070318914489609,0.312147724864544,0.209525275368257,0.102622449496287,8.81287537473173,8.7835,2.84320517365316,54.2483,0.395172219743813,0.30013860549374,0.394810952432542,0.348556659887202,0.0950336142500735,0.0462542925453398,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1736,23438,1011:1372,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.839515495409211,0.104643563140335,0.610345135702767,10.2613405308668,2.3972,0.802991523036191,0.866295116718191,0.0578997339234792,0.51239419897011,0.268493917678887,0.243900281291224,6.87904633833087,0.2299,3.38229419253594,2.1673,0.674123826271125,0.53806502641432,0.727268174082252,0.584404466214112,0.136058799856805,0.14286370786814,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1737,23438,1053:1372,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.914466951040328,0.104643563140335,0.610345135702767,10.2613405308668,2.3972,0.802991523036191,0.866295116718191,0.110800151455717,0.558140455328405,0.467820740457783,0.0903197148706213,9.13018726348777,1.0944,1.13115326737905,1.3028,0.734309209782135,0.666482844545445,0.792198254086409,0.749091776719564,0.0678263652366908,0.0431064773668448,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1738,23801,1194:1510,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.398227614929942,0.089418775093272,0.731137319357945,11.8118297198021,70.2175,0.888706906517695,0.914912145531311,0.0408747847495467,0.291159070874186,0.124720552847376,0.16643851802681,6.79288969587639,2.1657,5.0189400239257,68.0518,0.353907631754309,0.256632529412573,0.36434328158537,0.27506850255166,0.0972751023417364,0.0892747790337098,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1739,23801,1032:1510,Colon,C2BBe1,SIDM01233,910700,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.818868228316955,0.089418775093272,0.731137319357945,11.8118297198021,70.2175,0.888706906517695,0.914912145531311,0.0482307519896136,0.598705121359048,0.398046043284045,0.200659078075003,8.84360485420905,8.9726,2.96822486559304,61.2449,0.727733850033187,0.657969605354927,0.749192487676889,0.659673944595431,0.0697642446782595,0.0895185430814581,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1740,23805,2171:1549,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.872345918783438,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.0988634618866352,0.476674987391477,0.211906568777897,0.26476841861358,5.80490463838118,0.5459,3.71859461296556,6.6413,0.686643781085569,0.508494384801469,0.729897710777161,0.546257149242306,0.1781493962841,0.183640561534855,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1741,23805,1053:1549,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.874006608743688,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.127492884673547,0.477582436316059,0.330636752198224,0.146945684117835,7.60372694082204,1.8995,1.91977231052471,5.2877,0.687950948814521,0.581803847627899,0.731287221261703,0.646455826398904,0.106147101186622,0.0848313948627988,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1742,23805,1561:1549,Colon,C2BBe1,SIDM01233,910700,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.784757984929711,0.101888105540869,0.546428861679369,9.52349925134675,7.1872,0.78712328022713,0.83670674105413,0.135292846238429,0.428814412398937,0.211941686192394,0.216872726206543,6.20544662926541,0.7207,3.31805262208134,6.4665,0.617701279282307,0.442227638560393,0.656612296086745,0.512382614672514,0.175473640721914,0.144229681414231,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1743,23806,1372:1561,Colon,C2BBe1,SIDM01233,910700,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.62431012217361,0.103355552084834,0.411969221806678,7.99986538723176,4.9995,0.781001886216531,0.761952644905296,0.0726456682029666,0.257196555197894,0.105028269411792,0.152168285786103,4.50788441964006,0.4444,3.4919809675917,4.5551,0.487587383001663,0.314210489242304,0.475694748831331,0.334672935985122,0.173376893759358,0.141021812846209,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1744,23806,1194:1561,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.195766735280076,0.103355552084834,0.411969221806678,7.99986538723176,4.9995,0.781001886216531,0.761952644905296,0.0523507221499028,0.0806498695889667,0.0692638670726319,0.0113860025163348,7.30699605031674,3.0928,0.692869336915027,1.9067,0.152894189512192,0.105125969523124,0.149164981731129,0.141388672032998,0.0477682199890678,0.0077763096981304,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1745,23806,1053:1564,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.890357128881027,0.0932941813656033,0.560094687994046,9.67891528687945,8.0047,0.813359813413269,0.843300020831138,0.0638968009567862,0.498684298303893,0.33024764911179,0.168436649192103,7.51513477960143,1.7864,2.16378050727802,6.2183,0.724180708217847,0.665248690997034,0.750838185332523,0.653974669597009,0.0589320172208131,0.0968635157355136,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1746,23808,2171:2048,Colon,C2BBe1,SIDM01233,910700,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.909686589469774,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.125269505645081,0.64444279997761,0.414579709848302,0.229863090129308,8.50107644243871,0.0708,2.99408862898266,0.493,0.791977243985654,0.679509018830209,0.8245299042989,0.717317488446889,0.112468225155445,0.107212415852011,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1747,23808,1011:2048,Colon,C2BBe1,SIDM01233,910700,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,1.0,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.0501795833370751,0.708422887000273,0.645570463814204,0.0628524231860694,10.6853678273617,0.3216,0.809797244059647,0.2422,0.870604506159942,0.903758702122468,0.906388984781551,0.881361675450434,-0.0331541959625257,0.0250273093311171,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1748,23808,1053:2048,Colon,C2BBe1,SIDM01233,910700,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.790267820854993,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.071665110393075,0.559843811153509,0.285409046451069,0.27443476470244,7.39690000412605,0.0329,4.09826506729532,0.5309,0.688010725909554,0.538082799445593,0.716290047850286,0.574974161439153,0.149927926463962,0.141315886411133,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1749,23808,1194:2048,Colon,C2BBe1,SIDM01233,910700,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.248592950550383,0.0856525373334129,0.708422887000273,11.4951650714214,0.5638,0.870604506159942,0.906388984781551,0.0752385671557213,0.176108935716819,0.100686251362562,0.0754226843542565,7.91908081934822,0.0473,3.57608425207315,0.5165,0.216426142948759,0.14324182580835,0.225321912073212,0.188307762865372,0.0731843171404098,0.0370141492078405,True,0.345422582926677,0.0536287308165879,1.03134670320914,47.8771136297993
1750,23441,1549:2171,Colon,C2BBe1,SIDM01233,910700,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.755298111238421,0.120807180022927,0.652772987233412,10.7742586790829,34.2062,0.813174292480076,0.8843453301415,0.133726023391518,0.493038204324859,0.323526452658863,0.169511751665995,8.18878586633115,5.699,2.58547281275171,28.5072,0.614189007217841,0.486359938608896,0.667944357538393,0.583235328021598,0.127829068608945,0.0847090295167958,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1751,23441,1032:2171,Colon,C2BBe1,SIDM01233,910700,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.846918229531413,0.120807180022927,0.652772987233412,10.7742586790829,34.2062,0.813174292480076,0.8843453301415,0.126175872989259,0.552845342633654,0.252127693801306,0.300717648832347,6.58764692943792,1.8785,4.18661174964494,32.3277,0.688692132087686,0.495365749178318,0.748968181297813,0.573978148580969,0.193326382909367,0.174990032716844,True,0.651853366495297,0.0775931991800355,0.400921185365453,119.218872096122
1752,22255,1083:1025,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.377455391656463,0.0810177419869619,0.923586839555166,15.4350543421654,865.2555,0.940137078719929,0.979918227874206,0.0850501932239413,0.34861283225305,0.12920508720982,0.21940774504323,7.31374780296985,3.1073,8.1213065391956,862.1482,0.354859809258994,0.200243939860984,0.369875418493565,0.276787099292561,0.15461586939801,0.0930883192010046,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1753,21266,1083:1032,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.906111650373542,0.144889035153065,0.408619808920119,8.04543857741383,5.16,0.791518952869033,0.776562517189796,0.1106245856883,0.370255169435931,0.422718973511455,-0.0524638040755241,8.65367474441157,7.8659,-0.608236166997738,-2.7059,0.717204544686097,0.789581893758756,0.703652344069078,0.73321788732561,-0.0723773490726587,-0.0295655432565318,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
1754,21266,1510:1032,Colon,SW948,SIDM00832,909757,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.712695660488341,0.144889035153065,0.408619808920119,8.04543857741383,5.16,0.791518952869033,0.776562517189796,0.116403189697266,0.291221564606944,0.097219533322245,0.194002031284699,4.23479801674566,0.3677,3.81064056066817,4.7923,0.564112122904035,0.3432010674835,0.55345273609907,0.368859392718515,0.220911055420536,0.184593343380556,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
1755,18392,1053:1054,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.769553218237087,0.0951980616529011,0.821755922577043,12.9463053314292,61.6618,0.914502943065558,0.950471390216633,0.112005573331983,0.63238491482455,0.452221574394228,0.180163340430322,9.91466919082747,7.5405,3.03163614060169,54.1213,0.703758682923388,0.580878762020068,0.731438317183488,0.666790140996535,0.12287992090332,0.0646481761869537,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1756,22255,1011:1194,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.918664297267616,0.0864400968817952,0.576276350471944,9.79403273930342,17.3391,0.863881200295268,0.861598582746567,0.0579807843983306,0.529404508538255,0.468238446783083,0.0611660617551717,9.10014743883222,10.7188,0.6938853004712,6.6203,0.793616815791957,0.787121142440435,0.791519856545649,0.763494926177781,0.0064956733515223,0.0280249303678676,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1757,18390,1011:1510,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.214994964749006,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0398471372633526,0.110540223379334,0.0449547705415245,0.065585452837809,5.56473636834567,0.9244,3.58148058946819,10.1422,0.177351654159781,0.123275548338198,0.179144847068855,0.132320508460519,0.0540761058215836,0.046824338608336,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1758,18390,1053:1510,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.682475208220444,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0546096503440908,0.350896413111897,0.134708488690746,0.216187924421151,5.37789448719271,0.8122,3.76832247062115,10.2544,0.562981124893979,0.41112040583657,0.568673396363816,0.410836825480012,0.151860719057409,0.157836570883804,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1759,18390,1032:1510,Colon,SW948,SIDM00832,909757,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.906975845623483,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0759112742076138,0.466324002945484,0.371239935920066,0.0950840670254172,8.05287832373103,5.1867,1.09333863408282,5.8799,0.748174110459183,0.707126911626579,0.75573885811256,0.704702561449138,0.0410471988326042,0.0510362966634225,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1760,18390,2048:1510,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.892417170438903,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0411249785204394,0.458838622025566,0.424724864266333,0.0341137577592326,8.75115865964615,8.4157,0.395058298167713,2.6509,0.736164503027797,0.736011161861395,0.743607822194991,0.726538156572592,0.0001533411664023,0.0170696656223994,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1761,18390,1561:1510,Colon,SW948,SIDM00832,909757,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.327227637829669,0.0764319337266273,0.514152615194419,9.14621695781386,11.0666,0.824910733918018,0.833251361388838,0.0635518423780602,0.168244945754016,0.117660731483451,0.0505842142705656,7.50947338322345,3.5588,1.63674357459041,7.5078,0.269933590880332,0.222761884950552,0.272662874705625,0.24387508188975,0.0471717059297799,0.0287877928158753,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1762,21270,1053:1549,Colon,SW948,SIDM00832,909757,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.630524431079109,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.0695371606013281,0.55786389275972,0.456464293562466,0.101399599197253,11.4894960824074,28.0791,2.77378624521733,163.9539,0.597403633240708,0.563054070077682,0.611030738922093,0.579215716189653,0.034349563163026,0.0318150227324402,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
1763,21270,1083:1549,Colon,SW948,SIDM00832,909757,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.979221764330196,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.173117946914292,0.86637795206344,0.75500380467682,0.11137414738662,12.1350248153107,43.9245,2.12825751231404,148.1085,0.927784255334968,0.883742870895908,0.948947524845719,0.915028582365258,0.04404138443906,0.0339189424804609,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
1764,21270,2048:1549,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.902973125637892,0.0915343923798871,0.884761740008972,14.2632823276248,192.033,0.947471031722409,0.969083367438033,0.0472157005021746,0.798916073820722,0.714062916943112,0.0848531568776102,12.433511115042,54.0207,1.82977121258274,138.0123,0.855540878965742,0.882116806193691,0.875056237299215,0.849524325091535,-0.0265759272279491,0.0255319122076799,True,0.297292024152372,0.0736474137455505,1.15305018714611,42.609188659605
1765,22256,2048:1561,Colon,SW948,SIDM00832,909757,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.97574460741733,0.125444749457754,0.216155154189727,5.67360926950291,0.9969,0.585925213649164,0.623252344440132,0.0799641408231951,0.210912226066088,0.101476196416918,0.10943602964917,3.43913121088094,0.2118,2.23447805862197,0.7851,0.571713367568019,0.439577934378936,0.608135114147668,0.447013105609271,0.132135433189083,0.161122008538396,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1766,22256,1011:1561,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.673071476228346,0.125444749457754,0.216155154189727,5.67360926950291,0.9969,0.585925213649164,0.623252344440132,0.065359311308538,0.145487868724845,0.0452183121256828,0.100269556599162,2.20681324901229,0.0902,3.46679602049062,0.9067,0.394369548510252,0.217753874789748,0.419493375535097,0.24785378542014,0.176615673720504,0.171639590114957,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1767,22256,1011:1564,Colon,SW948,SIDM00832,909757,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.673071476228346,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.0422441639734503,0.303524582561497,0.123580397566472,0.179944184995025,5.14714082447018,0.3461,3.34464905255749,3.1694,0.526340921144219,0.397478541578957,0.539007146679528,0.393864713447301,0.128862379565262,0.145142433232227,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1768,22256,1194:1564,Colon,SW948,SIDM00832,909757,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.976204354213939,0.118444566313591,0.450954457708327,8.49178987702767,3.5155,0.781998553992582,0.800817098504803,0.112111197718116,0.440223705167055,0.234566737050579,0.205656968116476,6.02760956655425,0.6371,2.46418031047342,2.8784,0.763390393396563,0.590039166596933,0.781761138489361,0.632822352978384,0.17335122679963,0.148938785510978,True,0.336435317390915,0.0653459167376983,1.04089679696544,47.1947233830346
1769,18391,1025:2171,Colon,SW948,SIDM00832,909757,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.89413087940106,0.107503720041575,0.113977429828329,3.70463315648676,0.2546,0.47039672652348,0.477920057140366,0.0806998195830835,0.101910739564276,0.0325734557204808,0.0693372838437957,0.542759341158543,0.0285,3.16187381532822,0.2261,0.420596238753819,0.237462876717455,0.42732308097432,0.230589475840492,0.183133362036363,0.196733605133828,True,0.301433607553238,0.0603330809606757,1.14193672100903,43.0397231053888
1770,22646,2171:1032,Colon,T84,SIDM00782,909761,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.826618193212268,0.0982157347379647,0.468339742059285,8.68584492004188,8.0432,0.778628635700326,0.816994307491637,0.0960070589201674,0.387138151390546,0.183120987466385,0.204017163924161,5.88653332795515,1.1555,2.79931159208673,6.8877,0.643628596025937,0.480559229177829,0.675342358323446,0.530299013581316,0.163069366848108,0.14504334474213,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1771,22650,1510:1053,Colon,T84,SIDM00782,909761,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.800086864009393,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.092137342523446,0.586289968028508,0.321936899198184,0.264353068830324,8.02003561064802,5.0699,3.47909017734767,51.4644,0.743623189926652,0.580335960757442,0.739734475435131,0.624774863515332,0.16328722916921,0.1149596119198,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1772,22650,1372:1053,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.89503649535688,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0272280756435677,0.655867433715262,0.579785862862703,0.0760815708525595,10.509429594288,28.4697,0.989696193707701,28.0646,0.831872042546421,0.819779524451429,0.827521838154247,0.800877846736703,0.0120925180949921,0.0266439914175438,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1773,22650,1564:1053,Colon,T84,SIDM00782,909761,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.955352603323722,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0409062117202327,0.700066045893787,0.67536942751593,0.0246966183778573,11.1813859968167,45.3589,0.317739791179029,11.1754,0.887931526369838,0.892105986800543,0.883288163654894,0.874995155865439,-0.0041744604307054,0.0082930077894557,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1774,22650,2048:1053,Colon,T84,SIDM00782,909761,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.954197699711708,0.0674344437412892,0.73278289446035,11.4991257879957,56.5343,0.929428070097551,0.924567704721679,0.0489264547652766,0.699219752282153,0.618333680765108,0.0808860715170454,10.5119838052326,28.5202,0.987141982763058,28.0141,0.886858126534575,0.866083897941165,0.88222037707316,0.853898737696211,0.02077422859341,0.0283216393769491,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1775,22648,1011:1083,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929321060282679,0.0987577601441875,0.601793083054216,10.0230036031321,20.3215,0.913381398425977,0.877067463362614,0.119182058187611,0.559258986014727,0.492092389087329,0.067166596927398,9.29284847376712,12.2506,0.730155129364983,8.0709,0.848824569627705,0.81694551559993,0.815077264991585,0.786530357642026,0.0318790540277748,0.0285469073495588,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1776,22648,1372:1083,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.949861316139777,0.0987577601441875,0.601793083054216,10.0230036031321,20.3215,0.913381398425977,0.877067463362614,0.113783582323265,0.571619969913692,0.439410470636007,0.132209499277685,8.62874273108373,7.7311,1.39426087204838,12.5904,0.867585657246488,0.802623192161148,0.833092455092989,0.773239852193266,0.0649624650853404,0.0598526028997226,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1777,22647,1011:1372,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.90381503617455,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0462350966071165,0.283348687554253,0.101377259740523,0.18197142781373,3.87483481363855,0.0287,3.18343156859838,0.2316,0.591524067897134,0.433109950297064,0.652589450237351,0.443249530291241,0.15841411760007,0.20933991994611,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1778,22647,1053:1372,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.889549697641683,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0367126381649001,0.278876461723719,0.141601682080525,0.137274779643194,4.87690027520099,0.0574,2.18136610703594,0.2029,0.582187764847114,0.493772156431404,0.642289323487949,0.504222324037535,0.0884156084157094,0.138066999450414,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1779,22647,1561:1372,Colon,T84,SIDM00782,909761,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.536213333469903,0.132510526617733,0.313502958252988,7.05826638223694,0.2603,0.654474692522039,0.722038718230971,0.0553973611604133,0.168104466297511,0.0308334913124532,0.137270974985058,2.07156006246822,0.0082,4.98670631976872,0.2521,0.350938056548933,0.168462515728328,0.387166787996965,0.190601518905366,0.182475540820605,0.1965652690916,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1780,22649,1053:1510,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.835900038397371,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0412294211875939,0.724859144515849,0.435086336709439,0.289772807806409,9.20326138803232,11.513,4.44445137541277,239.1562,0.800726635784775,0.697333996934735,0.806943686150293,0.704024289874143,0.10339263885004,0.102919396276151,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1781,22649,1549:1510,Colon,T84,SIDM00782,909761,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.836151850439203,0.0467751417637643,0.867160080415339,13.6477127634451,250.6692,0.957921520520526,0.965359072954951,0.0215739511416638,0.725077505866294,0.513558302680817,0.211519203185477,10.1518966296353,22.2206,3.49581613380976,228.4486,0.800967851958773,0.740855284640418,0.807186775189556,0.737464955158629,0.0601125673183542,0.0697218200309264,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1782,22655,1510:1549,Colon,T84,SIDM00782,909761,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.88081668171289,0.109238343188126,0.705469702511386,11.1639246687888,22.4066,0.840398820767639,0.915386854287413,0.135204187059905,0.621389482415059,0.327950365523678,0.293439116891381,7.70619167233523,2.0394,3.45773299645354,20.3672,0.740237300623978,0.594528916637339,0.806288011477041,0.671629368388524,0.145708383986638,0.134658643088517,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1783,22656,1372:1561,Colon,T84,SIDM00782,909761,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.639440694547451,0.10257975989545,0.346249614367895,7.42547838188152,3.3575,0.699838590265757,0.745377706117625,0.0793265203734522,0.221406093898194,0.0606110844395051,0.160795009458689,3.40977375866759,0.2076,4.01570462321393,3.1499,0.447505274230645,0.271780317750157,0.47662483810004,0.29088933662003,0.175724956480488,0.18573550148001,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1784,22656,1011:1564,Colon,T84,SIDM00782,909761,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.899036791953243,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0940242014228341,0.551711191583362,0.312147260892617,0.239563930690745,7.4358934743103,1.6909,2.71053225957764,9.3773,0.7672593572224,0.688304701851398,0.79274340814285,0.670703529036281,0.0789546553710017,0.122039879106569,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1785,22656,1053:1564,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.880225144691997,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0572928985527012,0.540167063001483,0.326054593071402,0.214112469930082,7.68599204892103,2.011,2.46043368496691,9.0572,0.751205050529789,0.699699904497786,0.776155867459157,0.670112207681143,0.0515051460320035,0.106043659778013,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1786,22656,1561:1564,Colon,T84,SIDM00782,909761,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.561477057807613,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0500924277797489,0.344561178566171,0.129730794250082,0.214830384316088,6.02128667127723,0.6343,4.12513906261071,10.4339,0.479177860488493,0.358047456259404,0.495093460450477,0.365626668334756,0.121130404229089,0.129466792115721,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1787,22656,1549:1564,Colon,T84,SIDM00782,909761,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.883551027085256,0.0649324173359291,0.613669202997485,10.1464257338879,11.0682,0.853423757614475,0.881769706466116,0.0837020637123577,0.542208054599018,0.237379254825406,0.304828799773611,6.51916139260856,0.8957,3.62726434127938,10.1725,0.754043437579227,0.557666150898671,0.779088529800801,0.606146347286946,0.196377286680556,0.172942182513855,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1788,22658,1053:2048,Colon,T84,SIDM00782,909761,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.941254855072551,0.0855815623475856,0.589841283040469,9.90004599867347,0.1866,0.908605191334064,0.872243393769464,0.067074480513144,0.555190971384064,0.40498599699838,0.150204974385684,8.30440053862259,0.0617,1.59564546005089,0.1249,0.855229047687312,0.75642960159837,0.821003329190467,0.749987506253824,0.0987994460889419,0.0710158229366429,True,0.298809009659715,0.0413901211201272,1.12777045079347,43.3062985221309
1789,18397,2048:1011,Colon,HT55,SIDM00541,907287,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.891719822166366,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.113108263134533,0.396574942694986,0.308855610536264,0.0877193321587226,7.12457841020757,2.7255,1.21988854830122,3.6229,0.727488470046229,0.660232230616846,0.68924271791647,0.628815917077943,0.0672562394293827,0.0604268008385263,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
1790,18397,1510:1011,Colon,HT55,SIDM00541,907287,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.434680990504502,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.0429084450567986,0.193315865157208,0.0949230869610102,0.0983927781961981,5.23437491560363,0.7352,3.11009204290516,5.6132,0.354624177773747,0.250660420741224,0.335980764220413,0.254043246299097,0.103963757032524,0.0819375179213158,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
1791,18397,1194:1011,Colon,HT55,SIDM00541,907287,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.683679329545015,0.141266708391865,0.444730433076544,8.34446695850879,6.3484,0.81582628529985,0.772936409826582,0.0797991013325734,0.304053004314035,0.141009955675554,0.163043048638481,5.02026906602711,0.6338,3.32419789248167,5.7146,0.557763567759001,0.394001392288822,0.528440646451169,0.389669337045665,0.16376217547018,0.138771309405504,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
1792,21218,1194:1025,Colon,HT55,SIDM00541,907287,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.284955187912149,0.0933873789113566,0.798740386645388,13.0705977450465,168.0243,0.936089443362923,0.936146098730007,0.0249086946557397,0.227605216969559,0.10082112553717,0.126784091432389,7.22133254034381,2.9145,5.84926520470267,165.1098,0.26674354323606,0.184610894701104,0.266759687476834,0.202571363531414,0.0821326485349564,0.0641883239454199,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
1793,18394,1083:1032,Colon,HT55,SIDM00541,907287,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.992841494932777,0.120573219418433,0.327284392964259,6.87235043986921,2.2883,0.633818375003262,0.690019834750579,0.16561928771718,0.324941525978802,0.227836759727698,0.0971047662511039,5.42311515437691,0.838,1.4492352854923,1.4503,0.629281182954102,0.533515222377473,0.685080324267032,0.592828391026964,0.0957659605766297,0.0922519332400685,True,0.306262632082908,0.0422742255336387,1.10886005457665,44.0771149292623
1794,22622,1549:1054,Colon,HT55,SIDM00541,907287,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.61248878567062,0.127639479075977,0.568151517651558,9.81005996936796,7.0131,0.835964342284638,0.840542488509589,0.0898632074696877,0.347986433123323,0.246781665835577,0.101204767287746,7.83848193471651,1.7882,1.97157803465145,5.2249,0.512018784869856,0.409631187719303,0.514822848091799,0.456920679016004,0.102387597150553,0.0579021690757947,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
1795,21221,1083:1549,Colon,HT55,SIDM00541,907287,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.980325605302455,0.158304875346529,0.537739976340705,9.4466410604299,6.8143,0.740044662082104,0.82526487384718,0.0907191372471305,0.52716026780153,0.36134259081653,0.165817676984999,7.41051902987444,1.6615,2.03612203055546,5.1528,0.72548473130649,0.691741894693706,0.809028286989092,0.707702644399075,0.0337428366127844,0.101325642590017,True,0.241405951442356,0.0487509605429818,1.34398224312432,36.610006142732
1796,22623,1053:1561,Colon,HT55,SIDM00541,907287,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.788716435773446,0.102413749283125,0.209860414517392,5.08494889012724,0.6629,0.562833225105538,0.574343573936984,0.161550856682714,0.165520358148095,0.0435911860365433,0.121929172111552,0.6171957954587,0.03,4.46775309466854,0.6329,0.443915815240114,0.248089986294049,0.452994216544961,0.220599848720071,0.195825828946064,0.23239436782489,True,0.137834679944973,0.0449434440063534,1.85456844434429,26.6441096514902
1797,19223,1032:1011,Colon,NCI-H508,SIDM00777,908442,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.393950272678685,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0668150903013885,0.160996632839909,0.127000516559437,0.0339961162804721,6.59943698306888,1.8939,1.20667543703475,2.4773,0.316446162244333,0.283253551788699,0.288114771673479,0.261415408366182,0.0331926104556331,0.026699363307297,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
1798,19223,2048:1011,Colon,NCI-H508,SIDM00777,908442,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.794916917741126,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0845908066158348,0.324860663945225,0.164074160535469,0.160786503409755,4.64805051068131,0.4897,3.15806190942233,3.8815,0.638528325445385,0.439400169448091,0.581360953749536,0.430828834867049,0.199128155997293,0.150532118882487,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
1799,19223,1510:1011,Colon,NCI-H508,SIDM00777,908442,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.640447944331287,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.065950203069124,0.261733446319194,0.135960205721481,0.125773240597713,4.76295143777941,0.5303,3.04316098232423,3.8409,0.514448924537763,0.351444714087888,0.468390368142373,0.351853043546234,0.163004210449875,0.116537324596139,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
1800,19223,2171:1011,Colon,NCI-H508,SIDM00777,908442,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.432424892096384,0.159861016563322,0.408672474688757,7.80611242010364,4.3712,0.803264229499426,0.731348070187711,0.0439363750341173,0.176720150770048,0.0900351356890077,0.0866850150810402,4.6835591618828,0.5019,3.12255325822084,3.8693,0.347351447766175,0.220010714819244,0.31625311033582,0.23535599963498,0.127340732946931,0.0808971107008395,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
1801,19520,1011:1194,Colon,NCI-H508,SIDM00777,908442,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.427611612059372,0.0855870451910503,0.762263539054588,12.7650862488405,135.9577,0.957511770012617,0.916810499531412,0.0734015000954068,0.325952740749214,0.237821524187843,0.0881312165613711,9.72902650837639,16.5752,3.03605974046407,119.3825,0.409443151540918,0.370539646531507,0.392038815657585,0.351447863538473,0.0389035050094114,0.0405909521191121,True,0.313157782574321,0.0371845480838703,1.09873578111021,44.61243274509
1802,19223,1032:1510,Colon,NCI-H508,SIDM00777,908442,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.393950272678685,0.110914712756356,0.527023083687239,9.34963828859668,12.7424,0.834142857400345,0.805896468378695,0.0251783615931014,0.207620887526549,0.201140647036416,0.0064802404901336,9.13669489283798,10.9938,0.212943395758698,1.7486,0.328610806125843,0.323998067388431,0.317483133468576,0.31378467995147,0.004612738737412,0.0036984535171059,True,0.303828065256482,0.0809112345920737,1.12097657803301,43.667840710893
1803,19622,1510:1011,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.71110341147596,0.111900881393037,0.401673033081966,8.01632039380557,5.0569,0.816955033580985,0.781164978157922,0.0635136248137615,0.285631064122482,0.0930839245774715,0.192547139545011,4.32715553790319,0.392,3.68916485590238,4.6649,0.580939511401895,0.367680977971445,0.555489080893642,0.37338240604551,0.21325853343045,0.182106674848132,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1804,19622,1561:1011,Colon,LS-1034,SIDM00681,917486,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.990454168723508,0.111900881393037,0.401673033081966,8.01632039380557,5.0569,0.816955033580985,0.781164978157922,0.120944166078878,0.397838730079849,0.310667702539622,0.0871710275402273,7.06705870692639,2.6189,0.949261686879178,2.438,0.809156518669939,0.744877624591391,0.773708109077322,0.716120333004237,0.0642788940785484,0.0575877760730851,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1805,19619,1011:1032,Colon,LS-1034,SIDM00681,917486,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.907076504080284,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.132645437810843,0.604126698529657,0.270530569302847,0.33359612922681,6.88780734793606,2.313,3.81596670919384,30.2622,0.842342435080613,0.68896309875869,0.818016128600163,0.645168804066527,0.153379336321923,0.172847324533636,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1806,19619,1053:1032,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.980536209431523,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.128690355201941,0.653051975580906,0.48985205107675,0.163199924504156,8.99581040295538,9.971,1.70796365417452,22.6042,0.910559643670541,0.875443365340351,0.884263268184557,0.816743313148124,0.0351162783301899,0.0675199550364323,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1807,19619,1372:1032,Colon,LS-1034,SIDM00681,917486,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.984536101316133,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.100004396511002,0.655715964194716,0.441401540445106,0.21431442374961,8.48803573059568,7.0127,2.21573832653422,25.5625,0.914274080826597,0.778558078772358,0.887870434790184,0.79472376439351,0.135716002054239,0.0931466703966742,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1808,19619,1564:1032,Colon,LS-1034,SIDM00681,917486,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.959909268878256,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.0861703607164252,0.639314120569604,0.584334341274396,0.0549797792952081,10.0910981035122,21.3036,0.612675953617742,11.2716,0.891404757334333,0.841621216014978,0.86566156261689,0.84493122515318,0.0497835413193548,0.0207303374637097,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1809,19619,2048:1032,Colon,LS-1034,SIDM00681,917486,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.942857515499757,0.10611655092412,0.666015155074711,10.7037740571299,32.5752,0.928634388931387,0.901816026454768,0.076899678723658,0.627957394398928,0.502181442531278,0.125775951867649,9.3225080748932,12.505,1.38126598223669,20.0702,0.875569912755482,0.838960461944455,0.850284018141006,0.799769057567978,0.036609450811027,0.0505149605730282,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1810,19623,1194:1053,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.952958710836484,0.07277068369738,0.60167964190396,10.0181629884197,20.2534,0.863216169436832,0.877422371279174,0.0780772549372461,0.573375855885355,0.643277303756043,-0.0699014478706879,10.8045244348583,34.9314,-0.786361446438658,-14.678,0.822609367999731,0.888172861217907,0.836147291793292,0.862475267036481,-0.065563493218176,-0.0263279752431895,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1811,19623,1510:1053,Colon,LS-1034,SIDM00681,917486,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.617995364669342,0.07277068369738,0.60167964190396,10.0181629884197,20.2534,0.863216169436832,0.877422371279174,0.0875699202509141,0.371835229712557,0.284925810912238,0.0869094188003188,8.61461750890157,7.6558,1.40354547951812,12.5976,0.533463591419587,0.495775560260368,0.542242958307712,0.502955631383911,0.0376880311592191,0.0392873269238011,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1812,19624,1053:1054,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.90080063550236,0.0853508552548557,0.764171419962833,11.902138721608,29.9014,0.905170753936189,0.934929662365362,0.0659740745219573,0.68836610073526,0.477728312883037,0.210637787852223,9.29991579944026,4.9243,2.60222292216776,24.9771,0.815378390383869,0.735551641849805,0.842185234008724,0.76317200064002,0.0798267485340639,0.0790132333687039,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1813,19624,1561:1054,Colon,LS-1034,SIDM00681,917486,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.926568030875192,0.0853508552548557,0.764171419962833,11.902138721608,29.9014,0.905170753936189,0.934929662365362,0.0951323917576128,0.708056807846061,0.546342637548946,0.161714170297115,9.8947733465211,7.4373,2.00736537508692,22.4641,0.838702283080468,0.740921765660864,0.866275936264681,0.808502348291881,0.0977805174196033,0.0577735879728004,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1814,19622,1194:1510,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.952755344785127,0.0865184938219761,0.556383609706455,9.55910124016394,14.7335,0.84383307642529,0.858676399568289,0.0647614423826371,0.530097457898667,0.521142418244236,0.0089550396544312,9.46529073827506,13.806,0.0938105018888731,0.9275,0.803966473670672,0.841291672177855,0.818108529129537,0.81422622214388,-0.0373251985071831,0.0038823069856566,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1815,20300,2171:1549,Colon,LS-1034,SIDM00681,917486,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.705415044918266,0.0819891989133979,0.934129652790327,15.5461810664623,467.2689,0.938124513561566,0.983482630463951,0.065572921496668,0.658949110982573,0.399895204930535,0.259053906052039,9.66447990661152,7.925,5.88170115985075,459.3439,0.661767145872959,0.558787054868749,0.693763443945063,0.608882183865118,0.10298009100421,0.0848812600799447,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1816,20300,1054:1549,Colon,LS-1034,SIDM00681,917486,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.835507799758633,0.0819891989133979,0.934129652790327,15.5461810664623,467.2689,0.938124513561566,0.983482630463951,0.106017023011662,0.780472610892142,0.469913632265293,0.310558978626849,9.6196457830988,7.6825,5.92653528336346,459.5864,0.783810348225461,0.649087391782648,0.821707408679769,0.719591184608726,0.134722956442813,0.102116224071043,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1817,20301,1053:1564,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.940236993148713,0.0761231756944598,0.505187128250677,9.05121875626995,5.1807,0.836746839450525,0.835619115645597,0.096962897352555,0.47499562644385,0.212601588662618,0.262394037781232,5.96285314566354,0.6091,3.08836561060641,4.5716,0.786740332351651,0.561475095567476,0.785680004712203,0.608608238226014,0.225265236784175,0.177071766486189,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1818,20303,1011:2048,Colon,LS-1034,SIDM00681,917486,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.777852753974258,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.0715676241938717,0.40584890681828,0.107677387995002,0.298171518823278,4.48666429841267,0.0044,4.72828134616927,0.1117,0.609957345480673,0.420296089148583,0.655978170631549,0.417919206652557,0.18966125633209,0.238058963978991,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1819,20303,1194:2048,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.928948304463639,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.0606604517357877,0.484683832423301,0.358824981882013,0.125858850541288,7.85705774926892,0.0453,1.35788789531302,0.0708,0.728439719451278,0.690722039262812,0.783399951031738,0.717081464685256,0.0377176801884666,0.066318486346482,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1820,20303,1053:2048,Colon,LS-1034,SIDM00681,917486,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.912454761180186,0.146594128616753,0.521755441174039,9.21494564458194,0.1161,0.784155281785964,0.84331921084033,0.192510213099323,0.47607823647092,0.211147899985167,0.264930336485753,6.03689087342938,0.0128,3.17805477115256,0.1033,0.715506220370193,0.506264303278135,0.769490629125976,0.59546081499584,0.209241917092059,0.174029814130136,True,0.22619748666549,0.0368660011582517,1.24388228424017,38.269059378773
1821,19623,1194:2171,Colon,LS-1034,SIDM00681,917486,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,2.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.81796769816986,0.14691969672836,0.325485457783184,7.20129223846674,2.8743,0.657394055370287,0.731676309007775,0.0760090841588812,0.266236590690675,0.0559454408586139,0.210291149832061,2.55336719920929,0.1146,4.64792503925744,2.7597,0.537727102261784,0.305163799919739,0.598487586284509,0.319300894870775,0.232563302342044,0.279186691413735,True,0.271157623415435,0.0367741766136671,1.2270548595153,39.9632113096037
1822,23228,2048:1011,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.698364339464375,0.182676775668712,0.506884653646452,9.06655956231904,10.4722,0.88736383388261,0.839508661692955,0.0619429194416845,0.353990166328433,0.107906197198826,0.246083969129607,4.89231667369835,0.58,4.17424288862069,9.8922,0.619703257714005,0.3934296728572,0.586282911997822,0.397301002315564,0.226273584856805,0.188981909682258,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1823,23225,2171:1032,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.895013599601372,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.126534207760002,0.497058774128488,0.169229223228669,0.327829550899819,5.48114035763337,0.8724,4.05628318924544,13.6414,0.776934376081061,0.520641831433606,0.770543182581265,0.549056744878146,0.256292544647455,0.221486437703118,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1824,23225,1053:1032,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.8635046878234,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.0950164330018618,0.479559843308379,0.304822515260732,0.174737328047647,7.53577846228699,3.6243,2.00164508459182,10.8895,0.749582437826587,0.649517512174241,0.743416245994062,0.652216957037369,0.100064925652346,0.0911992889566928,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1825,23225,1510:1032,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.832017476397892,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.0707972884746091,0.462072964093518,0.115908623269683,0.346164340823834,4.59893249961268,0.4733,4.93849104726613,14.0405,0.722249336995153,0.436856770569454,0.716307991870073,0.454583705090408,0.285392566425698,0.261724286779665,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1826,23225,2048:1032,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.966067120780987,0.0993825297604828,0.555364493176274,9.53742354687881,14.5138,0.868069911370172,0.860929021552807,0.122925066725613,0.536519376906795,0.482091497648144,0.0544278792586508,8.99057298953099,9.9349,0.546850557347815,4.5789,0.838613799913989,0.865823598908959,0.831715221048313,0.807486986244459,-0.0272097989949701,0.0242282348038533,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1827,23229,2171:1053,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.890288991384888,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0439809060943776,0.571474928845989,0.33244089220232,0.239034036643669,7.74900420542223,4.2016,2.66147129805094,22.3809,0.782195011034084,0.657089514839252,0.796808033906494,0.684019690517204,0.125105496194832,0.11278834338929,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1828,23229,1083:1053,Colon,CaR-1,SIDM00488,924108,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.998315515607596,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.1009126740464,0.640816963669558,0.552265539449253,0.0885514242203049,9.51622384689628,14.3021,0.894251656576889,12.2804,0.877105550335389,0.782002715489957,0.893491698658713,0.858562298122056,0.0951028348454319,0.0349294005366577,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1829,23229,1510:1053,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.81934349226351,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.09754142983071,0.525935138446845,0.277625325941028,0.248309812505817,7.38443265912839,3.2634,3.02604284434478,23.3191,0.719863323228148,0.54925294919927,0.733311861072227,0.611113628982015,0.170610374028878,0.122198232090212,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1830,23229,1372:1053,Colon,CaR-1,SIDM00488,924108,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.887106426503712,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0266309786143059,0.569432046078014,0.526489023610583,0.0429430224674308,9.91454876707941,18.8498,0.495926736393761,7.7327,0.779398855632369,0.790038197627834,0.793959640530535,0.777579586343743,-0.0106393419954649,0.0163800541867918,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1831,23229,1564:1053,Colon,CaR-1,SIDM00488,924108,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.948690634885193,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0419436462458288,0.608962840509267,0.550561853936158,0.0584009865731088,9.78343941464691,17.2123,0.627036088826259,9.3702,0.833505849002629,0.838270857938829,0.849077464602249,0.826560533194946,-0.0047650089361999,0.0225169314073035,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1832,23229,2048:1053,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.930439611931844,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0500441664728422,0.597247541157528,0.548283766800775,0.0489637743567521,9.87237937063537,18.3068,0.538096132837801,8.2757,0.817470764621577,0.824654963123146,0.832742811633421,0.814002171079411,-0.0071841985015687,0.01874064055401,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1833,23229,1561:1053,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.629407624805232,0.0575004564573172,0.641898231221562,10.4104755034732,26.5825,0.878585513920981,0.894999311029355,0.0581237974616621,0.404015641079843,0.349505464976886,0.0545101761029574,9.53672099072305,14.5067,0.873754512750116,12.0758,0.552988421505289,0.52459498998946,0.563319390557305,0.541856185434784,0.0283934315158286,0.021463205122521,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1834,23230,1053:1054,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.844383156719165,0.0730877120009981,0.804761869513906,12.4229793443425,42.9022,0.91953796480596,0.948438875853107,0.0469134938455258,0.679527367787369,0.475933227711078,0.203594140076291,9.61863521967421,6.1417,2.80434412466826,36.7605,0.776442369445973,0.695528460512946,0.800845811948023,0.729889489464894,0.0809139089330265,0.0709563224831289,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1835,23226,2171:1372,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.892102363755923,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.118382466373159,0.716098463684856,0.507738312895841,0.208360150789015,9.67277951266357,1.5941,2.71874540251498,8.9001,0.779099623297613,0.678509540474975,0.845564730185192,0.773174327555645,0.100590082822638,0.0723904026295465,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1836,23226,1053:1372,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.873232641399618,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.157758928459214,0.700951570527193,0.314860297871487,0.386091272655706,7.61542191283698,0.383,4.77610300234157,10.1112,0.76262013150742,0.567091230785761,0.827679370453936,0.663843504688072,0.195528900721658,0.163835865765864,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1837,23226,2048:1372,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.959114569110302,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.0819236415601536,0.769889754070378,0.81149288808641,-0.0416031340160324,13.1187677155951,17.3729,-0.727242800416567,-6.8787,0.837623382530946,0.857480289375993,0.909081160184354,0.921044872753772,-0.0198569068450466,-0.011963712569418,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1838,23226,1561:1372,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.642150960499766,0.100259629347298,0.802708851336234,12.3915249151785,10.4942,0.873329849746674,0.947833751527349,0.134738376716286,0.515460259887227,0.230979648463283,0.284480611423944,7.60627828404041,0.3806,4.78524663113813,10.1136,0.560809601847943,0.392924199183976,0.608652353937384,0.487812508504692,0.167885402663967,0.120839845432692,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1839,23228,2048:1510,Colon,CaR-1,SIDM00488,924108,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.968436999953048,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0587572703053469,0.812013116766328,0.648924945175631,0.163088171590697,10.7123569363338,32.7696,2.26798641488213,125.0652,0.893448138503381,0.88736351406642,0.92792324561039,0.876562456546762,0.0060846244369606,0.0513607890636276,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1840,23228,1032:1510,Colon,CaR-1,SIDM00488,924108,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.90402438613032,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.103080307216034,0.75800455729184,0.422774328288636,0.335230229003204,8.68690710264341,8.0491,4.29343624857251,149.7857,0.834023178574296,0.682304259125381,0.866205279775202,0.741905684231374,0.151718919448914,0.124299595543827,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1841,23228,1549:1510,Colon,CaR-1,SIDM00488,924108,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.885848211347759,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0822492979386725,0.742764234651552,0.453131203291968,0.289633031359584,9.11140912533932,10.8028,3.8689342258766,147.032,0.817254437267036,0.706698205014621,0.848789490108105,0.745566985787848,0.110556232252415,0.103222504320257,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1842,23228,1053:1510,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.695861335476588,0.0696676416329101,0.838477997851896,12.9803433512159,157.8348,0.92256712470372,0.95816583386981,0.0766076376078392,0.583464419352956,0.356602585598378,0.226861833754578,9.12049896491849,10.8711,3.85984438629743,146.9637,0.641978791463127,0.536509448332625,0.666750556764685,0.585965267797856,0.105469343130501,0.0807852889668287,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1843,22574,2171:1549,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.959958965804216,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.102778439092818,0.698072525610011,0.239165598142804,0.458906927467207,6.33379386937038,0.7877,5.03566705444757,25.0497,0.843901708197532,0.599798254743415,0.887435275603094,0.648435371020001,0.244103453454117,0.238999904583093,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1844,22574,1053:1549,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.899574279527772,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.07310234121022,0.654161387781477,0.472212155578837,0.18194923220264,9.24118865340269,5.9098,2.12827227041526,19.9276,0.790817418438363,0.712456224295446,0.831612576282765,0.762573234673359,0.0783611941429166,0.0690393416094055,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1845,22574,1510:1549,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.857651481159458,0.0733485064398624,0.727189963818082,11.3694609238179,25.8374,0.879101855661658,0.924451260121973,0.131601596511455,0.623675549552871,0.271017782158471,0.352657767394399,7.13370707088001,1.3714,4.23575385293793,24.466,0.753963008598249,0.549625460564164,0.792856992503338,0.62590479445957,0.204337548034085,0.166952198043767,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1846,22575,2171:1564,Colon,CaR-1,SIDM00488,924108,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.937436109726689,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0976360527492465,0.720128755154913,0.481562891673751,0.238565863481162,9.13249411145419,5.4809,2.76311714664808,31.7271,0.852144121403812,0.743131544952704,0.878776600452243,0.789919340781846,0.109012576451108,0.0888572596703969,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1847,22575,1053:1564,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.881489241694715,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0437227986035178,0.677150947907411,0.493323431614373,0.183827516293038,9.57938557369124,7.4711,2.31622568441104,29.7369,0.801287541195587,0.75015379198175,0.826330574547158,0.760490143049116,0.0511337492138368,0.0658404314980418,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1848,22575,1510:1564,Colon,CaR-1,SIDM00488,924108,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.850794818620017,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0810228507937749,0.65357180854033,0.365742491386814,0.287829317153516,8.31767113602223,3.1158,3.57794012208004,34.0922,0.773385829375876,0.648573246080261,0.797556836814471,0.681508400839965,0.124812583295615,0.116048435974506,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1849,22575,1561:1564,Colon,CaR-1,SIDM00488,924108,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.665849673047615,0.0625642776464223,0.768189690671152,11.8956112581023,37.208,0.909015678574891,0.937425592351517,0.0978970237951932,0.511498854371935,0.28897482904685,0.222524025325085,8.35816149769713,3.2045,3.53744976040514,34.0035,0.605267792374247,0.470414959273953,0.624184524173724,0.534838709377383,0.134852833100295,0.0893458147963417,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1850,22577,1011:2048,Colon,CaR-1,SIDM00488,924108,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.912225598275418,0.105195914896838,0.443408108758016,8.45056032557358,0.0683,0.791683068390233,0.80824388715623,0.116199731178585,0.404488227291953,0.143607268399452,0.260880958892501,4.94578643524707,0.006,3.50477389032651,0.0623,0.722193560706798,0.534830247878194,0.737300763513541,0.522696254472213,0.187363312828605,0.214604509041328,True,0.622280279032064,0.0753201733935228,0.438208211513741,108.289947944377
1851,23229,1549:2171,Colon,CaR-1,SIDM00488,924108,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.834465617320031,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.0708371569297124,0.261049699170486,0.0892140550208684,0.171835644149618,3.86989669695699,0.2856,3.22832124584942,2.3905,0.614733420164177,0.395783147359315,0.607053273744425,0.408812346243831,0.218950272804862,0.198240927500593,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1852,23229,1032:2171,Colon,CaR-1,SIDM00488,924108,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.923971396475808,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.08965380258227,0.289050201812735,0.0907552351987678,0.198294966613968,3.64164502426203,0.2438,3.45657291854438,2.4323,0.68067046131106,0.421695847599141,0.672166533209879,0.436321014199963,0.258974613711919,0.235845519009916,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1853,23229,1053:2171,Colon,CaR-1,SIDM00488,924108,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.850427860435248,0.0775872986630299,0.312834577904927,7.09821794280641,2.6761,0.736679148193611,0.72747547789211,0.106017921214546,0.266043240757851,0.120275458782501,0.14576778197535,4.64137480262402,0.4874,2.45684314018239,2.1887,0.626492471825554,0.45019314633719,0.618665414182897,0.467423854124954,0.176299325488364,0.151241560057942,True,0.583055245967453,0.0656227401852064,0.489676574909742,96.1570361799303
1854,19630,1083:1011,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,1.0,0.140754266749859,0.307680589181906,6.65987375144943,1.9749,0.731454232052169,0.679495731196738,0.131970160252692,0.307680589181906,0.235627188132292,0.0720534010496142,5.60428858327769,0.9501,1.05558516817173,1.0248,0.731454232052169,0.634901652961311,0.679495731196738,0.610761751681165,0.0965525790908582,0.0687339795155737,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1855,19630,2048:1011,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.953341968175485,0.140754266749859,0.307680589181906,6.65987375144943,1.9749,0.731454232052169,0.679495731196738,0.117232769002046,0.293324818460071,0.244446724742257,0.0488780937178144,5.92774097251325,1.1889,0.732132778936172,0.786,0.697326017214903,0.643584723270283,0.647791797745939,0.602819081344205,0.0537412939446195,0.0449727164017342,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1856,19631,1011:1053,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.791817243571859,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0628223539888833,0.586100205842426,0.280682933457311,0.305417272385115,7.27039096347522,3.0153,4.75073286610816,78.1647,0.730006392177468,0.589880469940307,0.725573759994615,0.567505757692119,0.140125922237161,0.158068002302496,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1857,19631,1372:1053,Colon,SW837,SIDM00833,909755,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.87200978784089,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0514591385450326,0.645458431600542,0.359416810519235,0.286041621081306,7.97563690846505,4.9163,4.04548692111833,76.2637,0.803938944665579,0.626974029665859,0.799057390644464,0.65996661964564,0.17696491499972,0.139090770998824,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1858,19631,1032:1053,Colon,SW837,SIDM00833,909755,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.793371065236243,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0344859267104915,0.587250338912565,0.414725500427613,0.172524838484951,9.26263064357906,11.9966,2.75849318600432,69.1834,0.731438919388151,0.655565882929208,0.726997588834592,0.65131142839549,0.0758730364589424,0.0756861604391019,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1859,19631,2048:1053,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.937692861851977,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0305283143780095,0.694076800941179,0.660680086760591,0.0333967141805878,11.5081246509868,56.888,0.512999178596589,24.292,0.864494665414553,0.862223804190681,0.859245414288968,0.846473269338135,0.0022708612238714,0.0127721449508329,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1860,19631,1549:1053,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.832070816171164,0.0515275402932469,0.740196314996311,12.0211238295834,81.18,0.921937982664328,0.916339933090594,0.0211553446710922,0.615895751945868,0.356640861562427,0.259254890383441,8.17043674884786,5.627,3.85068708073552,75.553,0.767117689694704,0.638732239408875,0.76245971601692,0.638464567052919,0.128385450285829,0.123995148964001,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1861,19632,1083:1054,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.997746847530234,0.0547721104328635,0.91086997281535,15.7068601401678,417.8554,0.960801831572157,0.97394321608255,0.0931005609057432,0.908817643886466,0.873387062229856,0.0354305816566098,14.624484700738,197.3325,1.08237543942972,220.5229,0.958636998552395,0.897027620881227,0.971748773519822,0.960699378335591,0.0616093776711684,0.0110493951842308,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1862,19629,1011:1083,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.896145161522676,0.109630281264841,0.680117502152102,11.1765932212709,45.2085,0.940559214261522,0.892976603235323,0.154845018964005,0.609484008820494,0.332188744272418,0.277295264548076,7.4727623384485,3.4694,3.7038308828224,41.7391,0.842877588986033,0.716812790150496,0.800236662342289,0.652894337460226,0.126064798835537,0.147342324882062,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1863,19629,1549:1083,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.86087486801959,0.109630281264841,0.680117502152102,11.1765932212709,45.2085,0.940559214261522,0.892976603235323,0.117390250137631,0.585496064903004,0.421183309979967,0.164312754923037,8.87590663862264,9.1758,2.30068658264826,36.0327,0.809703789441998,0.747635634866802,0.768741115454791,0.691268253612526,0.0620681545751958,0.0774728618422649,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1864,19630,1011:1510,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.948883948105145,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.0620966678220586,0.693555804846534,0.520153968560834,0.1734018362857,9.5577668678234,14.7199,2.3256967365612,59.0721,0.847815572790316,0.759896486530745,0.866191371548942,0.791247989290566,0.0879190862595712,0.0749433822583762,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1865,19630,1372:1510,Colon,SW837,SIDM00833,909755,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.881900165203702,0.0535766088385526,0.730917417489795,11.8834636043846,73.792,0.893487106071659,0.91285280278865,0.128532180971187,0.644596191234514,0.351666951653492,0.292929239581022,7.81510593762137,4.3986,4.06835766676323,69.3934,0.787966426451974,0.578656065354606,0.805045037585973,0.659655371179745,0.209310361097368,0.145389666406229,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1866,20316,2171:1549,Colon,SW837,SIDM00833,909755,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.709197147814863,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.111227162593012,0.527758168261309,0.333132917793105,0.194625250468203,8.65022009369121,3.9235,3.43071976328432,38.3848,0.625678824629995,0.485784088753929,0.650913797763714,0.561667781417808,0.139894735876065,0.0892460163459062,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1867,20316,1053:1549,Colon,SW837,SIDM00833,909755,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.861890670079061,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0838811129315609,0.641387014434498,0.404691140375294,0.236695874059204,8.64797701438238,3.9174,3.43296284259315,38.3909,0.760390454299178,0.627353265852294,0.791058637287029,0.682501585270243,0.133037188446884,0.108557052016786,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1868,20316,1083:1549,Colon,SW837,SIDM00833,909755,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.997055470295704,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.10264939148835,0.741971636912935,0.584208017786442,0.157763619126493,10.0017970170377,10.0125,2.07914283993779,32.2958,0.879637624978684,0.774084253496759,0.915115302918117,0.849549096618249,0.105553371481925,0.0655662062998678,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1869,20316,1510:1549,Colon,SW837,SIDM00833,909755,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.731764938581812,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.1154534714004,0.544552279678094,0.354284251521497,0.190268028156597,8.81699981585907,4.4043,3.26394004111646,37.904,0.645588928393196,0.511172180905758,0.671626918847904,0.58552005265404,0.134416747487437,0.0861068661938639,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1870,20316,1564:1549,Colon,SW837,SIDM00833,909755,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.931347820637363,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0946925095060555,0.693074445305087,0.555934444315728,0.137140000989359,10.1329263217704,10.9652,1.94801353520514,31.3431,0.821668010839509,0.740235257190289,0.854807649520159,0.79829395906239,0.0814327536492203,0.056513690457769,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1871,20316,2048:1549,Colon,SW837,SIDM00833,909755,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.865982772156212,0.0731475812171591,0.744162846519344,12.0809398569755,42.3083,0.882235393300438,0.917817844825337,0.0754747876250287,0.644432204764479,0.512693825373862,0.131738379390617,10.0745517800818,10.5303,2.00638807689374,31.778,0.764000651584639,0.692177160201291,0.794814441596285,0.740322625547159,0.0718234913833476,0.0544918160491261,True,0.459104106274789,0.054451687200939,0.623085128501194,71.5573788824219
1872,21009,1011:2048,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.663303748966509,0.118639925684931,0.515942114611134,9.18406850954029,0.1136,0.788392679379476,0.817386463257389,0.100867702726972,0.342226338871274,0.125285934605702,0.216940404265572,4.79492986534743,0.0054,4.38913864419286,0.1082,0.522943819890158,0.370534338458387,0.542175505433102,0.36841810079102,0.152409481431771,0.173757404642082,True,0.50229362816937,0.0520374206622998,0.636959963706353,75.2493354432507
1873,19631,1549:2171,Colon,SW837,SIDM00833,909755,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.832070816171164,0.127321812949172,0.430692382785745,8.19485837957514,5.7231,0.690349811440046,0.768615572045757,0.144445867462256,0.358366562463238,0.180960269369352,0.177406293093886,5.30535541596483,0.7723,2.88950296361031,4.9508,0.574419931048528,0.430484647861902,0.639542586353979,0.49135728490141,0.143935283186626,0.148185301452568,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1874,19631,1011:2171,Colon,SW837,SIDM00833,909755,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.791817243571859,0.127321812949172,0.430692382785745,8.19485837957514,5.7231,0.690349811440046,0.768615572045757,0.0709876680977701,0.341029655364804,0.0788841221506892,0.262145533214115,2.64776121360617,0.1224,5.54709716596897,5.6007,0.54663088479481,0.299181921475563,0.608603063623678,0.321703388474667,0.247448963319247,0.286899675149012,True,0.404449675748226,0.0406437254522698,0.848002849507577,57.2623260352616
1875,19528,2048:1025,Colon,RKO,SIDM01090,909698,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.738252062407544,0.047461360819489,0.904700515000824,13.7476440073967,268.6478,0.973228389835752,0.979066888561242,0.0424197319850174,0.667897021060526,0.44813693986782,0.219760081192706,9.91726394640993,18.8853,3.83038006098675,249.7625,0.718487865989818,0.673840360323681,0.722798149715274,0.661389050290772,0.0446475056661367,0.0614090994245019,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1876,19202,1510:1053,Colon,RKO,SIDM01090,909698,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.870422486290557,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.0822987117834655,0.54225494971475,0.329952953697028,0.212301996017722,7.95897648992668,4.8598,2.10045012103071,15.9812,0.73205963307696,0.639872943224055,0.784495043280114,0.694916942147685,0.092186689852905,0.0895781011324281,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1877,19202,1564:1053,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.834813448204552,0.0833298410431048,0.622979022549906,10.0594266109574,20.841,0.841039431548635,0.901280763808577,0.105133736043814,0.520071265973989,0.297577961635293,0.222493304338695,7.75377901481701,4.2155,2.30564759614038,16.6255,0.702111027927112,0.574407277352668,0.75240130223547,0.655910355164676,0.127703750574444,0.0964909470707945,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1878,19203,1561:1054,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.733517704165656,0.0928492445925934,0.749990713311307,11.3174408046346,19.9379,0.881834227899378,0.93992362360907,0.110637602940788,0.550131466173672,0.328701915186359,0.221429550987314,8.56062732546292,2.9498,2.7568134791717,16.9881,0.646841018303446,0.516349080208736,0.689450618480789,0.610965916169511,0.130491938094709,0.0784847023112786,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1879,22245,1564:1083,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.816712511365745,0.104477500349338,0.397422539031496,8.12198338595251,5.4411,0.824237264067757,0.80811842668028,0.0524693850589331,0.324579959925763,0.284474571540178,0.0401053883855857,7.67849760632361,4.0012,0.443485779628902,1.4399,0.673164885898008,0.655346606537966,0.660000429734986,0.637803883354226,0.0178182793600424,0.0221965463807597,True,0.19037913541846,0.032440063069866,1.56738697633428,31.4782018961987
1880,19199,2171:1372,Colon,RKO,SIDM01090,909698,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.853465848860845,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.0989827775892122,0.0938526098574575,0.0079743743403644,0.0858782355170931,-0.838139484965642,0.0011,5.4269549962463,0.0459,0.431394267982875,0.176744773396215,0.468311108352549,0.130143945851433,0.25464949458666,0.338167162501116,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1881,19199,1053:1372,Colon,RKO,SIDM01090,909698,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.816561787715127,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.134164807101406,0.0897944012513513,0.033973455096708,0.0558209461546433,2.38237616869168,0.0102,2.20643934258898,0.0368,0.412740679834267,0.319578099210976,0.448061227468704,0.3004518369427,0.0931625806232915,0.147609390526005,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1882,19199,1561:1372,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.638742649716095,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.111530292568577,0.0702402618489514,0.0139288897315177,0.0563113721174336,0.976462463938615,0.0038,3.61235304734204,0.0432,0.322859922481379,0.193610437485229,0.350488866824431,0.167823344878369,0.129249484996151,0.182665521946062,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1883,19199,1083:1372,Colon,RKO,SIDM01090,909698,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.737138658529919,0.184428140513875,0.109966450306976,4.58881551128066,0.047,0.505461663824832,0.548716868961567,0.130931018200284,0.0810605216625816,0.0079318350525603,0.0731286866100213,-0.537296725341399,0.0013,5.12611223662206,0.0457,0.372595332810137,0.190799758129466,0.404480416699067,0.124089823805417,0.181795574680671,0.28039059289365,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1884,19201,1564:1510,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.765726261693721,0.0345038277147173,0.910535949127861,13.8945023852626,297.435,0.979252085016264,0.98041014522578,0.0688690257019401,0.697221288463421,0.672287066743138,0.0249342217202833,13.1628742760769,179.1225,0.731628109185687,118.3125,0.749839038315286,0.725602108967977,0.750725795430335,0.744900648207102,0.0242369293473089,0.0058251472232323,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1885,19531,1372:1549,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.572089035957272,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0324935293478831,0.53097723089724,0.38756914099413,0.14340808990311,10.5655532512809,14.7995,3.83149460046627,195.8902,0.559181416594705,0.525837986376257,0.563170607918945,0.525595735739067,0.0333434302184477,0.0375748721798786,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1886,19531,1564:1549,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.826245181577812,0.0442777882768806,0.928137400865864,14.3970478517472,210.6897,0.977437743862773,0.984410769167418,0.0660629172179932,0.766869055307574,0.725505313428015,0.0413637418795593,13.1648830375888,89.686,1.23216481415839,121.0037,0.807603226158904,0.781847050604148,0.813364654717887,0.803793666208833,0.0257561755547554,0.0095709885090542,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1887,19532,1372:1561,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.455600817702971,0.157471200148919,0.364991047336034,7.83181862569403,4.4498,0.682382754514355,0.790566871966061,0.0720608531019022,0.166290219620561,0.0464470088753379,0.119843210745223,4.41014915296779,0.4153,3.42166947272624,4.0345,0.310894140943146,0.213277629220502,0.360182913316617,0.243277207466395,0.0976165117226442,0.116905705850222,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1888,19532,1564:1561,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.5477351183562,0.157471200148919,0.364991047336034,7.83181862569403,4.4498,0.682382754514355,0.790566871966061,0.103874306707208,0.199918414511556,0.0359300166003521,0.163988397911204,3.39633093939667,0.2056,4.43548768629736,4.2442,0.37376499880815,0.232632295940957,0.433021239184821,0.246513330356929,0.141132702867194,0.186507908827893,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1889,19532,1083:1564,Colon,RKO,SIDM01090,909698,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.725935481770568,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.0908275156527225,0.248028688520618,0.0275188034391465,0.220509885081471,2.17792345739055,0.0442,5.43850250283133,1.8721,0.486029981730554,0.256627564441351,0.564034450512497,0.255442451820838,0.229402417289203,0.308591998691659,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1890,19532,2048:1564,Colon,RKO,SIDM01090,909698,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.259710317145063,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.072677524537921,0.0887346203269371,0.0288671014556012,0.0598675188713359,4.61423030884869,0.2392,3.00219565137319,1.6771,0.173881844691462,0.107625654065357,0.201788684672171,0.143051168135448,0.0662561906261046,0.0587375165367231,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1891,19532,1053:1564,Colon,RKO,SIDM01090,909698,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.5477351183562,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.102941635667254,0.187143384603854,0.0503648665080982,0.136778518095756,4.16911151613074,0.1757,3.44731444409115,1.7406,0.366720867422739,0.254258629793715,0.425577044057585,0.281545661264262,0.112462237629025,0.144031382793323,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1892,19532,2171:1564,Colon,RKO,SIDM01090,909698,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.785180811593967,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.122313042183329,0.268270902637537,0.0326585606610864,0.235612341976451,2.38175125398875,0.0509,5.23467470623314,1.8654,0.525696050265261,0.301218444898147,0.610066650193479,0.288866480696892,0.224477605367114,0.321200169496586,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1893,19532,1510:1564,Colon,RKO,SIDM01090,909698,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.8771486510325,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.140745928018979,0.299693340546728,0.0516338295854025,0.248059510961325,3.15276712393018,0.0869,4.46365883629171,1.8294,0.58727056817295,0.373218369877362,0.681523454668741,0.377222301381476,0.214052198295589,0.304301153287264,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1894,19532,1561:1564,Colon,RKO,SIDM01090,909698,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.713278154130086,0.165691532090022,0.341667675363755,7.61642596022189,1.9163,0.669522283915809,0.776976004998141,0.141402987923036,0.243704088809376,0.0324599638374787,0.211244124971898,2.58012150607341,0.0584,5.03630445414847,1.8579,0.477555618820428,0.27845157098656,0.554200010648443,0.27366727832111,0.199104047833867,0.280532732327333,True,0.183090916035041,0.0312930230709679,1.57842086498348,31.1650292683018
1895,19202,1372:2171,Colon,RKO,SIDM01090,909698,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.68763413197071,0.080388300681358,0.348342448059117,7.67873728956727,4.0018,0.767070996300363,0.780955741860954,0.078582614929647,0.239532156899683,0.0706886460963394,0.168843510803344,4.42973263079034,0.4209,3.24900465877693,3.5809,0.527464198700908,0.359627871497019,0.537011823662099,0.368289022815002,0.167836327203889,0.168722800847097,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1896,19202,1564:2171,Colon,RKO,SIDM01090,909698,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.834813448204552,0.080388300681358,0.348342448059117,7.67873728956727,4.0018,0.767070996300363,0.780955741860954,0.046503397752643,0.290800960220246,0.121664357077986,0.169136603142261,5.26947220436431,0.7534,2.40926508520296,3.2484,0.640361183439207,0.488485981604079,0.651952355758087,0.504437804143348,0.151875201835128,0.147514551614739,True,0.220241614142168,0.0345711494421503,1.40037504091982,34.9902775156483
1897,22892,1011:1053,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.343321406701428,0.109239031905041,0.333337153571312,7.29281966075075,3.0626,0.693967046174808,0.737767173791536,0.0741643862283673,0.114441780469953,0.064914999784539,0.0495267806854139,5.41386159335594,0.8327,1.87895806739481,2.2299,0.23825374249717,0.184052606600516,0.253291263924247,0.208513512720597,0.0542011358966537,0.0447777512036507,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
1898,22892,1564:1053,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.976604179703732,0.109239031905041,0.333337153571312,7.29281966075075,3.0626,0.693967046174808,0.737767173791536,0.0613059237145856,0.325538457428288,0.34433769891682,-0.0187992414885315,7.50326319588678,3.5435,-0.210443535136033,-0.4809,0.67773111787097,0.717153550279051,0.720506505573024,0.733353108803622,-0.0394224324080811,-0.0128466032305974,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
1899,22889,1564:1372,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.945976532511309,0.0779120118698567,0.102051580599217,3.64387215668001,0.0244,0.469504527509259,0.472674947417058,0.10471469587948,0.0965384003525457,0.0661246976529279,0.0304137026996177,2.625231411988,0.0121,1.01864074469201,0.0123,0.444140264931569,0.362109511275725,0.447139407762554,0.3741919993232,0.0820307536558442,0.0729474084393542,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
1900,22891,1011:1510,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.326562239496936,0.0917852846447759,0.291014601040111,6.80679183773102,2.1866,0.689024713499007,0.706109385668072,0.0433256526754643,0.0950343798419658,0.0825626353231441,0.0124717445188217,6.33106825582117,1.5724,0.475723581909855,0.6142,0.22500945350897,0.2070916048936,0.230588662313571,0.219961420980755,0.0179178486153699,0.0106272413328157,True,0.576479795863676,0.0679251441180702,0.505482167604042,93.8330460713588
1901,20636,2171:1549,Colon,NCI-H716,SIDM00779,908458,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.285163110045384,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0573974606584385,0.255365442736685,0.160882143964678,0.094483298772007,9.6357677655297,7.7688,4.65541384167919,188.0139,0.27661779761048,0.207690008077186,0.277552706014686,0.24589055457708,0.0689277895332941,0.0316621514376056,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1902,20636,1011:1549,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.370160802009998,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0543319726321422,0.331481435568597,0.200081489527747,0.13139994604085,9.40013890796866,6.5982,4.89104269924023,189.1845,0.359068414555581,0.284365388553402,0.360281988235051,0.315398414967793,0.0747030260021792,0.0448835732672575,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1903,20636,1372:1549,Colon,NCI-H716,SIDM00779,908458,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.593498871356216,0.0565740293572084,0.895506584621146,14.2911816072089,195.7827,0.970033597846708,0.973312101872201,0.0632303774935181,0.53148214726471,0.481548695305456,0.0499334519592541,12.5934048034017,60.3521,1.69777680380715,135.4306,0.575713845499631,0.547074881196911,0.577659633938498,0.563528361527386,0.0286389643027195,0.0141312724111121,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1904,20637,1011:1561,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.285750393413262,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.0384798987129296,0.0673309536891133,0.0993048502847654,-0.0319738965956521,7.44844491955608,3.4114,-1.34689837568251,-2.0702,0.169985377488484,0.193740892962184,0.187847259878005,0.213606630815855,-0.0237555154737001,-0.02575937093785,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1905,20637,1564:1561,Colon,NCI-H716,SIDM00779,908458,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.953752060959692,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.11518147633367,0.224731224619875,0.276046201663174,-0.0513149770432991,6.78786707415934,2.1582,-0.68632053028577,-0.817,0.567361962921898,0.609224503748684,0.626979753603247,0.672245220759481,-0.0418625408267861,-0.0452654671562344,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1906,20637,1372:1561,Colon,NCI-H716,SIDM00779,908458,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.313116154047786,0.144501044917956,0.235628559894008,6.10154654387357,1.3412,0.594873642895201,0.65738233160132,0.0627807001647099,0.0737791084578303,0.0951925468663823,-0.021413438408552,6.9600362689801,2.4317,-0.858489725106528,-1.0905,0.186264547207742,0.186535845197382,0.205837027409972,0.224277313983617,-0.0002712979896403,-0.0184402865736448,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1907,20637,1011:1564,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.843306759026573,0.0692937318452257,0.353996980304231,7.51846557636857,1.7905,0.752934926360308,0.751858156659909,0.0395000445403475,0.298528046165555,0.109193348785285,0.189334697380269,4.30664344036494,0.1933,3.21182213600363,1.5972,0.634955112506823,0.433576960080999,0.634047065340561,0.441498542003127,0.201378152425823,0.192548523337434,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1908,20637,1053:1564,Colon,NCI-H716,SIDM00779,908458,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.435687165965443,0.0692937318452257,0.353996980304231,7.51846557636857,1.7905,0.752934926360308,0.751858156659909,0.0711190166884419,0.154231941109075,0.0632816850032724,0.0909502561058028,4.63460704496254,0.2426,2.88385853140603,1.5479,0.328044084222322,0.223424581400281,0.327574949483158,0.239025187041852,0.104619502822041,0.088549762441306,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1909,20639,1011:2048,Colon,NCI-H716,SIDM00779,908458,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.358138774621046,0.0672288494895084,0.557373557701747,9.56774530489412,0.1482,0.846978827933909,0.859383342324988,0.0670601937165318,0.199617082961476,0.148181164213036,0.0514359187484402,8.14171768242847,0.0552,1.42602762246566,0.093,0.30333595956622,0.258405280063646,0.30777849715001,0.282424842244259,0.044930679502574,0.0253536549057511,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1910,20639,1561:2048,Colon,NCI-H716,SIDM00779,908458,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.608635844952591,0.0672288494895084,0.557373557701747,9.56774530489412,0.1482,0.846978827933909,0.859383342324988,0.0375895355515411,0.339237526246035,0.156058833446829,0.183178692799206,6.37758084959006,0.0162,3.19016445530406,0.132,0.51550167459651,0.414580585477396,0.523051506694151,0.411930844333801,0.100921089119114,0.11112066236035,True,0.39070401389069,0.0461992653042968,0.79909013567362,58.2716513966522
1911,18418,2048:1011,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.921539287788296,0.093538760051544,0.2201797133662,5.88759027721343,1.1563,0.666924742311082,0.642101953030592,0.0813605001822593,0.202904256240919,0.163980231607021,0.038924024633898,5.23357533796953,0.7348,0.654014939243893,0.4215,0.614597352037748,0.563124419103944,0.591722176483286,0.547344308315291,0.0514729329338034,0.0443778681679954,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1912,18415,1011:1032,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.919216570438613,0.0863334928370201,0.703577691393708,11.1273955198713,43.6928,0.942903764235642,0.915248354856752,0.130860085512971,0.646740272520041,0.47246503788942,0.174275234630621,9.13772845546359,11.0017,1.98966706440771,32.6911,0.866732764414346,0.822828880548416,0.841311453851006,0.772294511224783,0.0439038838659296,0.0690169426262229,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1913,18415,2048:1032,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.74764013689789,0.0863334928370201,0.703577691393708,11.1273955198713,43.6928,0.942903764235642,0.915248354856752,0.0667774221647434,0.526022921511893,0.182864506474077,0.343158415037817,6.22461024638835,1.4606,4.90278527348295,42.2322,0.704952699374672,0.500916816805405,0.684276405320671,0.498049813876298,0.204035882569267,0.186226591444373,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1914,18419,1564:1053,Colon,SNU-81,SIDM00193,1660036,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.966437973193645,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0600358265221325,0.691808622062411,0.692915894909354,-0.0011072728469436,11.2876975051643,48.8276,-0.0138791243802068,-0.467499999999994,0.865086211068985,0.859912982322372,0.888539493153178,0.888910817705538,0.0051732287466137,-0.0003713245523602,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1915,18419,1372:1053,Colon,SNU-81,SIDM00193,1660036,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.903292772004561,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0796298768376615,0.646607175268969,0.195815407311297,0.450791767957673,5.83857950988592,1.1177,5.43523887089819,47.2424,0.808563139377857,0.525848042913808,0.830484029051126,0.576802695288156,0.282715096464049,0.25368133376297,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1916,18419,2048:1053,Colon,SNU-81,SIDM00193,1660036,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.95084877565547,0.0965902962211319,0.715833443274474,11.2738183807841,48.3601,0.895128539093164,0.919396296295098,0.0904079404152947,0.680649353110773,0.666429624255366,0.0142197288554067,11.0956279628688,42.7412,0.17819041791533,5.6189,0.851131875451004,0.841090608257367,0.874206842674367,0.869385191915937,0.0100412671936362,0.0048216507584298,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1917,18417,1011:1083,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.618760000885752,0.0384284186463403,0.854271706359082,13.3525454778123,204.2898,0.961535910019386,0.961956368303263,0.0546040318731142,0.528589161783418,0.316126232546521,0.212462929236897,9.10735068263162,10.7725,4.24519479518069,193.5173,0.594959960535278,0.516610933833152,0.595220123303381,0.518974936319674,0.0783490267021254,0.0762451869837073,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1918,18416,1011:1372,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.611480105544664,0.0880255387543442,0.758785631016573,11.8205522382887,7.0643,0.870402093178885,0.9334052151515,0.095091762465885,0.463982317739789,0.268105783136312,0.195876534603477,8.39101576501649,0.6557,3.42953647327221,6.4086,0.532233563803321,0.426050010574055,0.570758719476779,0.490675878095407,0.106183553229267,0.0800828413813723,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1919,18416,1053:1372,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.760036717112049,0.0880255387543442,0.758785631016573,11.8205522382887,7.0643,0.870402093178885,0.9334052151515,0.0744962369351255,0.576704939989631,0.141935220539754,0.434769719449877,5.37896417891168,0.0813,6.44158805937702,6.983,0.661537549467135,0.411838752386227,0.709422235459011,0.459664711077216,0.249698797080908,0.249757524381795,True,0.925999351124554,0.0881708872528886,0.0443935543943987,669.766476452241
1920,19707,1053:1549,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.675645105924606,0.0377781829932963,0.92598144291577,15.2181732805931,372.2431,0.966804498995878,0.981411583501045,0.113532690856843,0.625634830083045,0.449412764712373,0.176222065370672,10.6892777391609,16.1248,4.52889554143221,356.1183,0.653216728132455,0.512888909058044,0.663085933290199,0.609279105959338,0.140327819074411,0.0538068273308614,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
1921,19708,1053:1564,Colon,SNU-81,SIDM00193,1660036,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.593153025051197,0.0617650632565572,0.690156343031918,10.9710074964136,19.6021,0.884997012858274,0.910624255588604,0.0837461549060188,0.409368322627654,0.068394226672452,0.340974095955202,3.98505033399147,0.1546,6.98595716242216,19.4475,0.524938655338158,0.274847362382994,0.540139531887376,0.295895365088257,0.250091292955165,0.244244166799119,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
1922,19710,1011:2048,Colon,SNU-81,SIDM00193,1660036,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.483949762874301,0.0486910208529425,0.492666127775566,8.92779597596977,0.0951,0.829457711002332,0.830089589074445,0.0701590926911142,0.238425655713185,0.10212432716741,0.136301328545775,5.75431157068798,0.0105,3.17348440528179,0.0846,0.401415862553839,0.312415110632828,0.401721659797004,0.306065404251165,0.0890007519210105,0.0956562555458387,True,0.50567577540225,0.0400445422033462,0.638339252090191,75.54931060814
1923,19440,1083:1011,Colon,SNU-C5,SIDM00498,1674021,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.935774414215023,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.0555176517190601,0.610900746051483,0.64867099218141,-0.037770246129927,11.4325027550774,53.9829,-0.547884096700827,-17.0574,0.812911628552055,0.870413533494909,0.821841397406234,0.837736519937112,-0.057501904942854,-0.0158951225308784,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
1924,19440,2048:1011,Colon,SNU-C5,SIDM00498,1674021,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.707417770241577,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.183766147518559,0.461822889198329,0.409092263168161,0.0527306260301679,9.94232861770448,19.2163,0.942290040672127,17.7092,0.614537139440964,0.577500057009133,0.621287780488245,0.597121241418766,0.037037082431831,0.024166539069479,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
1925,19440,1025:1011,Colon,SNU-C5,SIDM00498,1674021,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.906807923107802,0.0775091154620713,0.652829075866472,10.8846186583766,36.9255,0.868704696562973,0.87824734778161,0.0533167029376053,0.591990578430862,0.329002940371939,0.262987638058923,7.31929794186257,3.1193,3.56532071651404,33.8062,0.787748301684263,0.645223172470053,0.796401653416777,0.648600455235016,0.14252512921421,0.147801198181761,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
1926,20650,1011:1025,Colon,SNU-C5,SIDM00498,1674021,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.921502394882354,0.063878540559143,0.848773718115468,14.1480694574814,354.5874,0.954549093012015,0.952925847419729,0.0477901875737491,0.782147013956604,0.475341781589271,0.306805232367333,9.18907445989995,11.4003,4.95899499758142,343.1871,0.879619275243351,0.74047074899385,0.878123450542577,0.74835719483583,0.139148526249501,0.129766255706747,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
1927,19438,1053:1372,Colon,SNU-C5,SIDM00498,1674021,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.762583443026506,0.15961397986502,0.426767317862134,8.11945586484718,0.5432,0.661274126239955,0.759608533850988,0.128844439514927,0.325445690626493,0.155622556052745,0.169823134573748,4.93819207074201,0.0599,3.18126379410517,0.4833,0.504276699972409,0.38362809092994,0.579264891096402,0.430056923966993,0.120648609042469,0.149207967129409,True,0.368404837033656,0.0472892109324904,0.927985743407709,52.2815632844293
1928,20654,1053:1564,Colon,SNU-C5,SIDM00498,1674021,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.788338618888672,0.113859719258281,0.529602395603236,9.35379075965104,6.3896,0.747999263041855,0.819456161118806,0.132528303360179,0.417506021109988,0.271049251639028,0.146456769470959,7.07120153911317,1.3132,2.28258922053787,5.0764,0.589676705956161,0.472660409524415,0.646008938296213,0.55239552215387,0.117016296431746,0.0936134161423428,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
1929,20656,1510:2048,Colon,SNU-C5,SIDM00498,1674021,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.895863488784562,0.121031345076032,0.240320931434858,5.56523617588222,0.0092,0.615973330053516,0.605859936247737,0.105098971668744,0.215294748063187,0.0840432924957939,0.131251455567393,2.23162672912425,0.0009,3.33360944675798,0.0083,0.551828016459987,0.339123897429303,0.54276779620169,0.341146082098515,0.212704119030684,0.201621714103175,True,0.229827004623137,0.0376189007246153,1.21435473073504,39.0116085621949
1930,24115,1564:1053,Colon,SW1116,SIDM00835,909746,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.933179309038063,0.0638386891477655,0.847804110386447,13.6859470609707,257.4012,0.954655299887989,0.95620382749774,0.0597032621934226,0.791153253930054,0.65577352746812,0.135379726461934,11.3473213808605,50.8879,2.33862568011016,206.5133,0.890864573118998,0.816073901200624,0.892309627043892,0.846100914425619,0.074790671918374,0.0462087126182729,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1931,24115,1549:1053,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.632980204437619,0.0638386891477655,0.847804110386447,13.6859470609707,257.4012,0.954655299887989,0.95620382749774,0.0660813390304948,0.536643219115467,0.35924923689081,0.177393982224657,9.74176735245225,16.7222,3.94417970851841,240.679,0.604277906890556,0.49374753538989,0.605258094213553,0.538494517267947,0.110530371500666,0.0667635769456061,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1932,24109,1053:1372,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.970090690553081,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.0721082274674436,0.184608426848579,0.119126497894684,0.0654819289538949,3.63549595610105,0.0243,1.41363874311312,0.0404,0.529881765975571,0.440653539228069,0.558314497963782,0.459457744790411,0.0892282267475017,0.0988567531733716,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1933,24109,1510:1372,Colon,SW1116,SIDM00835,909746,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.799543769211354,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.0626342737482633,0.152153318105278,0.0766237339291059,0.0755295841761716,2.87643888810226,0.0143,2.17269581111192,0.0504,0.436725832471325,0.314955765932757,0.460159944275727,0.335155474402984,0.121770066538568,0.125004469872743,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1934,24109,1549:1372,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.631557074090674,0.112270461461592,0.190300173629465,5.04913469921417,0.0647,0.546218792877466,0.575528147420391,0.121089567231649,0.120185420856372,0.0442009390499731,0.0759844818063989,1.94198514993741,0.0075,3.10714954927676,0.0572,0.344968342643032,0.217822738834595,0.363478872841648,0.22375419661048,0.127145603808437,0.139724676231168,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1935,24112,1083:1510,Colon,SW1116,SIDM00835,909746,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.950487318430638,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0887297481745123,0.783281341498566,0.752308096879857,0.0309732446187094,12.639592923266,124.6312,0.573755378237177,60.8689,0.874081094153308,0.84651493548373,0.901724832510438,0.891591587141969,0.0275661586695776,0.0101332453684698,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1936,24112,1032:1510,Colon,SW1116,SIDM00835,909746,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.678037151428254,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0281771071272282,0.558759532355977,0.402156262661761,0.156603269694215,10.0282499775074,20.3955,3.18509832399576,165.1046,0.623532206800558,0.591261244738323,0.643252071807747,0.584623744980088,0.0322709620622359,0.0586283268276588,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1937,24112,2048:1510,Colon,SW1116,SIDM00835,909746,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.946505148654653,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.0648379138752443,0.779999699309633,0.740956344547695,0.0390433547619375,12.4984919887983,113.0189,0.714856312704882,72.4812,0.870419036546223,0.877404314636076,0.897946958461359,0.885105789368739,-0.0069852780898535,0.0128411690926207,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1938,24112,1549:1510,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.688206731652149,0.0715456841114959,0.824083947581597,13.2133483015032,185.5001,0.919613631033515,0.948697383989602,0.052927706188535,0.567140120172131,0.377655488490752,0.189484631681379,9.53376305685249,14.477,3.67958524465071,171.0231,0.63288429139634,0.543401382827222,0.652899925962428,0.579436848957977,0.089482908569118,0.0734630770044503,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1939,23813,2171:1549,Colon,SW1116,SIDM00835,909746,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.907008263832227,0.0791911632277995,0.532230218167759,9.35223396836281,6.3827,0.800572254823765,0.833997166643081,0.110971450478093,0.482737206139386,0.264561031099965,0.218176175039422,6.5793435699395,0.9339,2.77289039842331,5.4488,0.726125650919954,0.557501310600865,0.756442322157938,0.617034242263281,0.16862434031909,0.139408079894657,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1940,23813,1083:1549,Colon,SW1116,SIDM00835,909746,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.982901263528878,0.0791911632277995,0.532230218167759,9.35223396836281,6.3827,0.800572254823765,0.833997166643081,0.0710788914125718,0.52312975392534,0.419885767572675,0.103243986352666,8.19969842272266,2.8711,1.15253554564016,3.5116,0.786883480812441,0.724816707881774,0.819736868872988,0.763863904265379,0.0620667729306671,0.0558729646076099,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1941,23814,1032:1561,Colon,SW1116,SIDM00835,909746,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.756174145096373,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.142949146590678,0.578667391042808,0.3875025213622,0.191164869680608,9.13591719037686,10.9879,3.08826582213262,82.4613,0.684716240719734,0.516761715881089,0.702590088901521,0.62320821048023,0.167954524838645,0.0793818784212914,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1942,23814,1372:1561,Colon,SW1116,SIDM00835,909746,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.490612194653244,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.0616783444408261,0.375444308080113,0.23022279529078,0.145221512789333,8.66405228596458,7.9226,3.56013072654491,85.5266,0.444249700618122,0.363182336164293,0.455846404816792,0.39315518884146,0.0810673644538284,0.0626912159753326,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1943,23814,1564:1561,Colon,SW1116,SIDM00835,909746,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.775805040392288,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.0944039286536549,0.593690066756315,0.372491336946494,0.221198729809822,8.78309107035019,8.6041,3.4410919421593,84.8451,0.702492030749249,0.563369299050966,0.720829898554647,0.626293097263476,0.139122731698284,0.0945368012911714,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1944,23814,1011:1561,Colon,SW1116,SIDM00835,909746,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.912392166672835,0.0678795913907335,0.765256779533315,12.2241830125095,93.4492,0.905500730433554,0.929137941911486,0.106519132953462,0.698214291139477,0.46221303532609,0.236001255813386,9.07197564554335,10.5116,3.15220736696614,82.9376,0.826171773364105,0.691552096343805,0.847738179958559,0.74923567980754,0.1346196770203,0.0985025001510186,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1945,23814,1053:1564,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.974465927053422,0.0533304902859758,0.482635153697568,8.81041191989617,4.3843,0.811358642528599,0.808625124507764,0.048849384948098,0.470311512476471,0.288061360262747,0.182250152213724,6.63096194165494,0.9679,2.17944997824124,3.4164,0.790641351764438,0.647949826443486,0.787977631592147,0.666186637946453,0.142691525320952,0.121790993645694,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1946,23816,1011:2048,Colon,SW1116,SIDM00835,909746,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.956566397359876,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.0621355138906802,0.792858669637592,0.76471962736937,0.0281390422682218,12.7728420468622,1.3669,0.531352681835221,0.6087,0.890277984642419,0.901190237610844,0.908953480320084,0.899817373621696,-0.010912252968425,0.009136106698388,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1947,23816,1053:2048,Colon,SW1116,SIDM00835,909746,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.911302002225895,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.10034013579855,0.755340868252419,0.51817500002732,0.237165868225099,9.75352574514862,0.1686,3.55066898354877,1.807,0.848150334552304,0.713409147022115,0.865942112154559,0.775713260932849,0.13474118753019,0.0902288512217099,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1948,23816,2171:2048,Colon,SW1116,SIDM00835,909746,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.932666738284042,0.076926321243905,0.828859002183103,13.3041947286974,1.9756,0.930701713022314,0.950225183352454,0.161384967427834,0.77304922206348,0.464259177086342,0.308790044977138,8.97572882916734,0.0983,4.32846589953005,1.8773,0.868034530999892,0.644315392959392,0.886243422392689,0.761638176312076,0.2237191380405,0.124605246080613,True,0.495135089373144,0.0895383579279863,0.68175884072653,72.0886523598128
1949,24115,1549:2171,Colon,SW1116,SIDM00835,909746,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.632980204437619,0.0948500240132041,0.494917728485403,8.94453254933134,9.6228,0.780493353069882,0.815131918895207,0.0707663421549178,0.313273124956492,0.15356056006228,0.159712564894212,5.89378660480714,1.1613,3.0507459445242,8.4615,0.494036842188377,0.35703148268648,0.515962368665917,0.401654719911434,0.137005359501897,0.114307648754483,True,0.61090969612462,0.076405687476197,0.47199878234274,102.950812163568
1950,19251,1053:1011,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.731836687127451,0.135920660817656,0.667640981409581,11.0171590636365,40.4786,0.92721631498239,0.887666761081692,0.0803042427698234,0.488604164025308,0.249029320265406,0.239574843759902,7.08546569824314,2.6526,3.9316933653934,37.826,0.678570916207236,0.513136476944524,0.64962710170318,0.516239025765843,0.165434439262712,0.133388075937337,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1951,19251,1561:1011,Colon,SNU-407,SIDM00214,1660034,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.661516127129727,0.135920660817656,0.667640981409581,11.0171590636365,40.4786,0.92721631498239,0.887666761081692,0.104337988267201,0.441655276335156,0.239047866676451,0.202607409658705,7.35324023876202,3.1936,3.66391882487451,37.285,0.613368545698648,0.43795890689069,0.587205877972549,0.47715896894576,0.175409638807958,0.110046909026789,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1952,19248,1510:1032,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.572859310553189,0.122973707411221,0.388916394946819,7.69326603747145,4.0423,0.768626620080047,0.740864035592688,0.0669831493272819,0.222794377872066,0.108720492621209,0.114073885250857,4.80277364409127,0.5451,2.89049239338018,3.4972,0.440314915651884,0.300131092174238,0.424410860643281,0.318449814934997,0.140183823477646,0.105961045708283,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1953,19248,2048:1032,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.884291847924715,0.122973707411221,0.388916394946819,7.69326603747145,4.0423,0.768626620080047,0.740864035592688,0.122718471284948,0.343915597575741,0.256021190224428,0.0878944073513123,6.40396388129436,1.6539,1.28930215617709,2.3884,0.679690254234713,0.624690359061593,0.65514002709522,0.586352549096256,0.0549998951731191,0.0687874779989636,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1954,19252,1510:1053,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.877873703142865,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.132760793303594,0.488478173291848,0.195094423390847,0.293383749901001,5.37742679331113,0.8119,4.27815095158348,14.9406,0.744418697804378,0.474856274446571,0.735349372848648,0.522595692304265,0.269562423357807,0.212753680544383,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1955,19252,1032:1053,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.802371088122537,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0652035335481372,0.446466003053864,0.186049210805175,0.260416792248689,5.53627509689097,0.9064,4.11930264800364,14.8461,0.680394045792321,0.456720557925547,0.672104739361095,0.48626665251948,0.223673487866775,0.185838086841615,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1956,19252,1549:1053,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.824668856133997,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0385726138083268,0.458873223987501,0.229090081931197,0.229783142056303,6.23708295648088,1.4733,3.41849478841372,14.2792,0.699302090728181,0.527961279563434,0.690782425757726,0.537973404015347,0.171340811164747,0.152809021742379,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1957,19252,2048:1053,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.676006760667858,0.0828877213287835,0.556433313292166,9.65557774489461,15.7525,0.847979265285307,0.837648251925114,0.0458387765530386,0.376152681646321,0.15266935389117,0.223483327755151,5.43739223181091,0.8463,4.21818551308369,14.9062,0.57323971623903,0.395420022512833,0.56625588136299,0.405171727893412,0.177819693726197,0.161084153469578,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1958,19253,1549:1054,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.891345355205597,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.09356248976218,0.617300159129822,0.57929669399223,0.0380034651375913,10.7890530958622,13.8235,0.559301274540672,6.5462,0.771611755885088,0.727621995389494,0.800228114864394,0.784606942895729,0.043989760495594,0.0156211719686656,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1959,19253,1564:1054,Colon,SNU-407,SIDM00214,1660034,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.753474895316608,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.158960028866043,0.521818137114748,0.200006376784055,0.321811760330693,6.05652439627378,0.52,5.2918299741291,19.8497,0.652261307690864,0.3955457418997,0.676451379429446,0.482680031431723,0.256715565791164,0.193771347997723,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1960,19253,1053:1054,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.725221431501917,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.111912122975522,0.502251234559055,0.307431854553268,0.194819380005787,8.11300196764775,2.163,3.23535240275513,18.2067,0.627803105607273,0.474781859773163,0.65108610888108,0.554021481385145,0.15302124583411,0.0970646274959358,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1961,19253,1561:1054,Colon,SNU-407,SIDM00214,1660034,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.72070395897825,0.0986052168187083,0.692548803361897,11.3483543704029,20.3697,0.865670922475508,0.897775604249168,0.125194060851707,0.499122664368569,0.291776227261922,0.207346437106646,7.8857703366379,1.8478,3.46258403376498,18.5219,0.623892461000452,0.458683548772155,0.647030432256466,0.541677652827635,0.165208912228297,0.10535277942883,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1962,19249,1053:1372,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.675369384788636,0.186413734823482,0.264376887017802,6.04065802143181,0.1286,0.556742112370835,0.639566515867238,0.111495409509994,0.178552055537548,0.0782879748878356,0.100264080649712,3.12476592573314,0.017,2.91589209569867,0.1116,0.376006577917817,0.268268203496395,0.431943644352668,0.296552785763505,0.107738374421422,0.135390858589164,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1963,19251,1053:1510,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.731836687127451,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0495216193709473,0.468165061778811,0.351573412071549,0.116591649707262,8.77314874734724,8.545,1.88710414949993,23.0622,0.645737812835546,0.552680681604421,0.641012214493256,0.583767269908674,0.0930571312311249,0.0572449445845814,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1964,19251,1032:1510,Colon,SNU-407,SIDM00214,1660034,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.885437479763761,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.0764209575401516,0.566425405703505,0.25244101308165,0.313984392621855,6.34156841788523,1.5839,4.31868447896194,30.0233,0.781267831528778,0.541583245109632,0.775550405824149,0.5835750903856,0.239684586419146,0.191975315438549,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1965,19251,1549:1510,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.809560316762057,0.0939984503145765,0.639712479592156,10.6602528968472,31.6072,0.882352339249548,0.875895163180883,0.059011128799957,0.517885837615267,0.240578167456915,0.277307670158352,6.51069255049089,1.7809,4.14956034635628,29.8263,0.714317439258605,0.508852903730931,0.709089965755069,0.542296349783407,0.205464535527675,0.166793615971662,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1966,18955,1053:1549,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.7894536845149,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.056820095714324,0.559119868545876,0.331423615633187,0.227696252912689,8.06438139811916,2.6141,3.50020136759257,26.9651,0.657674216276437,0.58674395716253,0.713639062756914,0.601030402922452,0.0709302591139069,0.112608659834462,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1967,18955,1083:1549,Colon,SNU-407,SIDM00214,1660034,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.949458147986585,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.115813932049924,0.672440860439167,0.51023975252774,0.162201107911427,9.43344038690534,6.7523,2.13114237880639,22.8269,0.790969952528695,0.714119203807643,0.85827761165294,0.786292568932198,0.0768507487210517,0.071985042720742,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1968,18955,1510:1549,Colon,SNU-407,SIDM00214,1660034,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.548366413517654,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0604366241824331,0.388373077553453,0.169719586461798,0.218653491091655,6.67942468236542,1.0009,4.88515808334631,28.5783,0.45683041110151,0.347290196977056,0.495704435948735,0.373153607366293,0.109540214124454,0.122550828582442,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1969,18955,2171:1549,Colon,SNU-407,SIDM00214,1660034,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.730383343848943,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0587189840123419,0.517284100652279,0.316983355826291,0.200300744825988,8.23202460401248,2.9362,3.33255816169926,26.643,0.608464185637923,0.54351443818726,0.660241500143107,0.562579277515129,0.0649497474506635,0.0976622226279781,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1970,18955,2048:1549,Colon,SNU-407,SIDM00214,1660034,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.921658495518906,0.119404075697431,0.708236441874917,11.5645827657117,29.5792,0.833075111531794,0.903965712941637,0.0832668525559301,0.652752133490099,0.566000550224218,0.0867515832658805,10.3436229205519,12.6894,1.22095984515981,16.8898,0.767810753948638,0.775903762133406,0.833147678990464,0.796927235299789,-0.0080930081847677,0.0362204436906759,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1971,18956,1053:1564,Colon,SNU-407,SIDM00214,1660034,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.767639774840739,0.0740922411365162,0.416178965500004,8.02117255745255,2.537,0.751844872436527,0.758991200431823,0.0645474344039204,0.319475527369875,0.175664446421912,0.143811080947963,5.48673441913971,0.4379,2.53443813831284,2.0991,0.57714602859234,0.466069167639844,0.582631834205587,0.462653328278206,0.111076860952496,0.119978505927381,True,0.307879698043422,0.044967815678425,1.10100144627532,44.3472071688402
1972,19252,1549:2171,Colon,SNU-407,SIDM00214,1660034,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.859192006103419,0.0937023084483355,0.315978549736992,6.7665887471173,2.1266,0.660860287485197,0.685908513897388,0.0840016136473938,0.271486244034175,0.0865011973539745,0.1849850466802,2.66767802743116,0.1241,4.09891071968614,2.0025,0.567805876158488,0.338073073301703,0.589327112058911,0.350349372647252,0.229732802856785,0.238977739411659,True,0.461888619224743,0.0587461906520786,0.715713732915597,67.2313560949461
1973,19264,1510:1011,Colon,SNU-175,SIDM00216,1659928,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.809984299963149,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0975437077945875,0.452330189764497,0.196514674355321,0.255815515409176,6.24033005889718,1.4766,3.32897885782245,13.3615,0.717537811911876,0.547386083504461,0.698080891639111,0.541556379086476,0.170151728407415,0.156524512552636,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1974,19264,1549:1011,Colon,SNU-175,SIDM00216,1659928,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.833490040149239,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0702604099704086,0.465456809526649,0.191510371636752,0.273946437889897,6.06767755642636,1.31,3.50163136029327,13.5281,0.738360755493948,0.547307459249627,0.718339195495729,0.546995362679962,0.191053296244321,0.171343832815767,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1975,19264,1032:1011,Colon,SNU-175,SIDM00216,1659928,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.713499720573597,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.126299560913598,0.398449036627814,0.273754246639713,0.124694789988101,7.85102329134828,4.5094,1.71828562537136,10.3287,0.632065372530562,0.609967495941432,0.614926142574534,0.552240709434191,0.0220978765891297,0.0626854331403432,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1976,19264,1561:1011,Colon,SNU-175,SIDM00216,1659928,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.724464406778671,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.168963430995823,0.404572190610027,0.233495312220078,0.171076878389949,7.19830368728236,2.8684,2.37100522943728,11.9697,0.641778618760455,0.4849710438734,0.624376002186541,0.531480553060225,0.156807574887055,0.0928954491263155,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1977,19264,2171:1011,Colon,SNU-175,SIDM00216,1659928,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.86694681478715,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.116236136650886,0.484140516385613,0.290186422669015,0.193954093716598,7.33482331193507,3.1531,2.23448560478457,11.685,0.767998985356437,0.669475546370332,0.747173748303313,0.6435773717616,0.0985234389861048,0.103596376541713,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1978,19264,1083:1011,Colon,SNU-175,SIDM00216,1659928,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.916932427465664,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.122948286607857,0.512054639745036,0.239186574772198,0.272868064972838,6.47514857122256,1.7376,3.09416034549707,13.1005,0.812279556165091,0.648280916514709,0.79025359697363,0.628186852347887,0.163998639650382,0.162066744625743,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1979,19264,1053:1011,Colon,SNU-175,SIDM00216,1659928,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.704724865466137,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.122370094924528,0.393548778837516,0.232077501312629,0.161471277524887,7.27573432568263,3.0265,2.293574591037,11.8116,0.624292023918821,0.549953699293206,0.607363577870875,0.520501574899204,0.0743383246256144,0.086862002971671,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1980,19264,2048:1011,Colon,SNU-175,SIDM00216,1659928,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.545888339983354,0.196213702067916,0.558443157213142,9.56930891671963,14.8381,0.885866321044151,0.861844966218322,0.0538638710968274,0.304847608066145,0.0638511263153818,0.240996481750763,4.0996019687273,0.3348,5.46970694799234,14.5033,0.483584095441952,0.267072796294893,0.47047111793193,0.27715457468668,0.21651129914706,0.19331654324525,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1981,19265,1372:1053,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.885191713442594,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.152072905467515,0.453029941558246,0.154025973364884,0.299003968193362,5.22429538543341,0.7301,3.89002460265364,10.0945,0.726096591077695,0.472232775435622,0.744735017478171,0.525810419969612,0.253863815642073,0.218924597508559,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1982,19265,2048:1053,Colon,SNU-175,SIDM00216,1659928,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.501089487489485,0.0772897242385361,0.511787372925544,9.11431998808705,10.8246,0.82027043413436,0.841326241726583,0.0383702932333877,0.256451272402851,0.20248844894755,0.0539628234553007,8.0583870200281,5.2065,1.05593296805895,5.6181,0.411028891443164,0.396739469630323,0.421579735278228,0.393883633439515,0.0142894218128415,0.0276961018387131,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1983,19266,1083:1054,Colon,SNU-175,SIDM00216,1659928,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.97701295979866,0.114443283123161,0.495099816650789,8.95248279287076,3.8704,0.763588969057678,0.833544097735956,0.175061831647019,0.483718937261761,0.151155257739355,0.332563679522407,4.88346536954868,0.2306,4.06901742332209,3.6398,0.74603631872865,0.498211875379265,0.81438338605171,0.555055359614888,0.247824443349385,0.259328026436821,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1984,19264,1032:1510,Colon,SNU-175,SIDM00216,1659928,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.713499720573597,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0766676025647651,0.469800935076624,0.309642731653138,0.160158203423486,8.35603704111794,6.3995,2.23513606512521,23.7299,0.617736037011195,0.523414421808241,0.64266629413594,0.572722950368702,0.0943216152029546,0.0699433437672387,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1985,19264,1549:1510,Colon,SNU-175,SIDM00216,1659928,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.762363238948547,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0723114219303484,0.50197491631551,0.271161390866168,0.230813525449342,7.55969598312051,3.6849,3.03147712312264,26.4445,0.660041247966427,0.526777792709496,0.686678835930949,0.576655909153074,0.133263455256931,0.110022926777875,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1986,19264,1011:1510,Colon,SNU-175,SIDM00216,1659928,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.944646991959935,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.0662245833091382,0.621998898308356,0.410646538433067,0.211352359875289,8.36325582321283,6.4316,2.22791728303032,23.6978,0.817859450202383,0.709188005265263,0.85086617987951,0.75863547967661,0.10867144493712,0.0922307002029003,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1987,19264,1372:1510,Colon,SNU-175,SIDM00216,1659928,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.824404570701692,0.082412645099935,0.658445857132139,10.5911731062432,30.1294,0.865783151974586,0.900723960507353,0.146557973276357,0.542825774179328,0.209032538711554,0.333793235467774,6.3825240540858,1.6295,4.20864905215735,28.4999,0.713755587724366,0.482067770463398,0.742560949982792,0.559464863813152,0.231687817260968,0.18309608616964,True,0.343498074373501,0.0477659180681478,0.976135996110051,49.4682740641012
1988,19539,1053:1549,Colon,SNU-175,SIDM00216,1659928,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.688898052623861,0.16380708852286,0.375627513917348,7.76815557458231,2.1289,0.662712231529867,0.769061186513349,0.102224889673123,0.258769062849604,0.12094600375103,0.137823059098574,5.25053983816849,0.3718,2.51761573641382,1.7571,0.456541165750939,0.368060377609161,0.529804753737642,0.410574327735943,0.0884807881417787,0.1192304260017,True,0.190411427660888,0.0327857386121546,1.54004486756684,31.9152539374976
1989,18429,1053:1032,Colon,SW1417,SIDM00812,909747,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.847529516824152,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.0362382141536828,0.661923740892399,0.62784939435855,0.0340743465338486,13.0127281456864,161.4178,0.846000209425664,128.7325,0.781053764261348,0.773352890928884,0.774044425800917,0.758534978080866,0.0077008733324633,0.0155094477200511,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1990,18429,1372:1032,Colon,SW1417,SIDM00812,909747,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.749387223408249,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.102881051097762,0.585274240541024,0.425172187258321,0.160102053282703,10.0358733484699,20.5035,3.82285500664211,269.6468,0.690609235564612,0.530707486924966,0.684411565061673,0.602609517726415,0.159901748639646,0.0818020473352585,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1991,18429,1564:1032,Colon,SW1417,SIDM00812,909747,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.881797267759904,0.0772744107452297,0.781003761819114,13.858728355112,290.1503,0.921565265582842,0.913294947769374,0.0888798462664321,0.688686983282302,0.512240706392019,0.176446276890283,10.2475804927733,23.7443,3.61114786233869,266.406,0.812633733253381,0.655276738509726,0.805340989601958,0.716076027734361,0.157356994743654,0.0892649618675974,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1992,18434,1561:1054,Colon,SW1417,SIDM00812,909747,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.863151645411799,0.0596648316713478,0.81728359457219,14.7243231589595,211.472,0.921625674162389,0.929088166475339,0.073386253667262,0.705439679423056,0.622587769772626,0.0828519096504298,12.6335567585145,49.6443,2.09076640044493,161.8277,0.795502717107025,0.702903923765078,0.801943979625821,0.764572900450382,0.0925987933419472,0.0373710791754389,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1993,18430,1025:1372,Colon,SW1417,SIDM00812,909747,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,1.0,0.112124303315582,0.360051872725918,6.80228992290279,0.218,0.60874881572453,0.656293512977079,0.0934681040780607,0.360051872725918,0.281396182254503,0.0786556904714152,5.41746500162358,0.0835,1.38482492127921,0.1345,0.60874881572453,0.533039022716416,0.656293512977079,0.580815329538945,0.0757097930081142,0.0754781834381344,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1994,18430,1032:1372,Colon,SW1417,SIDM00812,909747,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.904409687282629,0.112124303315582,0.360051872725918,6.80228992290279,0.218,0.60874881572453,0.656293512977079,0.117050378315575,0.325634401617573,0.231687397492887,0.0939470041246855,4.92683705213441,0.0594,1.87545287076837,0.1586,0.550558326063093,0.447074946237498,0.593558210837218,0.500205960910627,0.103483379825596,0.0933522499265911,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1995,18432,1011:1510,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.923663754900941,0.0729545058679176,0.742035699852052,13.0373683830906,164.1984,0.869934890040923,0.895571309624651,0.0511043295170543,0.685391480795894,0.607399557198582,0.0779919235973117,11.4937364889867,56.3235,1.54363189410387,107.8749,0.803527327054536,0.790075777776977,0.827206758629458,0.78889220073417,0.0134515492775598,0.0383145578952884,True,0.648520762392188,0.0715490348241926,0.390111103998348,119.34394816505
1996,20662,1372:1549,Colon,SW1417,SIDM00812,909747,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.545185332961694,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0513125167463875,0.401203263811196,0.287384044083718,0.113819219727478,9.41509624866977,6.6669,3.50077107601643,68.8012,0.478943488312867,0.386979438102973,0.486689871882237,0.425011482851145,0.0919640502098939,0.0616783890310924,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
1997,20662,2171:1549,Colon,SW1417,SIDM00812,909747,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.809194749785902,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0439975265157401,0.595488460610878,0.55136711692124,0.0441213436896373,11.9045160821875,37.4383,1.01135124249873,38.0298,0.710874876404917,0.695372050100586,0.72237249480215,0.700952639433386,0.0155028263043314,0.0214198553687642,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
1998,20662,1564:1549,Colon,SW1417,SIDM00812,909747,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.749031394780279,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.0520883354582689,0.551214095673434,0.504169115079497,0.0470449805939369,11.7597171765687,33.8632,1.15615014811752,41.6049,0.658021570615373,0.642132115846635,0.668664344987067,0.645701244730613,0.0158894547687383,0.0229631002564539,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
1999,20662,1011:1549,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.957716906248747,0.0540360328146828,0.735902526268779,12.9158673246862,75.4681,0.878496649407329,0.892705365418246,0.056247635601708,0.704786290758772,0.746925854295837,-0.0421395635370646,13.8341701634289,142.6265,-0.918302838742651,-67.1584,0.841351093220277,0.862849056502524,0.85495902076002,0.87420898395446,-0.0214979632822462,-0.0192499631944399,True,0.426577842368687,0.0480263881547785,0.701232238719629,64.9549614983255
2000,21006,1011:2048,Colon,SW1417,SIDM00812,909747,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.779347310509503,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0450868877963694,0.560083458881111,0.482684055703294,0.077399403177817,10.8600156310791,0.363,1.72352582791665,0.8358,0.680252304921626,0.687940119712175,0.68935582352351,0.649745913483353,-0.0076878147905488,0.0396099100401576,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
2001,21006,1053:2048,Colon,SW1417,SIDM00812,909747,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.833356700332355,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0637076771787544,0.598897689014612,0.367123758212493,0.231773930802119,8.08678986806674,0.0531,4.49675159092904,1.1457,0.727394331870287,0.595892412313252,0.737128731567543,0.600551512368369,0.131501919557035,0.136577219199174,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
2002,21006,1510:2048,Colon,SW1417,SIDM00812,909747,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.768957423122842,0.0865652145052265,0.718657075386522,12.5835414589958,1.1988,0.872848723218031,0.884529675316182,0.0733367346540454,0.552616692798218,0.480786118216538,0.0718305745816796,10.9559378174892,0.388,1.62760364150657,0.8108,0.6711835049818,0.62782972879223,0.680165659806816,0.643556708332347,0.0433537761895699,0.0366089514744682,True,0.57409154378327,0.0519928564661112,0.509203079528235,93.1560991401707
2003,19447,1549:1011,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.598639341111062,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0757060222353606,0.428423928372489,0.162227491564012,0.266196436808477,6.29784671354245,1.5366,5.22261774989056,55.8401,0.526266753476874,0.391802274172322,0.545612245900701,0.396129024227091,0.134464479304551,0.14948322167361,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2004,19447,1032:1011,Colon,SW1463,SIDM00834,909748,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.572916056721229,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.069725656702795,0.410014729724633,0.25046936556481,0.159545364159823,8.31025031655344,6.1996,3.21021414687957,51.1771,0.503653289183874,0.438189267917609,0.522167513815719,0.44856473828423,0.065464021266265,0.0736027755314894,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2005,19447,1372:1011,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.321392597850035,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0509475047485316,0.230008737924236,0.142195097208035,0.087813640716201,8.36844647937665,6.4548,3.15201798405636,50.9219,0.28253779437235,0.227468659894424,0.292923844268841,0.252622938401966,0.055069134477926,0.0403009058668757,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2006,19447,1564:1011,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.818444454302149,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0725483281952968,0.585730278962324,0.232717983987183,0.353012294975141,6.47959798095476,1.7429,5.04086648247825,55.6338,0.719498496485941,0.515885345044286,0.745947160819694,0.551391213397536,0.203613151441655,0.194555947422158,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2007,19447,1510:1011,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.63509825666504,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.0829372579401162,0.454516219261434,0.35190656747011,0.102609651791323,9.59319744226968,15.0859,1.92726702116332,42.2908,0.558317963289227,0.47818622188706,0.578841653713409,0.536255845753643,0.0801317414021669,0.0425858079597665,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2008,19447,1561:1011,Colon,SW1463,SIDM00834,909748,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.956527525174112,0.104350235456805,0.71566283561876,11.520464463433,57.3767,0.879104858862322,0.911420630805948,0.06145139423249,0.6845512010135,0.472865873849212,0.211685327164288,8.93836023371374,9.5817,2.58210422971927,47.795,0.840887995016114,0.76165801653137,0.871798920377442,0.779291749846661,0.0792299784847443,0.0925071705307808,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2009,20668,1372:1025,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.408273771008423,0.0525606475626456,0.896913705504967,14.9073343897504,600.1846,0.953097442906878,0.971097014580492,0.0557223682692994,0.366186340815651,0.191625022109188,0.174561318706463,8.664856101321,7.9271,6.2424782884294,592.2575,0.389124687154076,0.32432854161966,0.396473440157799,0.327138606988359,0.0647961455344158,0.0693348331694397,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2010,20668,1564:1025,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.88428207275026,0.0525606475626456,0.896913705504967,14.9073343897504,600.1846,0.953097442906878,0.971097014580492,0.0627237157089655,0.793124710582049,0.499078377681433,0.294046332900616,9.70719725406831,16.3263,5.20013713568209,583.8583,0.842806982346666,0.723041622457219,0.858723680894827,0.750901557648465,0.119765359889447,0.107822123246362,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2011,19448,1194:1053,Colon,SW1463,SIDM00834,909748,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.980393775285872,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0605909502635849,0.815275520308896,0.75828030901576,0.056995211293136,12.3527921267514,102.1624,1.00758526616951,103.2395,0.938442074850721,0.952360161673306,0.932409893348732,0.913625847043519,-0.013918086822585,0.0187840463052129,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2012,19448,1510:1053,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.621868966800694,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.101982012145597,0.517133582702071,0.346056444322212,0.171077138379859,9.61951712544633,15.3636,3.74086026747463,190.0383,0.595258780911323,0.461558068265232,0.591432536219895,0.525780372978712,0.13370071264609,0.0656521632411831,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2013,19448,1372:1053,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.886519493462864,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0665815839061837,0.737211577140183,0.527556695156843,0.20965488198334,10.0513787966322,20.7251,3.30899859628878,184.6768,0.848584735861173,0.792558548528642,0.843130145446154,0.765065404088598,0.0560261873325315,0.0780647413575558,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2014,19448,1564:1053,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.977857724464131,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0598059564990302,0.813166592034008,0.65655682027972,0.156609771754289,10.9513628942948,38.674,2.40901449862613,166.7279,0.936014543327086,0.903095478489979,0.929997965676571,0.874826021669392,0.032919064837107,0.0551719440071793,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2015,19448,1549:1053,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.701932720015986,0.0389265931115184,0.831579657950369,13.360377392921,205.4019,0.957209336194614,0.9510565212196,0.0705301186189052,0.583712971215066,0.441420326332857,0.142292644882209,10.4399674018443,27.1315,2.92040999107665,178.2704,0.671896552979781,0.620244636728918,0.667577690828615,0.615911584808936,0.0516519162508636,0.0516661060196791,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2016,19449,1025:1054,Colon,SW1463,SIDM00834,909748,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1054,Palbociclib,"CDK4, CDK6",Cell cycle,Targeted,FDA approved,4.0,0.9191303092481,0.0695535448195085,0.670330803499904,10.9378477156572,15.3253,0.884413583465511,0.894207279552568,0.109755797674425,0.616121358719394,0.410686330535394,0.205435028184,8.41695048315125,2.6702,2.52089723250596,12.6551,0.812891330473875,0.649041423820311,0.821893013387054,0.724797723456791,0.163849906653564,0.0970952899302625,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2017,20667,1011:1083,Colon,SW1463,SIDM00834,909748,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.929463682157042,0.113611287573718,0.661327662301241,10.8273537541289,35.4886,0.939323705729005,0.890655578932198,0.109746386472389,0.61468004411482,0.386381651766031,0.228298392348789,8.07041310514823,5.2501,2.75694064898065,30.2385,0.873067270264279,0.764530954505474,0.827832013928032,0.715681969019766,0.108536315758805,0.112150044908266,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2018,20668,1510:1194,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.752420129299816,0.0978738961573146,0.487752572438638,8.86620254715844,9.1143,0.844001003220375,0.811223787126038,0.0966112611250313,0.366994853620598,0.157823473127703,0.209171380492895,5.37813201621565,0.8123,3.48807053094279,8.302,0.635043343972248,0.445350968629784,0.610381106800459,0.45050770812735,0.189692375342465,0.159873398673109,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2019,19447,1194:1510,Colon,SW1463,SIDM00834,909748,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,0.625,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.95085126203256,0.0807229521562195,0.548549740697664,9.53195328616948,14.4589,0.815386372709932,0.841744222044077,0.0651055794262711,0.521589213230008,0.544635558314853,-0.0230463450848457,9.80069716131835,17.4194,-0.268743875148868,-2.9605,0.77531116153539,0.812119002203197,0.800373555839226,0.811095324764758,-0.0368078406678067,-0.010721768925532,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2020,20671,2171:1549,Colon,SW1463,SIDM00834,909748,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.954300763410355,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0933797352854013,0.655028687313302,0.28026562291433,0.374763064398972,6.60378814397829,0.9498,4.53515179855938,21.0721,0.836013260931363,0.632150139921313,0.859283493815573,0.650640654263682,0.203863121010051,0.208642839551891,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2021,20671,1053:1549,Colon,SW1463,SIDM00834,909748,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.973222097106075,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0402209019617599,0.66801622420747,0.467738720816186,0.200277503391284,8.78809193694014,4.317,2.35084800559753,17.7049,0.852589257190236,0.768364847259244,0.876320879039499,0.785782112322444,0.0842244099309923,0.090538766717055,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2022,20671,1510:1549,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.777468973026861,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.116924394121129,0.533651968388523,0.212787033207411,0.320864935181112,6.33502632330985,0.7884,4.80391361922782,21.2335,0.681100127270517,0.464470433630023,0.700058389441374,0.516381189674744,0.216629693640494,0.18367719976663,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2023,20671,1564:1549,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.975086190487514,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0780092025192824,0.669295731347662,0.593195979656886,0.0760997516907758,10.2025279826571,11.5071,0.936411959880616,10.5148,0.854222292441019,0.820959046059061,0.877999369443172,0.847121879023607,0.0332632463819579,0.0308774904195647,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2024,20671,1561:1549,Colon,SW1463,SIDM00834,909748,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.906216184577129,0.0751533520542557,0.686396482564309,11.1389399425377,22.0219,0.876047985064718,0.900432575098,0.0853739654071722,0.62202360153659,0.315532417080345,0.306491184456244,7.28786876535475,1.526,3.85107117718292,20.4959,0.79388886253183,0.619053825129947,0.815986572674268,0.656768846441878,0.174835037401883,0.15921772623239,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2025,20672,1549:1561,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.749670702054161,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0608739061450127,0.508161583391422,0.346709274150724,0.161452309240698,8.58944458778584,7.5233,2.4418182550851,33.3529,0.653561932233939,0.554341503961999,0.672557455472632,0.597832895541296,0.0992204282719399,0.0747245599313365,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2026,20672,1372:1561,Colon,SW1463,SIDM00834,909748,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.440279488008791,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.065425403294928,0.298441864072138,0.15248834340435,0.145953520667788,7.26567591720721,3.0055,3.76558692566373,37.8707,0.383835078678593,0.290361312009134,0.394991095877978,0.318494246999312,0.0934737666694591,0.0764968488786659,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2027,20672,1564:1561,Colon,SW1463,SIDM00834,909748,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.883260139775665,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0476098201326737,0.598714702262039,0.257941640362134,0.340773061899905,6.58198899101534,1.8711,4.4492738518556,39.0051,0.770025028369453,0.590905112703141,0.792405506177839,0.600956127630294,0.179119915666312,0.191449378547545,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2028,20672,1011:1561,Colon,SW1463,SIDM00834,909748,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.870413477031706,0.0711943525633612,0.677846395756186,11.0312628428709,40.8762,0.871798685000127,0.897137174535124,0.0749701091547871,0.590006638223551,0.308952522782335,0.281054115441216,7.36887096699729,3.2284,3.66239187587365,37.6478,0.758825324682629,0.651951847146912,0.780880287461518,0.635074304630984,0.106873477535717,0.145805982830533,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2029,20672,1053:1564,Colon,SW1463,SIDM00834,909748,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.951645198937752,0.0752529597442804,0.498227804138526,8.98064337565785,4.9334,0.814612240161247,0.816731619447363,0.0525868098366097,0.474136097785727,0.329786957560449,0.144349140225277,7.26808312693822,1.5053,1.71256024871963,3.4281,0.775221827345377,0.693019195286517,0.777238724467738,0.688550766386667,0.0822026320588601,0.0886879580810709,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2030,20672,1510:1564,Colon,SW1463,SIDM00834,909748,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.739227663462906,0.0752529597442804,0.498227804138526,8.98064337565785,4.9334,0.814612240161247,0.816731619447363,0.0870574495199868,0.368303775525577,0.163976159812349,0.204327615713228,5.57287709050218,0.4648,3.40776628515567,4.4686,0.602183902922682,0.43522089825446,0.60375060672035,0.452669713639734,0.166963004668222,0.151080893080615,True,0.269741196153515,0.0416730931630788,1.10230436882875,42.9193037775805
2031,19448,1549:2171,Colon,SW1463,SIDM00834,909748,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.701932720015986,0.0709670077359729,0.417972794608051,8.09590017841424,5.3437,0.746580837892131,0.771392481894387,0.119847052437561,0.293388780611912,0.143733185856957,0.149655594754955,5.29525419584089,0.7669,2.80064598257335,4.5768,0.524049518253437,0.356522860083594,0.541465623016009,0.416187117556757,0.167526658169844,0.125278505459251,True,0.32415918469777,0.04283158651987,1.05797121998219,46.1794138522287
2032,19675,1510:1025,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.943587125335813,0.0787752179033489,0.879598909334269,14.8435284411539,574.2187,0.927073625575034,0.963637826118179,0.161767804021944,0.829978206307239,0.474569925866291,0.355408280440948,9.03458428730394,10.2426,5.80894415384993,563.9761,0.874774737330996,0.66967005418673,0.909276246211704,0.761995384625374,0.205104683144266,0.14728086158633,True,0.160298885117818,0.034838527019102,1.69591137707902,29.0360425779815
2033,18422,1053:1032,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.898501442248502,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0841875486089098,0.454586226637221,0.331488954470586,0.123097272166635,7.42267418129553,3.351,1.64712603355775,7.1447,0.727365449128063,0.663574710927691,0.72705425184529,0.64984964813824,0.0637907382003726,0.0772046037070504,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2034,18422,1510:1032,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.846980945143613,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0610091466313804,0.428520037678441,0.189979616417394,0.238540421261048,5.35405110046066,0.7988,3.71574911439262,9.6969,0.685657970704635,0.473122232957022,0.685364617621049,0.502065359669657,0.212535737747613,0.183299257951392,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2035,18422,1564:1032,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.957654849557039,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0867501326077111,0.484514196651192,0.41866828297239,0.0658459136788022,8.25771093232672,5.9779,0.812089282526562,4.5178,0.775252010741984,0.708980203096733,0.77492032559046,0.736621026156871,0.0662718076452511,0.0382992994335883,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2036,18422,1561:1032,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.646480635407588,0.0866143375443071,0.505938226987837,9.06980021485329,10.4957,0.809531754682363,0.809185403226326,0.0954258035547154,0.327079266460085,0.236040764529994,0.0910385019300911,7.3743715643419,3.2407,1.69542865051138,7.255,0.523346603149674,0.413770948283291,0.523122693640301,0.465766091513839,0.109575654866382,0.0573566021264624,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2037,18426,1510:1053,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.846582996911804,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0899475848162796,0.609042386312135,0.290644173870471,0.318398212441664,7.0942377726608,2.6688,4.67246561396338,65.3863,0.740134213704345,0.567601723766808,0.767866728055829,0.595973286566904,0.172532489937536,0.171893441488925,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2038,18426,1032:1053,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.817745590644919,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0414719584019761,0.588296395910835,0.394964230599179,0.193332165311656,8.80000863363238,8.7056,2.96669475299181,59.3495,0.71492280372981,0.649974224326901,0.741710657267088,0.651280551749562,0.0649485794029093,0.0904301055175262,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2039,18426,1564:1053,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.948701964936018,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0426695068832552,0.682508047918943,0.577868754228553,0.10463929369039,10.3034836500639,24.6824,1.4632197365603,43.3727,0.829412810579796,0.793022662877074,0.860490556003273,0.816390191572625,0.0363901477027222,0.0441003644306482,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2040,18426,1549:1053,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.77573544308802,0.119998473435879,0.71941249532984,11.7667033866242,68.0551,0.874260664818728,0.907018840275414,0.0427114970086882,0.558073770827752,0.355530384791635,0.202543386036116,8.50888924002123,7.1148,3.25781414660296,60.9403,0.678194984197583,0.598462315663699,0.70360666195023,0.606682507792092,0.0797326685338842,0.0969241541581382,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2041,18423,1561:1372,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.616852877939831,0.14543686851332,0.346420679923749,7.13463711088156,0.2745,0.635446071221789,0.706381575394615,0.0843626420640411,0.213690593388837,0.126318726746912,0.0873718666419255,5.01343276970059,0.0631,2.12120434118097,0.2114,0.391976737808719,0.31012643118963,0.43573350770584,0.351430697290998,0.0818503066190887,0.0843028104148416,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2042,18425,1053:1510,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.867498607959704,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0440769182926393,0.717929806842596,0.471367298044804,0.246562508797793,9.51097403126618,14.2501,4.09833686417035,229.8348,0.807522255989027,0.734470359224361,0.821019416643214,0.719038122110857,0.0730518967646663,0.101981294532357,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2043,18425,1032:1510,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.794076261173418,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0363923008207164,0.657166491763413,0.444019281909116,0.213147209854297,9.69868328844349,16.2302,3.91062760699304,227.8547,0.739176118516465,0.666809571402488,0.751530922052048,0.664476472495048,0.0723665471139775,0.0870544495569994,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2044,18425,1561:1510,Colon,LS-180,SIDM00680,998189,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.67508947537057,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0599153597289741,0.558694679400311,0.367648462261883,0.191046217138428,9.52552558702025,14.3946,4.08378530841627,229.6903,0.628415735937427,0.522791892113482,0.638919258388555,0.559978496836869,0.105623843823945,0.0789407615516866,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2045,18425,1549:1510,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.717444198926708,0.0911254013413339,0.827586119741583,13.6093108954365,244.0849,0.930862883905097,0.946421595504567,0.0610709603333948,0.593746860720863,0.474598091733392,0.119148768987471,10.968885825203,39.1466,2.64042507023354,204.9383,0.667842176053897,0.610303847564168,0.679004683433711,0.633887109856883,0.057538328489729,0.0451175735768279,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2046,19003,2171:1549,Colon,LS-180,SIDM00680,998189,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.833620850738005,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.110557525104103,0.483455080224701,0.151982219713103,0.331472860511598,4.59014929730248,0.2352,5.35765556561714,9.4095,0.663173404020842,0.420371004140722,0.705996385246347,0.450768924768504,0.24280239988012,0.255227460477843,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2047,19003,1053:1549,Colon,LS-180,SIDM00680,998189,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.911337088855866,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0854498384436,0.528526301872731,0.306397831084271,0.22212847078846,7.00113217453437,1.251,2.94667268838525,8.3937,0.724999283417558,0.60439769276724,0.77181453643292,0.636471607121814,0.120601590650318,0.135342929311106,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2048,19003,1083:1549,Colon,LS-180,SIDM00680,998189,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.940529313775073,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0842199826998005,0.54545621602706,0.436983147323853,0.108473068703207,8.58338310162963,3.7459,1.36442176128999,5.8988,0.748222679465622,0.683537114881682,0.796537532807127,0.739074831599522,0.0646855645839405,0.0574627012076058,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2049,19003,1510:1549,Colon,LS-180,SIDM00680,998189,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.884460786790853,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0113381631325589,0.512939497920454,0.320022115034091,0.192917382886363,7.33259634143478,1.5741,2.61520852148484,8.0706,0.703618281836123,0.627708508825226,0.749052903143771,0.635073783666216,0.075909773010897,0.113979119477555,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2050,19003,2048:1549,Colon,LS-180,SIDM00680,998189,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.851545618723443,0.107919276344984,0.579946002786156,9.94780486291962,9.6447,0.795533609114664,0.84690346291282,0.0705160809506155,0.493850477768725,0.439138654728953,0.0547118230397721,9.18454860999386,5.6823,0.763256252925764,3.9624,0.677433159388841,0.685628280006402,0.721176933325124,0.693536540646848,-0.0081951206175613,0.027640392678276,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2051,19004,1372:1561,Colon,LS-180,SIDM00680,998189,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.457583011213722,0.0992565128514196,0.332246998287411,6.9488393953436,2.4129,0.65213506405741,0.695236671188781,0.0758160254344012,0.152030581943074,0.0868862475460346,0.0651443343970391,4.73692969347967,0.5208,2.21190970186393,1.8921,0.298405926329443,0.214738339309255,0.318128489508766,0.25204499865102,0.0836675870201878,0.0660834908577468,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2052,19004,1564:1561,Colon,LS-180,SIDM00680,998189,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.679657112640142,0.0992565128514196,0.332246998287411,6.9488393953436,2.4129,0.65213506405741,0.695236671188781,0.104768139984437,0.225814035539376,0.0965979528087771,0.129216082730599,3.71744184609224,0.2569,3.23139754925136,2.156,0.443228234688653,0.295561873816918,0.472522548541711,0.326554529015655,0.147666360871735,0.145968019526056,True,0.239014046932689,0.0413235566498211,1.32784096807399,36.8710923103673
2053,18426,1549:2171,Colon,LS-180,SIDM00680,998189,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.77573544308802,0.105034321501531,0.537904774328535,9.44638286518155,13.6262,0.788093831954701,0.826074193485486,0.0860377891190439,0.417271798452908,0.202553878184659,0.214717920268248,5.94342546543605,1.2019,3.5029573997455,12.4243,0.611352317926315,0.446735412337848,0.640815030507043,0.490155942277328,0.164616905588468,0.150659088229715,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2054,18426,1032:2171,Colon,LS-180,SIDM00680,998189,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.817745590644919,0.105034321501531,0.537904774328535,9.44638286518155,13.6262,0.788093831954701,0.826074193485486,0.141948778968893,0.43986925739401,0.21844187333804,0.22142738405597,6.03436505512813,1.2801,3.41201781005342,12.3461,0.644460256095414,0.451735284944276,0.675518529268314,0.521542039801288,0.192724971151138,0.153976489467026,True,0.322432072654076,0.0551020714213911,1.0561335627985,46.15924765546
2055,22215,1549:1011,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.557770741750379,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.0387438503851825,0.125758565459247,0.0397196800593034,0.0860388853999433,2.40134188536037,0.1032,3.42785704129612,1.0072,0.365351051873329,0.18943486983788,0.35400617278119,0.212944792508862,0.175916182035449,0.141061380272328,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2056,22215,1032:1011,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.560960542756697,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.057025276163171,0.1264777584334,0.0599470016296009,0.0665307568037989,3.54484057231102,0.2279,2.28435835434547,0.8825,0.367440435675118,0.248119824555516,0.356030677047292,0.2613520574475,0.119320611119602,0.0946786195997927,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2057,22215,1025:1011,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.47836044879678,0.122261602650765,0.225466407693948,5.82919892665649,1.1104,0.655020108668296,0.634680427428408,0.0571361596833817,0.107854211973075,0.0325698510742618,0.075284360898813,2.27740893268785,0.0947,3.55178999396864,1.0157,0.313335713153482,0.154782702887293,0.303606014107185,0.17838207096067,0.158553010266188,0.125223943146515,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2058,19666,1083:1025,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.975086109386184,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.0502890498981591,0.701840630350159,0.724881716801753,-0.0230410864515935,11.7330889175277,66.4878,-0.309335022828826,-12.8313,0.896036618088857,0.931460813869976,0.894688233934907,0.90255692673275,-0.0354241957811186,-0.0078686927978431,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2059,19666,1011:1025,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.81578755002171,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.112406952507059,0.587181832278865,0.330593850711236,0.25658798156763,8.01425171907158,5.0496,3.40950217562726,48.6069,0.749652272106098,0.668271880034259,0.74852417173132,0.632644537274344,0.0813803920718384,0.115879634456975,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2060,19666,2171:1025,Colon,HT-115,SIDM00534,907289,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.865921593465468,0.0718529420925407,0.719772975529277,11.4237538946988,53.6565,0.918930758487486,0.917547922509237,0.145654664493489,0.623266961903693,0.393171444669761,0.230095517233932,8.52641532001461,7.2017,2.89733857468424,46.4548,0.795721986673915,0.745811887708567,0.794524559140128,0.695651269000935,0.0499100989653473,0.098873290139193,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2061,22212,1011:1032,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.958019639894852,0.114654618800141,0.121625841458871,3.92009084207612,0.2957,0.486488540808474,0.494006828645052,0.104418561326543,0.116519944836336,0.075014003636805,0.0415059411995308,2.66488013222707,0.1239,1.25521070984906,0.1718,0.466065576678306,0.369791822545583,0.473268244084131,0.384016608439544,0.0962737541327232,0.0892516356445864,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2062,22216,1564:1053,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.935761742959326,0.0696352639896416,0.575202734383107,9.77879514464938,17.157,0.854992176143593,0.861749595323826,0.0756778412602746,0.538252713281307,0.368583077715869,0.169669635565438,7.8925917001717,4.6413,1.88620344447768,12.5157,0.800068968964716,0.672600704534284,0.806392303314718,0.719187696760815,0.127468264430432,0.0872046065539029,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2063,19666,1510:1194,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1194,SB505124,"TGFBR1, ACVR1B, ACVR1C",RTK signaling,Targeted,Experimental only,10.0,0.678229596594926,0.0511093112453615,0.776499273238017,12.1998120189478,91.8839,0.934941756034283,0.936510498037149,0.0771744237091721,0.526644788844473,0.347913393652151,0.178731395192322,9.13335714703372,10.9684,3.06645487191405,80.9155,0.634105170034883,0.535865018142352,0.635169137290649,0.565248510192228,0.0982401518925314,0.0699206270984203,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2064,22213,1011:1372,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.689675362669411,0.124760801329486,0.275162448990374,6.51136981251689,0.1782,0.632094201741158,0.681904760378295,0.06812655013504,0.18977276180044,0.045325153913533,0.144447607886907,2.17998469649359,0.0089,4.3313851160233,0.1693,0.435939797827065,0.222585262435001,0.470292912919899,0.25240111854524,0.213354535392064,0.217891794374659,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2065,22215,1011:1510,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.751560997949068,0.0770956823403337,0.473899907441532,8.73151552086409,8.3019,0.795286655162663,0.813886803874161,0.0297012512091461,0.356164687364729,0.129234993554819,0.22692969380991,4.96142407630864,0.6085,3.77009144455545,7.6934,0.597706432209628,0.41563507947114,0.611685578537242,0.429698914965955,0.182071352738488,0.181986663571287,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2066,22215,1549:1510,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.557770741750379,0.0770956823403337,0.473899907441532,8.73151552086409,8.3019,0.795286655162663,0.813886803874161,0.0458165535896331,0.264327502889099,0.139975317853587,0.124352185035513,6.19035632336059,1.4263,2.5411591975035,6.8756,0.443587627554256,0.346263799129094,0.453962246297736,0.368118798641644,0.0973238284251619,0.0858434476560918,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2067,19669,2171:1549,Colon,HT-115,SIDM00534,907289,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.917906644341671,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0997008110680475,0.653421616802418,0.277754322980754,0.375667293821664,6.85467719687379,1.1302,4.46913478766598,23.9025,0.801344668526048,0.605381334087878,0.839690126856728,0.646828730112392,0.19596333443817,0.192861396744336,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2068,19669,1025:1549,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.905636123637253,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.120347769917387,0.644686716007099,0.459533092645752,0.185153623361347,9.07620936077294,5.2712,2.24760262376684,19.7615,0.79063234128979,0.687741723795487,0.828465199844373,0.752337558953802,0.102890617494302,0.0761276408905711,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2069,19669,1011:1549,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.857062633149871,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0819988232282689,0.610109159690612,0.141293979280254,0.468815180410358,4.83120292348204,0.278,6.49260906105774,24.7547,0.748227040191135,0.483641867882363,0.784030746035101,0.481759014838242,0.264585172308773,0.302271731196859,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2070,19669,1053:1549,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.943378258952548,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.105001018194621,0.671553856833804,0.457355790641854,0.21419806619195,8.84380129165861,4.4869,2.48001069288117,20.5458,0.823581725739873,0.728184275163351,0.862991258225259,0.7730885597495,0.0953974505765223,0.0899026984757589,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2071,19669,1083:1549,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.943372413063694,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0452149198788388,0.671549695375588,0.600421669657639,0.0711280257179486,10.4389490555469,13.5562,0.884862928992844,11.4765,0.823576622201409,0.837606592008879,0.862985910475372,0.836664409296815,-0.0140299698074695,0.0263215011785571,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2072,19669,1510:1549,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.71517706477591,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0795403757544901,0.509106407330826,0.133059478251111,0.376046929079715,5.20796659537699,0.361,6.11584538916278,24.6717,0.624359058127657,0.404082243524675,0.654235508533015,0.421863620859318,0.220276814602981,0.232371887673697,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2073,19669,1372:1549,Colon,HT-115,SIDM00534,907289,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.880646025660925,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0982593229522116,0.626897248718239,0.355504585012893,0.271392663705346,7.99762322388112,2.4959,3.32618876065866,22.5368,0.768815654481038,0.652464815193817,0.805604554190201,0.682113008127006,0.116350839287222,0.123491546063195,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2074,19669,1564:1549,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.991971440855016,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.0269820001547521,0.706145430693755,0.553535575709032,0.152609854984723,9.59894610520322,7.573,1.72486587933656,17.4597,0.866004217704933,0.843172832000747,0.907443725507833,0.847373491474755,0.0228313857041861,0.0600702340330787,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2075,19669,1561:1549,Colon,HT-115,SIDM00534,907289,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.826868617219275,0.0970408980118839,0.711860645993097,11.3238119845398,25.0327,0.87301325626723,0.914788156326027,0.114765021742911,0.588615228005132,0.263791778465996,0.324823449539136,7.0517796040346,1.2957,4.27203238050518,23.737,0.72186726402378,0.53461217279986,0.756409617869872,0.593203353988349,0.187255091223921,0.163206263881523,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2076,19670,1549:1561,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.764181506204162,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.166196730547435,0.433660539047603,0.203740097454758,0.229920441592845,6.40013357254936,1.6495,3.29767954296441,14.5709,0.639183274419528,0.423430213728316,0.655973687839033,0.515343686230216,0.215753060691212,0.140630001608818,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2077,19670,1032:1561,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.731472749662903,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0882298728646807,0.415098853272562,0.28429697314858,0.130801880123982,7.83626100737678,4.4635,1.861552108137,11.7569,0.611824734676684,0.502138582364421,0.627896479114662,0.559798194181298,0.109686152312263,0.0680982849333633,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2078,19670,1372:1561,Colon,HT-115,SIDM00534,907289,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.687871467905488,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.130096175787211,0.390355837121847,0.277588405753001,0.112767431368846,7.99613720615047,4.9866,1.70167590936331,11.2338,0.575355375216489,0.448263196431273,0.590469122712139,0.532739615393562,0.127092178785216,0.0577295073185764,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2079,19670,1564:1561,Colon,HT-115,SIDM00534,907289,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.913174205606436,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0887908830892264,0.518211465512559,0.300598945050873,0.217612520461686,7.17089742413281,2.8144,2.52691569138097,13.406,0.763805030763245,0.635195247141055,0.783869076165652,0.662028013952759,0.12860978362219,0.121841062212894,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2080,19670,1510:1561,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.713860742049568,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.12916281674026,0.405104326248155,0.160233517456634,0.244870808791521,5.81437511555865,1.0991,3.88343799995512,15.1213,0.597093547643239,0.385909206065797,0.612778325259101,0.452322786929425,0.211184341577442,0.160455538329677,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2081,19670,1011:1561,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.900031459293623,0.0855837226171287,0.567483687483722,9.69781311551377,16.2204,0.836428609211541,0.858400370217518,0.0407677331085673,0.510753171371301,0.287202556199027,0.223550615172274,7.05269937858153,2.593,2.64511373693224,13.6274,0.752812061743599,0.642976698778656,0.772587337865059,0.645743983094305,0.109835362964943,0.126843354770754,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2082,19670,1510:1564,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.950757575054543,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.075024945492839,0.628085224143229,0.460077043337673,0.168008180805556,8.8345360422102,4.4582,1.87674569897907,11.9144,0.876247855050531,0.789445304909227,0.852029496125188,0.778700328380073,0.0868025501413032,0.073329167745115,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2083,19670,1561:1564,Colon,HT-115,SIDM00534,907289,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.804851784038909,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0267804645636115,0.531697591945198,0.316061798192569,0.215635793752629,7.87977854649725,2.3001,2.83150319469201,14.0725,0.741776524217783,0.627161230271821,0.721274779189416,0.61798151604192,0.114615293945962,0.103293263147496,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2084,19670,1549:1564,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.805688471328891,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0669943636251548,0.532250320566935,0.313043595797669,0.219206724769265,7.83494104585618,2.2297,2.87634069533309,14.1429,0.742547641337888,0.577536579548861,0.72202458362832,0.616533985918208,0.165011061789027,0.105490597710112,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2085,19670,1011:1564,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.950973242896371,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.060292032056741,0.62822769766995,0.470141807367959,0.158085890301992,8.94223499641635,4.8038,1.76904674477291,11.5688,0.876446621264719,0.821181477436077,0.852222768697949,0.783895405706331,0.0552651438286422,0.0683273629916178,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2086,19670,1083:1564,Colon,HT-115,SIDM00534,907289,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.635456387118208,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0372832861889615,0.419792361174182,0.166997773874601,0.252794587299581,6.3498059784299,0.7965,4.36147576275937,15.5761,0.585656439454133,0.405085455134314,0.569469651919206,0.426354877844963,0.180570984319818,0.143114774074243,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2087,19670,1053:1564,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.819948532966834,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0705436931006702,0.541670738815667,0.181088535096837,0.360582203718829,5.76083016170213,0.5295,4.95045157948713,15.8431,0.755690159210985,0.534418861470532,0.734803859282678,0.516422165003337,0.221271297740453,0.218381694279341,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2088,19670,1025:1564,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.96417575258704,0.0747458884796307,0.660615535045511,10.7112817411893,16.3726,0.921631210774483,0.896158514515447,0.0375528283246081,0.636949480673195,0.501761756295442,0.135187724377753,9.20982502809159,5.7827,1.50145671309767,10.5899,0.888614466256192,0.821222272437483,0.864054310170215,0.806986371897108,0.0673921938187094,0.0570679382731066,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2089,19672,1025:2048,Colon,HT-115,SIDM00534,907289,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,2.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.889981270925071,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.159553001338159,0.568294886331589,0.2706747913634,0.297620094968189,6.87339988998543,0.0229,3.58871945761079,0.2526,0.826129308093097,0.699354819679897,0.790036372265042,0.628236544591368,0.1267744884132,0.161799827673674,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2090,19672,1011:2048,Colon,HT-115,SIDM00534,907289,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.843214580270716,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.194025035531539,0.538432155487943,0.210867231933461,0.327564923554482,6.17832061298526,0.0141,4.28379873461096,0.2614,0.782717907140886,0.621430285884047,0.748521581072858,0.555804428078138,0.161287621256839,0.19271715299472,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2091,19672,1053:2048,Colon,HT-115,SIDM00534,907289,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.945811509970401,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.135257322067806,0.603945118969801,0.387761591722592,0.21618352724721,8.06461056212055,0.0523,2.39750878547566,0.2232,0.877953990544278,0.802421200655814,0.839596875344185,0.736162704182469,0.0755327898884633,0.103434171161716,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2092,19672,1510:2048,Colon,HT-115,SIDM00534,907289,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.714062951808947,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.0581687480767953,0.455962768306423,0.249832943196174,0.206129825110249,7.40806627908578,0.0332,3.05405306851044,0.2423,0.662832299492857,0.526075668961476,0.633873680768169,0.528216697924683,0.136756630531381,0.105656982843486,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2093,19672,1032:2048,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.762330151896837,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.0964916715025852,0.486783644973839,0.272317008619544,0.214466636354295,7.49059955442078,0.0351,2.97151979317544,0.2404,0.707636555396751,0.617659492879464,0.676720474181238,0.567762655206594,0.0899770625172864,0.108957818974644,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2094,19672,1549:2048,Colon,HT-115,SIDM00534,907289,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.76152718553678,0.103676721931554,0.638547017670256,10.4621193475962,0.2755,0.928254711736119,0.887699997825635,0.114266884900659,0.486270913199335,0.216756167787435,0.2695147454119,6.63211209139557,0.0194,3.83000725620065,0.2561,0.706891198089662,0.546749166252572,0.676007680945161,0.525451714088969,0.16014203183709,0.150555966856192,True,0.39385775161168,0.05983366634193,0.873474037723235,55.6471708708203
2095,22216,1032:2171,Colon,HT-115,SIDM00534,907289,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.525644546829026,0.114848557584554,0.186890062515285,5.22217622519228,0.7291,0.561338469366698,0.590912817724965,0.0677327996288307,0.0982377422176954,0.0409604472300548,0.0572772949876407,2.65143304530403,0.1227,2.57074317988825,0.6064,0.295064505347957,0.191541579867794,0.310610100288502,0.210187114887704,0.103522925480163,0.100422985400799,True,0.282784465500255,0.0479108274369462,1.18897457011574,41.2284136632928
2096,19258,1372:1011,Colon,NCI-H747,SIDM00778,908457,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.397111646441281,0.161848130538613,0.484357823480769,8.77472741239634,8.5543,0.837491430172689,0.762136184092885,0.0573190602237207,0.192344132749164,0.113661976821438,0.0786821559277262,5.71100458310377,1.0231,3.06372282929257,7.5312,0.33257760071634,0.220348747136911,0.302653154877601,0.238900053046956,0.112228853579429,0.0637531018306453,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
2097,19255,2171:1032,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.729316238196891,0.0728859978492952,0.369682191786166,7.07952197033817,2.6417,0.660728551409825,0.678082353423881,0.0572639836494651,0.269615225441868,0.146582639933335,0.123032585508533,4.03255788163604,0.3196,3.04696408870213,2.3221,0.481880061583495,0.336828319603966,0.494536471186799,0.366085008090142,0.145051741979529,0.128451463096657,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
2098,19259,2171:1053,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.784024802942897,0.0548760866110176,0.596704384632212,10.4100049750055,26.5738,0.838160044439606,0.828967139345594,0.0711207483217464,0.467831037576432,0.301189121400601,0.166641916175831,7.30138720343527,3.0808,3.10861777157023,23.493,0.657138263676372,0.502169990110007,0.649930798071566,0.540851308784822,0.154968273566365,0.109079489286745,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
2099,19259,1564:1053,Colon,NCI-H747,SIDM00778,908457,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.877376177214606,0.0548760866110176,0.596704384632212,10.4100049750055,26.5738,0.838160044439606,0.828967139345594,0.0298769024840508,0.523534211915804,0.344756133406278,0.178778078509526,7.43443994101961,3.3785,2.9755650339859,23.1953,0.735381655684446,0.601629959287265,0.727316019755565,0.611346822955962,0.133751696397182,0.115969196799603,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
2100,21242,2171:1549,Colon,NCI-H747,SIDM00778,908457,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.05,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.649143069722519,0.13720086063699,0.517492948382942,9.25194730941753,5.9541,0.712734935901774,0.78316908232113,0.0819093204876805,0.33592696107306,0.380155890683893,-0.0442289296108331,10.2450368432155,11.8512,-0.99308953379796,-5.8971,0.46266694418976,0.484768702497347,0.508388782209706,0.534181487666197,-0.0221017583075873,-0.0257927054564905,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
2101,21242,1011:1549,Colon,NCI-H747,SIDM00778,908457,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.930593887585295,0.13720086063699,0.517492948382942,9.25194730941753,5.9541,0.712734935901774,0.78316908232113,0.0771245019754686,0.481575774633659,0.620611466198719,-0.13903569156506,11.4985471937141,28.2558,-2.24659988429661,-22.3017,0.663266774818688,0.762386089391972,0.728812360953828,0.805140594258518,-0.0991193145732845,-0.0763282333046902,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
2102,21244,1011:2048,Colon,NCI-H747,SIDM00778,908457,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.511495045383488,0.104765503539487,0.544175926233364,9.63765969709692,0.1556,0.776250381793508,0.799256095206003,0.0875309295604487,0.278343290085336,0.161784599255114,0.116558690830222,6.22557171159622,0.0146,3.4120879855007,0.141,0.397048224264421,0.303421600126126,0.408815532690424,0.32278661791108,0.0936266241382944,0.086028914779344,True,0.51985444688515,0.0578948867755601,0.615403056837906,78.4987485414859
2103,19259,1032:2171,Colon,NCI-H747,SIDM00778,908457,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.731993278084693,0.110802614986979,0.429386400107322,7.97654113720297,4.9194,0.671492938554407,0.72427990688243,0.0841323556354088,0.314307958579544,0.218060161941365,0.096247796638179,5.91430165202133,1.1779,2.06223948518164,3.7415,0.491528317303163,0.404811813823791,0.530168023289746,0.448949747683967,0.0867165034793725,0.0812182756057788,True,0.426136587833001,0.0420140301828437,0.790043916089502,61.058594957668
2104,24157,1372:1011,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.451531378710925,0.152708339554006,0.253677987988611,5.88699269960425,1.1558,0.675407624187602,0.629646618735494,0.0662303522641666,0.114543571665111,0.0455757033789376,0.0689678682861734,2.69122996601676,0.1261,3.19576273358749,1.0297,0.304967735741299,0.144349071531019,0.28430520585831,0.184780314595979,0.16061866421028,0.0995248912623306,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2105,24154,1011:1032,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.984524856310005,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.112169134453352,0.603905096043351,0.570510087122326,0.0333950089210253,9.92496427440127,18.9864,0.406725036176743,6.1833,0.874806577827542,0.879607420854768,0.851248432872778,0.835920500497793,-0.0048008430272266,0.0153279323749854,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2106,24154,1564:1032,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.722099784603445,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.02731459574252,0.442934210323802,0.214465845027316,0.228468365296486,6.51439184164412,1.7855,3.81729746893388,23.3842,0.641626910047294,0.475942021400966,0.624348187942451,0.484059385984298,0.165684888646328,0.140288801958153,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2107,24154,1053:1032,Colon,CL-11,SIDM00944,1290769,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,10.0,0.837421351225978,0.0910210489296948,0.613397510659898,10.331689310578,25.1697,0.888557127045338,0.864628686027547,0.133256111081907,0.513672172215463,0.26776370654432,0.245908465671143,6.82214507693448,2.21,3.50954423364353,22.9597,0.744096709971779,0.625629565710421,0.72405852256193,0.577503198271481,0.118467144261359,0.146555324290449,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2108,24099,1011:1053,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.707265748425344,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0702298681423219,0.526551056177738,0.282219699639703,0.244331356538035,7.81862394227819,4.4093,4.26650811539351,80.4535,0.616464520603981,0.503235816890803,0.649238799540746,0.529192392019901,0.113228703713178,0.120046407520845,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2109,24099,1564:1053,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.663817536688005,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0724227003185504,0.494204372020807,0.189581643677491,0.304622728343316,6.35493227769177,1.5987,5.73019977997994,83.2641,0.578594340859817,0.390485775173945,0.609355255210563,0.438235551733297,0.188108565685872,0.171119703477266,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2110,24099,1372:1053,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.689146684775796,0.0865085111965909,0.744488273820768,12.0851320576717,84.8628,0.871616534487182,0.917955946525348,0.0850105769802138,0.513061625758037,0.337386805090692,0.175674820667345,8.87964812231987,9.1996,3.20548393535183,75.6632,0.600671645137609,0.512476428937303,0.632606297318171,0.553523317594096,0.0881952162003058,0.0790829797240754,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2111,24157,1564:1510,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.924694294361574,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0717186128758904,0.695049863344197,0.600524861297643,0.0945250020465545,10.7786133040499,34.3096,1.41620799675352,57.257,0.844275084965559,0.819143084041296,0.85127824213346,0.814004605433688,0.0251320009242638,0.0372736366997717,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2112,24157,1372:1510,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.451531378710925,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0674480073094733,0.339395219568565,0.162249121066376,0.177146098502189,7.33178315108055,3.1464,4.86303814972284,88.4202,0.412262404397101,0.289223358651275,0.415682069934817,0.325267290939665,0.123039045745826,0.0904147789951524,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2113,24157,1011:1510,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,0.1,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.972879864135273,0.0619394528873582,0.751653673632833,12.1948213008034,91.5666,0.913031571746058,0.920605055448296,0.0705841674051844,0.731268723880689,0.725147368058631,0.0061213558220584,12.0983924698588,85.6464,0.0964288309446157,5.92019999999999,0.888270031471519,0.876382701651701,0.895638121266783,0.893376273745291,0.0118873298198185,0.0022618475214922,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2114,19012,1372:1561,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.283031840745605,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.0334576632274648,0.219382878419108,0.169997466818267,0.0493854116008408,10.1772792966753,22.615,2.3925253409568,96.1308,0.252413077909885,0.248948017309808,0.26296865927689,0.243086648004975,0.0034650606000763,0.0198820112719151,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
2115,19012,1564:1561,Colon,CL-11,SIDM00944,1290769,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.5,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.625314568482482,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.109972630792732,0.484692144847379,0.211170819303051,0.273521325544329,7.05692757358231,2.6006,5.51287706404977,116.1452,0.557667202660856,0.372789480043184,0.580988108146976,0.440205168898926,0.184877722617673,0.14078293924805,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
2116,19012,1011:1561,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.291961436178851,0.0958978655508333,0.775117307795393,12.5698046376321,118.7458,0.891818663387625,0.92911334139699,0.0450599800638421,0.226304362391027,0.115544724862652,0.110759637528375,7.77916069502517,4.2903,4.79064394260691,114.4555,0.260376657773754,0.178230044807512,0.271265265527196,0.217810002295387,0.0821466129662416,0.053455263231809,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
2117,19012,1510:1564,Colon,CL-11,SIDM00944,1290769,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.976348648954123,0.0759758364181694,0.338448449220448,7.06653304402906,1.309,0.718755893246654,0.704554414708074,0.0903014109159187,0.330443686137003,0.123588665915055,0.206855020221948,3.42787394201924,0.1051,3.63865910200982,1.2039,0.701756345299185,0.436618117616796,0.687890750914891,0.44915803172298,0.265138227682389,0.238732719191911,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
2118,19014,2171:2048,Colon,CL-11,SIDM00944,1290769,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.1,0.848041104508268,0.0869562521455316,0.612688381104043,10.3230656054904,0.2502,0.860886817077582,0.864311656329769,0.176919741730272,0.519584931430856,0.314086130965124,0.205498800465732,7.46917565927575,0.0346,2.85388994621468,0.2156,0.73006740721108,0.528787167048402,0.732971811673268,0.617698620156428,0.201280240162678,0.11527319151684,True,1.07377915509701,0.139743052593617,-0.0949087246180258,-718.534644018198
2119,24099,1372:2171,Colon,CL-11,SIDM00944,1290769,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.344144696479761,0.180797062648639,0.31563725553414,6.76743747381685,2.1278,0.61034849454028,0.686231942643481,0.0763518655688347,0.108624887503502,0.0418046070684337,0.0668202804350678,3.2922094749661,0.1913,3.47522799885074,1.9365,0.210048197400444,0.0998934248419948,0.236163083615758,0.155073875821514,0.110154772558449,0.0810892077942441,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2120,24099,1011:2171,Colon,CL-11,SIDM00944,1290769,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,10.0,0.707265748425344,0.180797062648639,0.31563725553414,6.76743747381685,2.1278,0.61034849454028,0.686231942643481,0.0899635488392268,0.223239419766275,0.0330948530253014,0.190144566740974,0.304783794705244,0.0241,6.4626536791116,2.1037,0.431678584791313,0.168643180974788,0.48534834850712,0.18296319428461,0.263035403816525,0.30238515422251,True,0.493452263343676,0.0666688096947567,0.679037987672109,72.0570940142605
2121,24123,2171:1053,Colon,SNU-1040,SIDM00217,1659823,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.861095905584462,0.0621108012128943,0.608455963019837,10.3774823215561,25.9815,0.844262957479189,0.852840694390851,0.119143750984395,0.523938938484832,0.280737012035644,0.243201926449188,6.73070216446439,2.0743,3.64678015709169,23.9072,0.726991375921958,0.516483379417332,0.734377630055771,0.581286534305417,0.210507996504625,0.153091095750353,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
2122,24120,1053:1372,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.873905023352008,0.121151584948014,0.609033359653505,10.3850575748441,2.6118,0.781200432663985,0.853117744964791,0.139812927729338,0.532237312390148,0.417239712512762,0.114997599877386,8.71786481839961,0.8224,1.66719275644452,1.7894,0.682694982349819,0.591561967828196,0.745543882835468,0.683933740024768,0.0911330145216231,0.0616101428107004,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
2123,24122,1053:1510,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.833422057991458,0.069570940578093,0.841195428586945,14.2094621162362,370.0022,0.927720613476083,0.948357759270136,0.0494469174889834,0.701070825265938,0.614439607990469,0.0866312172754693,12.2238865068412,93.43,1.98557560939504,276.5722,0.773182822924335,0.78898094170155,0.790382275443084,0.757791926526443,-0.0157981187772154,0.0325903489166415,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
2124,24128,1053:1549,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.801619769768884,0.112741677731265,0.767032138011265,12.7235660381989,66.0503,0.850705742796324,0.92096674502305,0.091439007673705,0.614868125877925,0.479999525870126,0.134868600007799,10.2512011888427,11.902,2.47236484935623,54.1483,0.681942541681456,0.62684479069963,0.738265150110175,0.679905356284788,0.055097750981826,0.058359793825387,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
2125,24129,1053:1564,Colon,SNU-1040,SIDM00217,1659823,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.8787691396191,0.0806113270988909,0.646106941391193,10.8810196339147,18.4168,0.833626572246705,0.870411279222222,0.0843489820453485,0.567778840988267,0.424738017132051,0.143040823856216,8.79159897981464,4.3275,2.08942065410009,14.0893,0.732565305656857,0.626766622088819,0.764890570956872,0.69083376368255,0.105798683568038,0.0740568072743224,True,1.05879986570871,0.140484699452236,-0.0693721155591084,-884.535851004785
2126,21212,1372:1025,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.373869533115314,0.0878388795557856,0.747895632924708,12.4057517576174,105.9823,0.920662550653561,0.913323638545855,0.0371683595438129,0.279615391100543,0.210049188875781,0.0695662022247621,9.77851443037324,17.1536,2.62723732724415,88.8287,0.344207677969601,0.297476647239276,0.341463882326319,0.310047385000496,0.0467310307303251,0.0314164973258227,True,0.476222046130431,0.076292859072651,0.703203720824386,69.1414293878976
2127,21212,1011:1025,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1025,SB216763,"GSK3A, GSK3B",WNT signaling,Targeted,Experimental only,10.0,0.458159209868403,0.0878388795557856,0.747895632924708,12.4057517576174,105.9823,0.920662550653561,0.913323638545855,0.0534527407006808,0.342655272244813,0.177737793890838,0.164917478353975,7.57187806335544,3.7161,4.83387369426195,102.2662,0.421810026762864,0.337163914221731,0.418447636590304,0.331289743592224,0.0846461125411324,0.0871578929980795,True,0.476222046130431,0.076292859072651,0.703203720824386,69.1414293878976
2128,22203,1011:1083,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.766149496171132,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.133116878400543,0.563201843218749,0.295629455222153,0.267572387996596,7.54448099926352,3.6462,4.65227448876853,88.0432,0.717011608688087,0.608111727845854,0.695829761577613,0.552835336967965,0.108899880842234,0.142994424609648,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
2129,22203,1510:1083,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.708332289225922,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.112216226610592,0.520700010764331,0.33237536688567,0.188324643878661,8.61411298836556,7.6531,3.58264249966649,84.0363,0.662902575439598,0.595224936534333,0.643319209100812,0.550542090753364,0.0676776389052658,0.0927771183474478,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
2130,22203,1372:1083,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.911893783205484,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0316396603958157,0.670339486076397,0.665513287465052,0.004826198611345,12.1121661760463,86.468,0.0845893119857752,5.2214,0.85340841665552,0.853781142052489,0.82819715593763,0.826247451303936,-0.0003727253969685,0.001949704633694,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
2131,22203,1032:1083,Colon,DiFi,SIDM00049,1789883,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.226505953982354,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0587827139586543,0.1665061080382,0.0851848890106777,0.0813212190275224,7.41457195247693,3.3323,4.78218353555512,88.3571,0.211978731636523,0.170349038452801,0.205716488417877,0.161803839080193,0.0416296931837222,0.0439126493376845,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
2132,22203,1549:1083,Colon,DiFi,SIDM00049,1789883,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,10.0,0.287956269201824,0.11430539695899,0.735106981122322,12.196755488032,91.6894,0.935863838939249,0.908216692766953,0.0537850190778576,0.211678663748199,0.101117640909937,0.110561022838263,7.07710253051081,2.6372,5.11965295752124,89.0522,0.269487859541843,0.202919072817933,0.261526690475991,0.200167856881533,0.0665687867239101,0.061358833594458,True,0.331892179768896,0.0500699863387572,1.05250605167914,46.6621748946023
2133,19391,1011:1510,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.419181973104197,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0514240619617084,0.266308062913778,0.16676394200878,0.0995441209049974,7.70178172816958,4.0663,3.03657971536225,29.2993,0.36026182116281,0.301843722804468,0.362681977539404,0.306086855476651,0.0584180983583412,0.0565951220627526,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
2134,19391,1372:1510,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.01,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.896190669429317,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0776905491980939,0.569353685249719,0.382196759111018,0.187156926138701,8.07207722221979,5.2561,2.66628422131204,28.1095,0.770222250462733,0.682946467132461,0.77539642707916,0.672071486441864,0.0872757833302719,0.103324940637296,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
2135,19391,1032:1510,Colon,DiFi,SIDM00049,1789883,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.33394787249896,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0420895302514121,0.212158481865987,0.125050423071077,0.0871080587949098,7.39291097622602,3.2826,3.34545046730581,30.083,0.287008212278288,0.225708251694442,0.288936267693204,0.238149014686208,0.0612999605838463,0.0507872530069952,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
2136,19391,1564:1510,Colon,DiFi,SIDM00049,1789883,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,0.05,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.977177739494252,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.0722204023493074,0.620805110010044,0.589522663674418,0.0312824463356266,10.3129069083566,24.8442,0.425454535175231,8.5214,0.839825790748996,0.795901879287381,0.84546754800251,0.830667196837699,0.043923911461615,0.0148003511648106,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
2137,19391,1549:1510,Colon,DiFi,SIDM00049,1789883,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,2.0,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.383326845487931,0.0654564823760409,0.635304187681709,10.7383614435318,33.3656,0.859440157922198,0.865213680000621,0.051687090979207,0.243529150189302,0.117412866355388,0.126116283833914,6.43970050845119,1.6954,4.29866093508064,31.6702,0.329446484621965,0.231760107354964,0.331659630627642,0.251950780395722,0.0976863772670019,0.0797088502319201,True,0.685976473863846,0.0935507009277229,0.340878093723021,136.45536482418
2138,18979,1510:1549,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.815382094953737,0.184803756355309,0.0727869426574603,1.03027989599884,0.0199,0.327891613682256,0.311107108133843,0.0774493552056524,0.0593491697893176,0.0236458097985733,0.0357033599907443,-1.99642809994406,0.0024,3.02670799594289,0.0175,0.267356950881999,0.126914738864854,0.253671165585172,0.132090584079486,0.140442212017145,0.121580581505686,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2139,18980,1372:1561,Colon,DiFi,SIDM00049,1789883,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,0.1,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,10.0,0.418719525511971,0.0940286196901874,0.219842335330908,5.0331110940171,0.6395,0.547711238451194,0.568152879049699,0.0880219038009933,0.0920522783372015,0.0660502296475221,0.0260020486896795,3.7536137897495,0.2634,1.27949730426761,0.3761,0.229337389881858,0.170927208422898,0.237896703933951,0.202521348715458,0.0584101814589597,0.0353753552184929,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2140,18980,1011:1564,Colon,DiFi,SIDM00049,1789883,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.336653064228521,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0274208930969281,0.12324854775964,0.0555409925765377,0.0677075551831022,3.92112079227432,0.1479,3.35947809466261,1.3705,0.241416495359577,0.140506439491816,0.237943938395962,0.166565880082199,0.10091005586776,0.0713780583137626,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2141,18980,1053:1564,Colon,DiFi,SIDM00049,1789883,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.705459668277573,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0783761280493686,0.258268493166569,0.137639501402949,0.12062899176362,4.56149687203101,0.2306,2.71910201490592,1.2878,0.50589054082542,0.381691731578909,0.498613764987241,0.378954453570213,0.124198809246511,0.119659311417028,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2142,18980,1510:1564,Colon,DiFi,SIDM00049,1789883,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.760373305728464,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0553114312888235,0.278372353155283,0.135566492380605,0.142805860774678,4.21443405802855,0.1813,3.06616482890838,1.3371,0.54526953157134,0.387715086386549,0.537426324726318,0.390995188200128,0.157554445184791,0.146431136526191,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2143,18980,1561:1564,Colon,DiFi,SIDM00049,1789883,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.457436315069907,0.0909388120208222,0.366099586950376,7.28059888693693,1.5184,0.717107672591101,0.706792730199077,0.0538266154807007,0.167467246003195,0.097655025623,0.069812220380195,4.91575737204332,0.2948,2.36484151489362,1.2236,0.32803109125843,0.252312721146285,0.323312662020465,0.256382484011215,0.0757183701121455,0.0669301780092493,True,0.701728345506927,0.0932668669161269,0.311947475710476,146.015648084567
2144,19583,1032:1053,Colon,HCT-15,SIDM00789,905937,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.93662430692898,0.0791605486921203,0.594885241679393,9.70290725518551,16.2778,0.879778726554135,0.905502035741293,0.0423052592808758,0.55718397719024,0.351207101643575,0.205976875546665,8.06519708764493,5.2311,1.63771016754058,11.0467,0.824022140009627,0.753641880821769,0.848115216648968,0.769740357163772,0.0703802591878586,0.0783748594851964,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2145,19583,2048:1053,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.965078473343677,0.0791605486921203,0.594885241679393,9.70290725518551,16.2778,0.879778726554135,0.905502035741293,0.0626609868843671,0.574110940854633,0.472743491968083,0.101367448886551,8.92570881876461,9.4981,0.777198436420903,6.7797,0.849055510303109,0.819430656628819,0.873880522262799,0.839847380194238,0.0296248536742904,0.034033142068561,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2146,19580,1053:1372,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.874827143371527,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.110382474207433,0.599740053468604,0.136672614628451,0.463067438840154,5.91435609394159,0.1178,4.51160591652001,2.5691,0.785490074455174,0.531036133199754,0.814712312333726,0.581312225681291,0.254453941255419,0.233400086652435,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2147,19580,1083:1372,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.972954136474514,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.065746643666735,0.667011272173013,0.671051074934758,-0.0040398027617454,10.4613283608021,2.7536,-0.0353663503404764,-0.0667,0.873596370313205,0.862073753131504,0.906096387529641,0.907164645988808,0.0115226171817007,-0.0010682584591679,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2148,19580,2048:1372,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.996180683718996,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.107214666431775,0.682934292842687,0.571964722414682,0.110969570428005,9.54673102870949,1.4608,0.879230981752112,1.2261,0.894451029959558,0.834760334489236,0.927726893803317,0.895626651234104,0.059690695470322,0.0321002425692127,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2149,19580,1561:1372,Colon,HCT-15,SIDM00789,905937,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1372,Trametinib,"MEK1, MEK2",ERK MAPK signaling,Targeted,FDA approved,1.0,0.729268764301221,0.0824473462997922,0.685552635183729,10.4259620104616,2.6869,0.897880318879849,0.931283761034069,0.144602135036581,0.499952123123884,0.0971705544757958,0.402781568648088,5.574038564908,0.093,4.85192344555361,2.5939,0.654796070639894,0.390516169860352,0.679156157623109,0.463965613776075,0.264279900779542,0.215190543847034,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2150,19582,1032:1510,Colon,HCT-15,SIDM00789,905937,1032,Afatinib,"EGFR, ERBB2",EGFR signaling,Targeted,FDA approved,0.25,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,0.959476309611267,0.059342383760969,0.694438789263491,10.5019709899153,28.3229,0.922195409625779,0.933625569557762,0.0792220454378971,0.666297566773451,0.48784292150403,0.17845464526942,9.06182303899507,10.4378,1.44014795092019,17.8851,0.884824648368193,0.815087193426961,0.895791616037999,0.841458016183552,0.0697374549412321,0.0543335998544473,True,0.122422380174148,0.0262902013554606,1.91411019602722,25.7402793695913
2151,20928,1083:1549,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,2.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.673606494251723,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0427802644627728,0.540858287326913,0.174370626751361,0.366487660575552,7.07551110786048,1.3172,4.49445460186949,28.3726,0.62131385362917,0.497713273336767,0.646684703774831,0.50853633849887,0.123600580292403,0.138148365275961,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
2152,20928,2048:1549,Colon,HCT-15,SIDM00789,905937,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.738887379426844,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0483614301191419,0.593274212725943,0.163014093186935,0.430260119539008,6.69102263693726,1.009,4.87894307279272,28.6808,0.681526928595934,0.511454833963364,0.709356531098182,0.536589144302603,0.17007209463257,0.172767386795579,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
2153,20928,1053:1549,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.376795977441097,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.033039745753789,0.302540472471017,0.140284355771774,0.162256116699243,8.04438202239016,2.5781,3.52558368733982,27.1117,0.347544987724558,0.296884123668882,0.361736707015752,0.309174250527956,0.0506608640556762,0.0525624564877963,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
2154,20928,2171:1549,Colon,HCT-15,SIDM00789,905937,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.609999300591845,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.0701042692938967,0.489786217627274,0.161826900591043,0.327959317036231,7.13633403195503,1.3739,4.43363167777495,28.3159,0.56264454009285,0.436908821356857,0.585619676134947,0.463210571642875,0.125735718735993,0.122409104492072,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
2155,20928,1510:1549,Colon,HCT-15,SIDM00789,905937,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.5865607032978,0.086610307718814,0.802929146233553,11.56996570973,29.6898,0.92236915607436,0.960033356705092,0.154570042243392,0.470966684713055,0.176702625715001,0.294264058998054,7.46072679657548,1.7203,4.10923891315449,27.9695,0.541025500887175,0.345965818961449,0.563117840898287,0.458852171040971,0.195059681925726,0.104265669857316,True,0.0815614553839107,0.0215367248282488,2.23928402347549,22.044031053242
2156,20034,1053:1564,Colon,HCT-15,SIDM00789,905937,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.694295892004303,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.0258908807768591,0.431184220390445,0.301323045925748,0.129861174464697,8.51415081051267,3.5704,1.38956485027605,5.784,0.610314869520608,0.590803152825766,0.634113517601351,0.588965242777424,0.0195117166948416,0.045148274823927,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
2157,20034,1083:1564,Colon,HCT-15,SIDM00789,905937,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.842083839179664,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.100153723636604,0.522966170305132,0.646348612130187,-0.123382441825055,11.1855291855977,22.7447,-1.28181352480894,-13.3903,0.740226601299211,0.774841859112627,0.76909103384722,0.801525115463608,-0.0346152578134159,-0.0324340816163873,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
2158,20034,1561:1564,Colon,HCT-15,SIDM00789,905937,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.733722258161495,0.116997124436006,0.62103812705228,9.90371566078872,9.3544,0.879041452713687,0.913318838414532,0.141363725814466,0.455669496985185,0.0842897592421655,0.371379737743019,5.26436730769373,0.3753,4.63934835309499,8.9791,0.644972279702648,0.383651104967569,0.670122360542944,0.447553272690858,0.261321174735079,0.222569087852086,True,0.114299271286458,0.037342189154545,1.96644644918607,25.0563183075642
2159,19637,2048:1011,Colon,SNU-C2B,SIDM00781,909740,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.941406275025143,0.0586431052503158,0.590988280261723,10.0655406995427,20.9295,0.858668272323203,0.853996772302184,0.0323744330744978,0.556360075504704,0.440202656995701,0.116157418509003,8.62428464956575,7.7072,1.44125604997695,13.2223,0.808355699730062,0.746347260715276,0.803957920296494,0.743872322810749,0.0620084390147858,0.0600855974857452,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
2160,19638,2048:1053,Colon,SNU-C2B,SIDM00781,909740,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.01,1053,MK-2206,"AKT1, AKT2",PI3K/MTOR signaling,Targeted,Early clinical trials,10.0,0.649848468766713,0.0459626660962103,0.706450870418455,11.5424833834262,58.2591,0.895820883001732,0.903173949714109,0.0447876216320658,0.459086016400345,0.284882445549063,0.174203570851282,8.28280891995241,6.0828,3.25967446347378,52.1763,0.58214782910792,0.475474521065223,0.586926208251698,0.502169117485088,0.106673308042697,0.0847570907666101,True,0.407045196922232,0.038164825261396,0.835125698178497,57.9266400930893
2161,19553,1083:1549,Colon,SNU-C2B,SIDM00781,909740,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.941522488908826,0.0499771951125048,0.698412611589301,11.4311432767605,26.966,0.891680923822576,0.900008079868727,0.0377218367362193,0.657571180348872,0.557036751201836,0.100534429147036,10.0732767749658,10.521,1.35786650179467,16.445,0.839537642709953,0.791004500592106,0.847377847396058,0.804339267801849,0.048533142117847,0.0430385795942085,True,0.301437846817851,0.0313999186014628,1.12035622121367,43.5948771528688
2162,22678,1083:1011,Colon,COLO-678,SIDM00957,910689,1083,Crizotinib,"MET, ALK, ROS1",RTK signaling,Targeted,FDA approved,0.625,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.966307130285157,0.102973311239062,0.706487848055553,13.624377572692,246.6473,0.893108994664511,0.848834821331525,0.11173866557207,0.682684245035898,0.678768578572433,0.0039156664634649,13.5219087029062,229.7366,0.102468869785787,16.9107,0.863017589666125,0.875002497565409,0.82023514028698,0.817893761961884,-0.0119849078992834,0.0023413783250961,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
2163,22678,2048:1011,Colon,COLO-678,SIDM00957,910689,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1011,Navitoclax,"BCL2, BCL-XL, BCL-W",Apoptosis regulation,Targeted,Advanced clinical trials,10.0,0.946776423394244,0.102973311239062,0.706487848055553,13.624377572692,246.6473,0.893108994664511,0.848834821331525,0.177767777855238,0.668886037953533,0.429731330850808,0.239154707102725,8.02620297779556,5.0916,5.59817459489645,241.5557,0.845574539669695,0.669346738622697,0.803656796192753,0.635577534583842,0.176227801046998,0.168079261608911,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
2164,22684,2171:1549,Colon,COLO-678,SIDM00957,910689,2171,BMS-754807,"IGF1R, IR",IGF1R signaling,Targeted,Early clinical trials,0.5,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.783420786812047,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.109557853909218,0.529591251288916,0.272140151734297,0.25745109955462,5.6801202154028,0.5007,7.19170877490396,72.6986,0.61567338010506,0.383717866657535,0.65049299710643,0.449510041144869,0.231955513447525,0.200982955961561,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
2165,22684,1510:1549,Colon,COLO-678,SIDM00957,910689,1510,Linsitinib,IGF1R,IGF1R signaling,Targeted,Advanced clinical trials,10.0,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.855130881451565,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.115272722006801,0.578067165369174,0.447255890885951,0.130811274483223,9.48524129901881,6.9991,3.38658769128795,66.2002,0.672028785906869,0.554948891760961,0.71003560201313,0.620941821808769,0.117079894145909,0.0890937802043613,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
2166,22684,2048:1549,Colon,COLO-678,SIDM00957,910689,2048,Vinorelbine,Microtubule destabiliser,Mitosis,Chemotherapeutic,FDA approved,0.0025,1549,Sapitinib,"EGFR, ERBB2, ERBB3",EGFR signaling,Targeted,Advanced clinical trials,5.0,0.930526593157871,0.118149855637094,0.675998467495314,12.8718289903068,73.1993,0.785878279551916,0.830323892417335,0.0993858116806022,0.629034550938356,0.502354895657067,0.126679655281289,9.84119516976725,8.9577,3.03063382053952,64.2416,0.731280638108213,0.624944099183789,0.772638462828685,0.687347798803221,0.106336538924424,0.0852906640254637,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
2167,22685,1561:1564,Colon,COLO-678,SIDM00957,910689,1561,Taselisib,PI3K (beta sparing),PI3K/MTOR signaling,Targeted,Advanced clinical trials,1.0,1564,SCH772984,"ERK1, ERK2",ERK MAPK signaling,Targeted,Experimental only,5.0,0.915410292367614,0.10473100269563,0.551473735730449,10.0878134456794,10.6276,0.728233506827914,0.747137464278122,0.0767864487913443,0.50482473365807,0.332900359704435,0.171924373953635,6.0544266947815,0.649,4.03338675089791,9.9786,0.666632447397233,0.483426983718059,0.683937324613633,0.540013039165442,0.183205463679174,0.14392428544819,True,0.829645477106352,0.0754333092735834,0.147816011870294,276.906111506539
